Multispecific antibodies and antibody combinations

JP2023551981A5Inactive Publication Date: 2024-12-09UCB BIOPHARMA SPRL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534294
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-07
Filing Date
2021-12-06
Publication Date
2024-12-09
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for atopic dermatitis, such as systemic immunosuppressants and monoclonal antibodies, provide only temporary and incomplete relief, and there are no therapeutic options that specifically target biologically active IL22 not bound to IL22BP, which is implicated in the pathogenesis of the condition.

Method used

Development of multispecific antibodies that bind to both IL13 and IL22 to inhibit their activity, restoring normal skin phenotype.

Benefits of technology

The antibodies effectively inhibit IL13 and IL22, addressing the underlying pathogenesis of atopic dermatitis and providing a more sustained therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000148_0000
    Figure 00000148_0000
  • Figure 00000148_0001
    Figure 00000148_0001
  • Figure 00000148_0002
    Figure 00000148_0002
Patent Text Reader

Abstract

The present invention relates to antibodies that bind to IL13 and IL22. The present invention provides novel multispecific antibodies that bind to both IL13 and IL22, and compositions comprising antibodies that bind to IL13 and antibodies that bind to IL22. The present invention further relates to the therapeutic use of combinations of anti-IL13 and anti-IL22 antibodies and multispecific antibodies that bind to both IL13 and IL22.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention relates to antibodies that bind to IL13 and IL22. Such antibodies provided herein are useful in the treatment of inflammatory conditions, particularly skin inflammation. [Background technology]

[0002] Atopic dermatitis (AD), also known as atopic eczema, is an inflammatory condition resulting in epidermal dysfunction and thickening, eczematous lesions, and pruritus. It is common in people of all ages and ethnicities and has the highest disease burden among all skin diseases, as measured by disability-adjusted life years (Laughter et al, Br.J.Dermatol. 2020; Epub ahead of print). AD is a complex condition, and its pathophysiology is influenced by multiple factors, including genetic, environmental, and immunological factors. While type 2 immune mechanisms are important in the pathogenesis of atopic dermatitis, increasing evidence supports the role of several immune pathways.

[0003] Treatments used for AD include systemic immunosuppressants such as cyclosporine, methotrexate, mycophenolate mofetil, and azathioprine. Pruritus can be controlled using antidepressants and naltrexone. In 2016, crisabolol, a topical phosphodiesterase-4 inhibitor, was approved for mild to moderate eczema, and in 2017, dupilumab, a monoclonal antibody antagonist of IL-4Rα, was approved for the treatment of moderate to severe eczema. However, current treatment options only provide temporary, incomplete, or symptomatic relief.

[0004] IL22 is a member of the IL10 cytokine family that has multiple functions in various inflammatory and tissue responses depending on the environmental conditions. IL22 is mainly produced by lymphoid cells such as T helper 1 (Th1), Th17, and Th22 cells, γδ T cells, natural killer (NK) cells, and innate lymphoid cells (ILCs)3, as well as non-lymphoid cells such as fibroblasts, neutrophils, macrophages, and mast cells (see Lanfranca MP, et al. J.Mol.Med.(Berl)(2016)94(5):523-534 for an overview). IL22 signals via a heterodimeric transmembrane receptor complex composed of IL22 receptor 1 (IL22RA1 or IL22R1, also known as interleukin-22 receptor subunit alpha-1) and IL10 receptor 2 (IL10R2), while IL10 signals via IL10R1 and IL10R2. Like other members of the IL-10 family, IL22 mediates its effects via the IL22R1 / IL10R2 complex, which includes Jak1, Tyk2, and STAT3, and subsequent JAK-signaling and STAT signaling pathways. In contrast to IL10, IL22 has also been reported to signal via numerous MAPK pathways, including ERK1 / 2, JNK, and p38. In the skin, IL22 acts on keratinocytes by binding to IL22R1 expressed on these cells.

[0005] Unlike other members of the IL10 cytokine family, IL22 has a soluble secretory receptor known as IL22-binding protein (IL22BP, also known as IL22RA2 or interleukin-22 receptor subunit alpha 2). IL22BP shares the highest structural homology with the IL22R1 chain, but exhibits a much higher affinity for IL22 than IL22R1, and therefore prevents IL22 from binding to IL22R1.

[0006] IL22-specific IL22BPs have been shown to block its activity. Inhibition of total IL22 showed an effective signal in patients with severe atopic dermatitis or high baseline IL22 expression (Guttman-Yassky E et al. J Am Acad Dermatol. 2018;78(5):872-881 and Brunner PM et al. J Allergy Cin Immunol. 2019;143(1):142-154). Inhibition of IL22R1 has also been proposed as a potential therapeutic option to inhibit IL22, which also partially blocks the effects of IL-20 and IL-24. To date, there are no therapeutic options that specifically target biologically active IL22 that is not bound to IL22BP and are therefore designed not to affect the normal biological function of IL22BP.

[0007] Elevated expression of the Th22 cytokine IL22 is a characteristic finding in atopic dermatitis (AD). However, the specific role of IL22 in the pathogenesis of AD in vivo is not fully understood. Although the role of IL22 in the onset and maintenance of AD has not been specifically investigated, it is hypothesized that IL22 plays an important role in the development of AD by impairing skin barrier function, immunomodulation, and pruritus.

[0008] U.S. Patent No. 8906375 and U.S. Patent No. 7901684 disclose antibodies that bind to IL22 and the usefulness of such antibodies in the treatment of Alzheimer's disease (AD). U.S. Patent No. 7737259 discloses a specific anti-IL22 antibody useful in the treatment of psoriasis.

[0009] IL13 is a short-chain cytokine that shares 25% sequence identity with IL4. It contains approximately 132 amino acids that form a secondary structure of four helices, spanning residues 10-21 (Helix A), 43-52 (Helix B), 61-69 (Helix C), and 92-110 (Helix D), along with two β-chains spanning residues 33-36 and 87-90. The solution structure of IL13 has been elucidated, revealing the predicted upper and lower four-helix bundle conformation, which is also observed in IL4.

[0010] Human IL-13 is a 17kDa glycoprotein produced by activated Th2 lineage T cells, but several non-T cell populations, including Th0 and Th1 CD4+ T cells, CD8+ T cells, and mast cells, also produce IL-13. Functions of IL-13 include immunoglobulin isotype switching to IgE in human B cells and suppression of inflammatory cytokine production in both humans and mice. IL-13 has been shown to play a role in epidermal thickening.

[0011] IL13 binds to its cell surface receptors, IL13R-alpha1 and IL13R-alpha2. IL13R-alpha1 interacts with IL13 at low affinity (KD approximately 10 nM), and subsequently recruits IL4R-alpha to form a high-affinity (KD approximately 0.4 nM) heterodimeric receptor signaling complex.

[0012] The IL4R / IL13R alpha-1 complex is expressed in many cell types, including B cells, monocytes / macrophages, dendritic cells, eosinophils, basophils, fibroblasts, endothelial cells, airway epithelial cells, and airway smooth muscle cells. Ligation of the IL13R-alpha / IL4R receptor complex leads to activation of various signaling pathways, including the signaling and transcriptional activator 6 (STAT6) and insulin receptor substrate 2 (IRS2) pathways.

[0013] Only the IL13R-alpha 2 chain exhibits high affinity for IL13 (KD approximately 0.25-0.4 nM). It functions both as a decoy receptor that negatively regulates IL13 binding and as a signaling receptor that induces TGF-β synthesis and fibrosis via the AP-1 pathway in macrophages and possibly other cell types. [Overview of the project]

[0014] This invention addresses the need for new treatments for inflammatory skin conditions, particularly inflammatory conditions such as atopic dermatitis, by providing antibodies that bind to both IL13 and IL22. This invention is the first to demonstrate that inhibiting both IL13 and IL22 restores a normal skin phenotype.

[0015] The present invention provides a multispecific antibody comprising at least two antigen-binding domains, wherein one antigen-binding domain binds to IL13 and a second antigen-binding domain binds to IL22.

[0016] The present invention also provides a pharmaceutical composition comprising an antibody that binds to IL13 and an antibody that binds to IL22.

[0017] The present invention also provides a combination of an antibody that binds to and neutralizes IL-13 and an antibody that binds to and neutralizes IL-22, for use in the treatment of inflammatory skin conditions.

[0018] The present invention will be described below with reference to the following drawings. [Brief explanation of the drawing]

[0019] [Figure 1] Figure 1 shows schematic diagrams of two examples of multispecific antibodies according to the present invention: (A) a TrYbe molecule having an IL13-binding domain, an IL22-binding domain, and an albumin-binding domain; (B) a Knobs-into-Holes molecule having an IL13-binding domain and an IL22-binding domain (in two possible orientations).

[0020] [Figure 2] Figure 2 shows the Ab650 humanization alignment. (A) Light chain graft, (B) Heavy chain graft

[0021] [Figure 3] Figure 3 shows the humanization of the antibody 11041 light chain. Various variants generated for this chain are also shown. The CDR sequence is underlined.

[0022] [Figure 4] Figure 4 shows the humanization of the heavy chain of antibody 11041. Various variants generated for that chain are also shown. The CDR sequence is underlined.

[0023] [Figure 5] Figure 5 shows the humanization of the light chain (A) and heavy chain (B) of antibody 11070. Various variants generated for these chains are also shown. The CDR sequence is underlined.

[0024] [Figure 6] Figure 6 shows the IL22 peptide coverage map from an HDX-MS experiment.

[0025] [Figure 7] Figure 7 shows the results of HDX-MS analysis of 11041gL13gH14 Fab. (A) Peptides showing significantly reduced deuterium uptake upon antibody binding are listed. Peptides showing similar exchange patterns in the presence and absence of antibody have insignificant deuterium uptake and are shown in light gray. (B) The determined 11041gL13gH14 Fab epitopes are projected onto the IL22 3D structure and highlighted in black. For reference, the relative binding of 11041gL13gH14 Fab to IL22 from the X-ray data is shown.

[0026] [Figure 8]Figure 8 shows the results of HDX-MS analysis of 11070gL7gH16 Fab. (A) Peptides showing significantly reduced deuterium uptake upon antibody binding are listed. Peptides showing similar exchange patterns in the presence and absence of the antibody have insignificant deuterium uptake and are shown in light gray. (B) The 11070gL7gH16 Fab epitope is determined to be projected onto the IL22 3D structure and highlighted in black.

[0027] [Figure 9] Figure 9 shows the results of X-ray analysis of 11041gL13gH14 Fab bound to IL-22. (A) Illustration of 11041gL13gH14 Fab bound to IL-22. (B) Detailed diagram of the interaction interface between IL-22 and 11041gL13gH14 Fab.

[0028] [Figure 10] Figure 10 shows that the 11041gL13gH14 Fab molecule, in its complex with its receptor IL22R1 (PDB:3DLQ), inhibits the interaction (surface manifestation) between IL22 and the IL22R1 receptor (A)IL22. (B) The light chain of 11041gL13gH14 Fab blocks the interaction site between IL22 and IL22R1.

[0029] [Figure 11] Figure 11 shows the cryo-EM structure of IL22 complexed with fezakinumab and Fab-formatted 11070gL7gH16 Fab (VR11070) in (A), and the model of IL22 in complex with fezakinumab and 11041gL13gH14 Fab (VR11041) in (B). The model was created by overlaying the IL22 / 11041gL13gH14 Fab crystal structure onto the cryo-EM structure of panel (A). This reveals that 11070gL7gH16 Fab and 11041gL13gH14 Fab have similar epitopes on IL22.

[0030] [Figure 12] Figure 12 shows (A) the superposition of the crystal structure of IL-22 bound to IL-22 on the cryo-EM structure of IL-22 in a complex with 11070gL7gH16 Fab and fezakinumab Fab, and (B) the side chain of the IL-22 residue known to contribute to the interaction with IL-10R2 is shown as a rod. This site is occupied by the fezakinumab Fab molecule.

[0031] [Figure 13] Figure 13 shows the SDS-PAGE results of IL13 / IL22 TrYbe under reducing (lane 1) or non-reducing (lane 2) conditions. The Mark 12 protein marker (Life Technologies) was used as the standard (M). Molecular weight (MW) was measured in kilodaltons (kDa).

[0032] [Figure 14] Figure 14 shows the activity of IL13 / IL22 TrYbe (TRYBE) in an in vitro human primary keratinocyte assay. (A) Example of eotaxin-3 response in the assay. Geometric mean n=4-6, stimulation: IL-13 and IL-22 at 100 ng / ml, lebrikizumab (Leb) and fezakinumab (Fez) at 100 nM, IL13 / IL22 TrYbe (TRYBE) at 25 nM. (B) Example of S100A7 response in the assay. Geometric mean n=5-6, stimulation: IL-13 and IL-22 at 100 ng / ml, lebrikizumab (Leb) and fezakinumab (Fez) at 100 nM, IL13 / IL22 TrYbe (TRYBE) at 25 nM.

[0033] [Figure 15]Figure 15 shows the activity of IL13 / IL22 TrYbe and IL13 / IL22 KiH molecules in an in vitro human primary keratinocyte assay. (A) Inhibition rates of eotaxin-3 and S100A7 by IL13 / IL22 TrYbe in the assay. Mean ± SD, n=3 donors, statistics: log(inhibitor) vs. response (3 parameters), stimulation: IL-13 and IL-22 at 100 ng / ml. (B) Inhibition rates of eotaxin-3 and S100A7 by bispecific IL13 / IL22 in KiH form (IL13 K / IL22 H and IL13 H / IL22 K) in the assay. Mean ± SD, n=2 donors, statistics: log(inhibitor) vs. response (3 parameters), stimulation: IL-13 and IL-22 at 100 ng / ml.

[0034] [Figure 16] Figure 16 shows the effects of IL-13, IL-22, or a combination thereof (100 ng / ml each) on reconstituted human epidermis (MatTek EpiDerm FT) after 7 days of culture (treatment every other day).

[0035] [Figure 17] Figure 17 shows the titration of 66 nM to 0.2 nM IL13 / IL22 TrYbe(TRYBE) using a combination of 100 ng / ml IL-13 and IL-22, or 66 nM IL13 / IL22 TrYbe(TRYBE) using only IL-13 or IL-22, in the EpiDermFT model.

[0036] [Figure 18] Figure 18 shows the effects of molar equivalents of lebrikizumab, fezakinumab (alone or in combination), and IL13 / IL22 TrYbe on a combination of 100 ng / ml IL-13 and IL-22 in the EpiDermFT model. [Modes for carrying out the invention]

[0037] Abbreviation Table 1. Abbreviations used throughout this specification [Table 1]

[0038] Table 2. Amino acid abbreviations [Table 2]

[0039] definition The following terms will be used throughout this specification.

[0040] The term “receptor human framework” is used herein to refer to a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework. A receptor human framework derived from a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence or may comprise a change in the amino acid sequence.

[0041] The term "affinity" refers to the strength of all non-covalent interactions between the antibody and the target protein. Unless otherwise indicated, as used herein, the term "binding affinity" refers to the intrinsic binding affinity that reflects the 1:1 interaction between the members of a binding pair (e.g., antibody and antigen). The affinity of a molecule to its binding partner can generally be expressed by its dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein.

[0042] In the context of antibodies, the term "affinity maturation" refers to an antibody that has one or more changes in its hypervariable region compared to a parent antibody that does not have such changes, and such changes result in an improvement in the antibody's affinity for the antigen.

[0043] The term “antibody” as used herein is used in its broadest sense and encompasses a variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, and multispecific antibodies, as long as they exhibit the desired antigen-binding activity. The term “antibody” as used herein refers to a whole (full-length) antibody (i.e., comprising two heavy chains and two light chain elements) and its functionally active fragment (i.e., a molecule containing an antigen-binding domain that specifically binds to an antigen (also called an antibody fragment or antigen-binding fragment)). The characteristics described herein with respect to antibodies also apply to antibody fragments unless otherwise indicated by the context. An antibody may comprise a Fab linked to two scFv or dsscFv, each scFv or dsscFv binding to the same or different targets (e.g., one scFv or dsscFv binding to a therapeutic target, and another scFv or dsscFv extending its half-life by binding to albumin, for example). Such antibodies are described in International Publication No. 2015 / 197772. The term "antibody" encompasses both monovalent antibodies, i.e., antibodies containing only one antigen-binding domain (for example, a one-arm antibody consisting of a full-length heavy chain and an interconnected full-length light chain, also called a "half-antibody"), and multivalent antibodies, i.e., antibodies containing two or more antigen-binding domains, such as bivalent antibodies.

[0044] An antibody that "binds to the same epitope as the reference antibody" refers to an antibody that blocks 50% or more of the binding of the reference antibody to its antigen in a competitive assay, and conversely, the reference antibody blocks 50% or more of the binding of the antibody to its antigen in a competitive assay.

[0045] The term "antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a mechanism that induces cell death through the interaction between antibody-coated target cells and effector cells with lytic activity, such as natural killer cells, monocytes, macrophages, and neutrophils, via the Fc gamma receptor (Fc gamma R) expressed on effector cells.

[0046] As used herein, the term “antigen-binding domain” refers to a portion of an antibody that includes, or is part of, one or more variable domains that specifically interact with a target antigen, for example, a pair of variable domains VH and VL, or part of or all of them. In the context of the present invention, this term is used in relation to three different antigens: IL13, IL22, and albumin. Thus, such antigen-binding domains are referred to as “IL13-binding domains,” “IL22-binding domains,” and “albumin-binding domains.” Binding domains may include single-domain antibodies. Each binding domain may be monovalent. Each binding domain may include one or fewer VH and one VL. Antigen-binding domains may include or consist of an antibody or an antigen-binding fragment of an antibody. An example of an antigen-binding domain is a VH / VL unit, which consists of a heavy-chain variable domain (VH) and a light-chain variable domain (VL).

[0047] As used herein, the term “antigen-binding fragment” refers to, but is not limited to, a functionally active antibody-binding fragment, including, Fab, modified Fab, Fab', modified Fab', F(ab')2, Fv, single-domain antibodies, scFv, Fv, bivalent antibodies, trivalent or tetravalent antibodies, Bis-scFv, diabodies, triabodies, tetrabodies, and any of the above epitope-binding fragments (see, for example, Holliger and Hudson, 2005, Nature Biotech. 23(9):1126-1136; Adair and Lawson, 2005, Drug Design Reviews-Online 2(3), 209-217). As used herein, “binding fragment” refers to a fragment that can bind to a target peptide or antigen with sufficient affinity to characterize the fragment as specific to the peptide or antigen.

[0048] The term "antibody variant" refers to a polypeptide, for example, an antibody comprising VH and / or VL having the desired features described herein and having at least about 80% amino acid sequence identity with the VH and / or VL of a reference antibody. Such antibody variants include, for example, antibodies in which one or more amino acid residues are added to or deleted from the VH and / or VL domains. Typically, antibody variants have at least about 80% amino acid sequence identity with the antibodies described herein, or at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity. In some cases, a variant antibody may have one or fewer conserved amino acid substitutions compared to the antibody sequence provided herein, or about two, three, four, five, six, seven, eight, nine, or ten or fewer conserved amino acid substitutions compared to the antibody sequence provided herein.

[0049] As used herein, the terms “bispecific” or “bispecific antibody” refer to an antibody that has two antigen specificities.

[0050] The term “complementarity-determining region” or “CDR” generally refers to an antibody containing six CDRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). The CDRs of the heavy chain variable domain are located at residues 31-35 (CDR-H1), residues 50-65 (CDR-H2), and residues 95-102 (CDR-H3), according to the Kabat numbering system. However, according to Chothia (Chothia, C. and Lesk, AMJ Mol. Biol., 196, 901-917 (1987)), the loop equivalent to CDR-H1 extends from residue 26 to residue 32. Therefore, unless otherwise specified, “CDR-H1” as used herein is intended to refer to residues 26-35 as described by the combination of the Kabat numbering system and Chothia’s topological loop definition. The CDRs of the light chain variable domain are located at residues 24-34 (CDR-L1), 50-56 (CDR-L2), and 89-97 (CDR-L3) according to the Kabat numbering system. Unless otherwise indicated, CDR residues and other residues (e.g., FR residues) in the variable domain are numbered herein according to Kabat.

[0051] The term "chimeric" antibody refers to an antibody in which the variable domains (or at least a portion thereof) of the heavy chain and / or light chain originate from a particular source or species, and the remaining portion of the heavy chain and / or light chain (i.e., the constant domain) originates from a different source or species. (Morrison; PNAS 81, 6851 (1984)). Chimeric antibodies may include, for example, a non-human variable domain and a human constant domain. Chimeric antibodies are typically produced using recombinant DNA methods. A subcategory of "chimeric antibodies" is "humanized antibodies."

[0052] The "class" of an antibody refers to the type of constant domain or constant region in its heavy chain. Antibodies have five main classes: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0053] In the context of multiple antibodies, the terms “combination” or “combination of antibodies” refer to multiple (two or more) antibodies that are not physically mixed (are part of a composition) but are provided in the form of separate antibodies or compositions combined with other components.

[0054] The term "complement-dependent cell injury" or "CDC" refers to a cell death induction mechanism in which the Fc effector domain of a target-binding antibody binds to and activates complement component C1q, which then activates the complement cascade, leading to the death of the target cell.

[0055] As used herein, the terms “constant domain” or “constant region” are interchangeable to refer to the domain(s) of an antibody located outside the variable region. The constant domain is identical in all antibodies of the same isotype, but differs from isotype to isotype. Typically, the constant region of a heavy chain is formed from three or four constant domains, CH1-hinge-CH2-CH3-and possibly CH4, from the N-terminus to the C-terminus.

[0056] The terms “competitive antibody” or “cross-competitive antibody” shall be interpreted as meaning that the claimed antibody binds to either (i) the same site on the antigen to which the reference antibody binds, or (ii) a site on the antigen to which the antibody sterically interferes with the binding of the reference antibody to the antigen.

[0057] As used herein, the term “derivative” is intended to include reactive derivatives, such as thiol-selective reactive groups, including maleimide. The reactive group may be linked directly to the polymer or via a linker segment. It will be understood that residues of such a group may, in some cases, form part of the product as linking groups between the antibody fragment and the polymer.

[0058] In the context of generating variable sequences, the term "derived" refers to the fact that the sequence used, or a sequence very similar to the sequence used, is derived from the original genetic material, such as the light or heavy chain of an antibody.

[0059] As used herein, the term “diabody” refers to two Fv pairs having two Fv linkers such that the VH of a first Fv is linked to the VL of a second Fv, and the VL of a first Fv is linked to the VH of a second Fv, a first VH / VL pair, and further VH / VL pairs.

[0060] As used herein, the term "DiFab" refers to two Fab molecules linked via the C-terminus of a heavy chain.

[0061] As used herein, the term “DiFab'” refers to two Fab' molecules linked via one or more disulfide bonds within their hinge region.

[0062] As used herein, the term "dsFab" refers to a Fab having a disulfide bond within a variable region.

[0063] As used herein, the terms “dsscFv” or “disulfide-stabilized single-stranded variable fragment” refer to a single-stranded variable fragment stabilized by a peptide linker between the VH and VL variable domains, and also containing an interdomain disulfide bond between VH and VL (see, for example, Weatherill et al., Protein Engineering, Design & Selection, 25(321-329), 2012, International Publication No. 2007109254).

[0064] The term "DVD-Ig" (also known as dual V-domain IgG) refers to a full-length antibody that has four additional variable domains, one at the N-terminus of each heavy chain and one at the N-terminus of each light chain.

[0065] The term "effector function" refers to the biological activity resulting from the Fc region of an antibody, which varies depending on the antibody isotype. Examples of antibody effector functions include Clq binding and complement-dependent cell-mediated cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation.

[0066] As used herein, the term “effector molecule” includes, for example, antineoplastic agents, drugs, toxins, biologically active proteins such as enzymes, other antibodies or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and their fragments such as DNA, RNA and their fragments, radionuclides, particularly radioactive iodides, radioisotopes, chelated metals, nanoparticles, and reporter groups such as fluorescent compounds or compounds detectable by NMR or ESR spectroscopy.

[0067] In the context of antibodies, the term “epitope” or “binding site” refers to the site (or portion) on an antigen to which an antibody paratope binds or recognizes. Epitopes can be formed from both consecutive amino acids (often called “linear epitopes”) or discontinuous amino acids formed by the tertiary folding of proteins (often called “conformal epitopes”). Epitopes formed from adjacent amino acids are typically retained upon exposure to denaturing solvents, while epitopes formed by folding are typically lost upon processing with denaturing solvents. Epitopes typically contain at least three, and more commonly at least five to ten, amino acids in a unique spatial conformation. Epitopes usually consist of chemically active surface groups of molecules such as amino acids and sugar side chains, and typically have a specific 3D structure and charge properties.

[0068] The terms "EU index," "Kabat-like EU index," or "EU numbering scheme" refer to the numbering of EU antibodies (Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85). This is generally used to refer to residues in the constant region of the antibody heavy chain (e.g., as reported by Kabat et al.). Unless otherwise specified, the EU numbering scheme is used to refer to residues in the constant region of the antibody heavy chain as described herein.

[0069] As used herein, the term "Fab" refers to a light chain fragment comprising a VL (variable light chain) domain and a constant domain (CL) of the light chain, and an antibody fragment comprising a VH (variable heavy chain) domain and a first constant domain (CH1) of the heavy chain. Dimerization of Fab' according to this disclosure produces F(ab')2, where dimerization may, for example, be via a hinge.

[0070] The term "Fab'-Fv" as used herein is similar to FabFv, where the Fab portion is replaced with Fab'. The format may be provided as its PEGylated version.

[0071] As used herein, the term "Fab'-scFv" refers to a Fab' molecule in which scFv is attached to the C-terminus of either the light chain or the heavy chain.

[0072] As used herein, the term "Fab-dsFv" refers to a FabFv in which an intracellular disulfide bond stabilizes the added C-terminal variable region. The format may be provided as a PEGylated version thereof.

[0073] As used herein, the term "Fab-Fv" refers to a Fab fragment in which a variable region is added to the C-terminus of both the CH1 of the heavy chain and the CL of the light chain. The format may be provided as a PEGylated version thereof.

[0074] As used herein, the term "Fab-scFv" refers to a Fab molecule in which scFv is attached to the C-terminus of either the light chain or the heavy chain.

[0075] The terms “Fc,” “Fc fragment,” and “Fc region” are used interchangeably to refer to the C-terminal region of an antibody, including the constant region of the antibody excluding the first constant-region immunoglobulin domain. Therefore, Fc refers to the last two constant domains, CH2 and CH3, of IgA, IgD, and IgG, or the last three constant domains of IgE and IgM, as well as the movable hinge N-terminus to these domains. The human IgG1 heavy chain Fc region is defined herein as including residue C226 to its carboxyl terminus, with numbering following the EU index. In the context of human IgG1, according to the EU index, the lower hinge points to positions 226–236, the CH2 domain points to positions 237–340, and the CH3 domain points to positions 341–447. The corresponding Fc regions of other immunoglobulins can be identified by sequence alignment.

[0076] The term "framework" or "FR" refers to variable domain residues other than hypervariable region residues. The variable domain FR generally consists of four FR domains: FR1, FR2, FR3, and FR4. Therefore, the HVR and FR sequences generally appear in VH (or VL) in the following sequence: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0077] As used herein, the term “full-length antibody” refers to an antibody having a structure substantially similar to that of a naturally occurring antibody, or an antibody having a heavy chain containing an Fc region as defined herein. Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region (CL). Each heavy chain, depending on the Ig class, consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region (CH) consisting of three constant domains CH1, CH2, and CH3, or four constant domains CH1, CH2, CH3, and CH4. The constant region of the antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

[0078] The term "Fv" refers to two variable domains in a full-length antibody, such as a congeneral pair or affinity maturation variable domain, i.e., cooperative variable domains such as the VH and VL pair.

[0079] In the context of amino acid sequences, the term "very similar" is intended to refer to amino acid sequences that are 95% or more similar across their full length, such as 96%, 97%, 98%, or 99% similarity.

[0080] The term "human antibody" refers to an antibody that is produced by a human or human cell, or has an amino acid sequence that corresponds to the amino acid sequence of an antibody derived from the human antibody repertoire or a non-human source utilizing other human antibody coding sequences. Specifically, this definition of human antibody excludes humanized antibodies that contain non-human antigen-binding residues.

[0081] The term "human consensus framework" refers to a framework representing the most commonly present amino acid residues in the selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences derives from subgroups of variable domain sequences. Generally, the sequence subgroups are those such as those described in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In some embodiments, for VL, the subgroup is subgroup kappa I, as described by Kabat et al. In some embodiments, for VH, the subgroup is subgroup I, III, or IV, as described by Kabat et al.

[0082] The term "humanized" antibody refers to an antibody that contains amino acid residues from non-human HVRs and amino acid residues from human FRs. Typically, the heavy and / or light chain contains one or more CDRs (including, optionally, one or more modified CDRs) derived from a donor antibody (e.g., a non-human antibody such as a mouse or rabbit monoclonal antibody) and is grafted onto the heavy and / or light chain variable region framework of a receptor antibody (human antibody) (see, e.g., Vaughan et al., Nature Biotechnology, 16, 535-539, 1998). The advantage of such a humanized antibody is that it reduces immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. Rather than all CDRs being transferred, only one or more specificity-determining residues derived from any one of the CDRs described above may be transferred to the human antibody framework (see, e.g., Kashmiri et al., 2005, Methods, 36, 25-34). A "humanized" antibody refers to a chimeric antibody containing amino acid residues derived from non-human HVR and human FR. The "humanized form" of an antibody, such as a non-human antibody, refers to an antibody that has undergone humanization.

[0083] As used herein, the terms “hypervariable region” or “HVR” refer to each region of an antibody variable domain that is sequence-hypervariable (“complementarity-determining region” or “CDR”) and / or forms a structurally distinct loop (“hypervariable loop”) and / or contains an antigen contact residue (“antigen contact”).

[0084] As used herein, the term "IC50" refers to the maximum half-dose inhibitory concentration, which is a measure of the effectiveness of a substance, such as an antibody, in inhibiting a specific biological or biochemical function. IC50 is a quantitative measure that indicates how much of a particular substance is needed to inhibit a given biological process by 50%.

[0085] "Identity" between amino acids in a sequence indicates that at any specific position within the aligned sequence, the amino acid residues are identical across sequences.

[0086] As used herein, the term "IgG-scFv" refers to a full-length antibody having an scFv at the C-terminus of each heavy chain or each light chain.

[0087] As used herein, the term "IgG-V" refers to a full-length antibody having a variable domain at the C-terminus of each heavy chain or each light chain.

[0088] The term "isolated" throughout this specification means, in some cases, that an antibody or polynucleotide exists in a physical environment different from that in which it could occur in nature. The term "isolated" nucleic acid refers to a nucleic acid molecule that has been isolated from its natural environment or has been synthetically produced. Isolated nucleic acids may include, for example, synthetic DNA, cDNA, genomic DNA, or any combination thereof, produced by chemical processes.

[0089] The terms “Kabat residue designation” or “Kabat” refer to the residue numbering scheme commonly used for antibodies. This does not always directly correspond to the linear numbering of amino acid residues. Actual linear amino acid sequences may contain fewer or additional amino acids than the strict Kabat numbering corresponding to the shortening or insertion of structural components, regardless of the framework of the basic variable domain structure or the complementarity-determining region (CDR). The correct Kabat numbering of residues can be determined for a given antibody by aligning homologous residues in the antibody sequence with the “standard” Kabat numbering sequence. For further details, see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). Unless otherwise indicated, Kabat numbering is used throughout this specification.

[0090] As used herein, the term "KD" refers to the dissociation constant, which is derived from the ratio of Kd to Ka (i.e., Kd / Ka) and expressed as molar concentration (M). Kd and Ka refer to the dissociation rate and association rate of a particular antigen-antibody interaction, respectively. The KD value of an antibody can be determined using methods well established in the art.

[0091] The term "monoclonal antibody" (or "mAb") refers to an antibody obtained from a substantially homogeneous population of antibodies; that is, each individual in a monoclonal antibody preparation is identical except for any possible minor variations (e.g., naturally occurring variations). Nevertheless, certain differences in protein sequences linked to post-translational modifications (e.g., cleavage of the heavy chain C-terminal lysine, deamidation of asparagine residues, and / or isomerization of aspartate residues) may exist among the various different antibody molecules present in the composition. In contrast to polyclonal antibody preparations, each monoclonal antibody in a monoclonal antibody preparation is effective against a single determinant on an antigen.

[0092] As used herein, the term “multiparatopic antibody” refers to an antibody described herein that contains two or more different paratopes that interact with different epitopes from the same antigen or two different antigens. Multiparatopic antibodies described herein may be biparatopic, triparatopic, or tetraparatopic.

[0093] As used herein, the terms “multispecific” or “multispecific antibody” refer to an antibody described herein having at least two binding domains, i.e., two or more binding domains, for example, two or three binding domains, where at least two binding domains independently bind to two different antigens or two different epitopes on the same antigen. Multispecific antibodies are generally monovalent for each specificity (antigen). The multispecific antibodies described herein include monovalent and polyvalent, for example, bivalent, trivalent, and tetravalent multispecific antibodies.

[0094] In the context of antibodies and antigen-binding domains, the term "neutralizing" (or "neutralizing") refers to an antibody (or antigen-binding domain) that can inhibit or attenuate the biological signaling activity of its target (target protein).

[0095] The term "paratope" refers to the region of an antibody that recognizes and binds to an antigen.

[0096] The term “sequence identity (or similarity) percent (%)” for polypeptides and antibody sequences is defined as the percentage of amino acid residues in a candidate sequence that are identical (or similar) to the amino acid residues in the polypeptide being compared, after the sequences have been aligned to achieve the maximum sequence identity percent and gaps have been introduced as necessary, without considering any conservative substitutions as part of the sequence identity.

[0097] A "pharmaceutically acceptable carrier" refers to a component in a pharmaceutical preparation other than the active ingredient that is non-toxic to the target substance. Examples of pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0098] The term "polyclonal antibody" refers to a mixture of different antibody molecules that bind to (or otherwise interact with) two or more epitopes of an antigen.

[0099] In the context of antibodies, the term “hinder” is used herein interchangeably with the term “inhibit” and refers to the effect that the antibody according to the present invention has with respect to a particular biological process or molecular interaction.

[0100] The term "sc diabody" refers to a diabody containing an intra-Fv linker such that the molecule contains three linkers, and the VH and VL ends are each linked to one of the variable regions of a further Fv pair, forming a normal scFv.

[0101] As used herein, the term "Scdiabody-CH3" refers to two scdiabody molecules, each linked to a CH3 domain via, for example, a hinge.

[0102] As used herein, the term "Sc diabody-Fc" refers to two sc diabodies, each attached, for example, via a hinge, to the N-terminus of the CH2 domain of a constant-region fragment-CH2CH3.

[0103] As used herein, the terms “single-stranded variable fragment” or “scFv” refer to a single-stranded variable fragment stabilized by a peptide linker between the VH variable domain and the VL variable domain.

[0104] As used herein, the term "ScFv-Fc-scFv" refers to four scFvs, one of which is attached to the N-terminus and C-terminus of both heavy chains of the -CH2CH3 fragment.

[0105] As used herein, the term "scFv-IgG" refers to a full-length antibody having an scFv at the N-terminus of each heavy chain or each light chain.

[0106] As used herein, the term "similarity" indicates that, at any particular position in an aligned sequence, amino acid residues are of a similar type between sequences. For example, leucine may be used instead of isoleucine or valine. Other amino acids that may be substituted for each other include, but are not limited to, the following: - Phenylalanine, tyrosine, and tryptophan (amino acids with aromatic side chains); - Lysine, arginine, and histidine (amino acids with basic side chains); - Aspartate and glutamate (amino acids with acidic side chains); -Asparagine and glutamine (amino acids with amide side chains); and - Cysteine ​​and methionine (amino acids with sulfur-containing side chains).

[0107] As used herein, the term "single-domain antibody" refers to an antibody fragment consisting of a single monomeric variable domain. Examples of single-domain antibodies include VH, VL, VHH, or V-NAR.

[0108] In the context of antibodies, the term "specific" as used herein is intended to mean an antibody that recognizes only the antigen to which it is specific, or an antibody that has a significantly higher binding affinity to the antigen to which it is specific, for example, at least 5, 6, 7, 8, 9, or 10 times higher, compared to its binding to the antigen to which it is nonspecific.

[0109] As used herein, the terms “sterically blocking” or “sterically obstructing” are intended to refer to means of blocking the interaction between the first protein and the second protein by binding the third protein to the first protein. The binding between the first protein and the third protein prevents the second protein from binding to the first protein due to undesirable van der Waals interactions or electrostatic interactions between the second and third proteins.

[0110] In the context of treatment and diagnosis, the terms “subject” or “individual” generally refer to mammals. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates, e.g., monkeys), rabbits, and rodents (e.g., mice and rats). More specifically, the individual or subject is a human being.

[0111] As used herein, the term “tandem scFv” refers to at least two scFvs linked via a single linker such that a single inter-Fv linker exists.

[0112] As used herein, the term “tandem scFv-Fc” refers to at least two tandem scFvs, each attached, for example, via a hinge, to the N-terminus of the CH2 domain of a constant-region fragment-CH2CH3.

[0113] As used herein, the terms “target” or “antibody target” refer to the target antigen to which an antibody binds.

[0114] As used herein, the term "tetrabody" refers to a format similar to a diabody, including four Fvs and four inter-Fv linkers.

[0115] The term "therapeutic dose" refers to the amount of antibody administered to a subject to treat a disease that is sufficient to produce such a cure for the disease. The therapeutic dose varies depending on the antibody, the disease and its severity, and the age, weight, etc., of the subject being treated.

[0116] As used herein, the term “tribody” (also called Fab(scFv)2) refers to a Fab fragment in which a first scFv is attached to the C-terminus of the light chain and a second scFv is attached to the C-terminus of the heavy chain.

[0117] As used herein, the terms “triply specific” or “triply specific antibody” refer to an antibody having three antigen-binding specificities. For example, an antibody is one that has three antigen-binding domains (trivalent) that independently bind to three different antigens or three different epitopes on the same antigen; that is, each binding domain is monovalent for each antigen. One example of a triply specific antibody format is TrYbe.

[0118] The terms "prevent" or "prevention" refer to achieving a preventive effect in that they completely or partially prevent a disease or its symptoms. Therefore, prevention includes stopping the onset of a disease in individuals who are susceptible to the disease but have not yet been diagnosed with it.

[0119] The terms "treatment" and "treating" refer to obtaining a desired pharmacological and / or physiological effect. The effect may be therapeutic in relation to the partial or complete cure of a disease and / or adverse effects caused by the disease. Therefore, treatment includes (a) inhibiting the disease, i.e., stopping its occurrence; and (b) alleviating the disease, i.e., causing its regression.

[0120] As used herein, the term "TrYbe" refers to a tribody containing two dsscFv(Fab(dsscFv)2). As used herein, the term "IL13 / IL22 TrYbe" refers to a TrYbe containing an IL13-binding domain, an IL22-binding domain, and an albumin-binding domain.

[0121] The term "variable region" or "variable domain" refers to a domain in the heavy or light chain of an antibody that is involved in the binding of the antibody to an antigen. Full-length heavy chain (VH) and light chain (VL) variable domains generally have similar structures, and each domain contains four conserved framework regions (FRs) and three CDRs. (See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The CDRs and FRs together form the variable region. By convention, CDRs in the heavy chain variable region of an antibody are called CDR-H1, CDR-H2, and CDR-H3, while CDRs in the light chain variable region are called CDR-L1, CDR-L2, and CDR-L3. They are numbered sequentially from the N-terminus to the C-terminus of each chain. CDRs are traditionally numbered according to a system devised by Kabat.

[0122] As used herein, the term “vector” refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is ligated. This term includes vectors as self-replicating nucleic acid structures, as well as vectors integrated into the genome of a host cell into which they are introduced. Certain vectors can direct the expression of the nucleic acid to which they are operably ligated. Such vectors are referred to herein as “expression vectors.” The term “vector” includes “expression vectors.”

[0123] The term "VH" refers to the variable domain (or sequence) of the heavy chain.

[0124] As used herein, the term "V-IgG" refers to a full-length antibody having a variable domain at the N-terminus of each heavy chain or each light chain.

[0125] The term "VL" refers to the variable domain (or sequence) of the light chain.

[0126] Interleukin-22 (IL-22) The term "interleukin-22" or "IL22" refers to a class II cytokine capable of binding to IL22R1 (also known as IL22RA1, IL22 receptor 1, or interleukin-22 receptor subunit alpha-1) and / or the receptor complex of IL22R1 and IL10RA2 (also known as IL22BP, IL22-binding protein, or interleukin-22 receptor subunit alpha-2). IL22 is also known as interleukin-10-associated T cell-derived inducer (IL-TIF). This term refers to the naturally occurring or endogenous mammalian IL22 protein, and proteins having the same amino acid sequence as the naturally occurring or endogenous corresponding mammalian IL22 protein (e.g., recombinant protein, synthetic protein). Therefore, as defined herein, the term includes mature IL22 protein, polymorphic or allele variants, and other isoforms of IL22 (e.g., produced by alternative splicing or other cellular processes), as well as the modified or unmodified forms described above (e.g., lipid addition, glycosylation). Naturally occurring or endogenous IL22 includes wild-type protein, e.g., mature IL22, polymorphic or allele variants, and other isoforms and variants naturally occurring in mammals (e.g., humans, non-human primates). These proteins and those having the same amino acid sequence as the corresponding naturally occurring or endogenous IL22 are referred to by the name of the corresponding mammal.

[0127] The amino acid sequence of mature human IL22 corresponds to amino acids 34-179 of SEQ ID NO: 1. Analysis of recombinant human IL22 reveals many structural domains. (Nagem et al. (2002) Structure, 10:1051-62; U.S. Patent Application Publication No. 2002 / 0187512).

[0128] Interleukin-13 (IL-13) "Interleukin-13" or "IL13" refers to naturally occurring or endogenous mammalian IL13 proteins, and proteins having the same amino acid sequence as the corresponding naturally occurring or endogenous mammalian IL13 protein (e.g., recombinant protein, synthetic protein). Therefore, as defined herein, this term includes mature IL13 protein, polymorphic or allele variants, and other isoforms of IL13 (e.g., produced by alternative splicing or other cellular processes), as well as the modified or unmodified forms described above (e.g., lipid addition, glycosylation). Naturally occurring or endogenous IL13 includes wild-type proteins, e.g., mature IL13, polymorphic or allele variants, and other isoforms and variants naturally occurring in mammals (e.g., humans, non-human primates). These proteins and those having the same amino acid sequence as the corresponding naturally occurring or endogenous IL13 are named after the corresponding mammal. For example, if the corresponding mammal is human, the protein is named human IL13. Several mutant IL13 proteins, such as those disclosed in International Publication No. 03 / 035847, are known in the art.

[0129] As used herein, the term “human IL13” includes the human IL13 cytokine. This term includes the monomeric protein of the 13 kDa polypeptide. The structure of human IL13 is further described, for example, in (Moy, Diblasio et al. 2001 J MoI Biol 310 219-30). The term human IL13 is intended to include recombinant human IL13 (which can be prepared by standard recombinant expression methods). The amino acid sequence of mature human IL13 corresponds to amino acids 25-146 of SEQ ID NO: 5.

[0130] Antibodies and antigen-binding domains that bind to IL22 and IL13. The present invention provides an antibody (multispecific antibody) comprising an antigen-binding domain that binds to IL13 ("IL13-binding domain") and an antigen-binding domain that binds to IL22 ("IL22-binding domain").

[0131] Alternatively, the IL13 antigen-binding domain and the IL22 antigen-binding domain may also be present on different antibodies. Therefore, in some embodiments, the present invention utilizes antibodies containing an IL22-binding domain and antibodies containing an IL13-binding domain. Such antibodies may be part of a composition. Alternatively, they may be provided individually or in the form of a composition. The antibodies may be full-length antibodies or fragments of full-length antibodies.

[0132] Antibodies may be polyclonal, monoclonal, fully human, humanized, or chimeric (or may be derived from them).

[0133] Antibodies described further for reference and illustrative purposes only do not limit the scope of the present invention.

[0134] The antibodies used in accordance with the present invention may be monoclonal antibodies or polyclonal antibodies, and are preferably monoclonal antibodies. The antibodies used in accordance with the present invention may be chimeric antibodies, CDR graft antibodies, nanobody antibodies, human antibodies or humanized antibodies. For the production of both monoclonal and polyclonal antibodies, the animals used to produce such antibodies are typically non-human mammals such as goats, rabbits, rats or mice, but antibodies may also be produced in other species.

[0135] Polyclonal antibodies can be produced by routine methods such as immunization of appropriate animals with the target antigen. Blood can then be extracted from such animals, and the produced antibodies can be purified.

[0136] Monoclonal antibodies can be produced by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of a human immunoglobulin locus. Several exemplary methods for producing monoclonal antibodies are described herein.

[0137] For example, monoclonal antibodies can be prepared using hybridoma technology (Kohler & Milstein, 1975, Nature, 256:495-497), trioma technology, human B-cell hybridoma technology (Kozbor et al., 1983, Immunology Today, 4:72), and EBV-hybridoma technology (Cole et al., Monoclonal Antibodies and Cancer Therapy, pp77-96, Alan R Liss, Inc., 1985).

[0138] Monoclonal antibodies can also be produced using monolymphocyte antibody methods by cloning and expressing immunoglobulin variable region cDNA generated from a single lymphocyte selected for the production of a specific antibody, for example, by the methods described in International Publication No. 9202551, International Publication No. 2004051268, and International Publication No. 2004106377.

[0139] Antibodies produced against target polypeptides can be obtained by administering polypeptides to animals, preferably non-human animals, using well-known, conventional protocols when animal immunization is required (see, for example, Handbook of Experimental Immunology, DM Weir (ed.), Vol. 4, Blackwell Scientific Publishers, Oxford, England, 1986). Many animals can be immunized, including rabbits, mice, rats, sheep, cattle, camels, or pigs. However, mice, rabbits, pigs, and rats are commonly used.

[0140] Monoclonal antibodies can also be produced using various phage display methods known in the art, including those disclosed by Brinkman et al. (in J.Immunol.Methods, 1995, 182:41-50), Ames et al. (J.Immunol.Methods, 1995, 184:177-186), Kettleborough et al. (Eur.J.Immunol.1994, 24:952-958), Persic et al. (Gene, 1997 187 9-18), and Burton et al. (Advances in Immunology, 1994, 57:191-280). In certain phage display methods, as described in Winter et al., Ann. Rev. Immunol, 12:433-455 (1994), the VH and VL gene repertoires can be cloned separately by polymerase chain reaction (PCR) or randomly recombined in a phage library and screened against antigen-binding phages. The phages typically present antibody fragments as either single-stranded Fv(scFv) fragments or Fab fragments. Libraries from immunized sources provide high-affinity antibodies against immunogens without the need to construct hybridomas. Alternatively, as described in Griffiths et al., EMBO J 12:725-734 (1993), naive repertoires can be cloned without immunization (e.g., human-derived) to provide a single antibody source against a wide range of non-self and self-antigens. Finally, as described by Hoogenboom and Winter, J. Mol. Biol, 227:381-388 (1992), naive libraries can also be synthetically constructed by cloning an unreorganized V gene segment from stem cells, encoding a highly variable CDR3 region using PCR primers containing random sequences, and achieving rearrangement in vitro.Patent publications describing human antibody phage libraries include, for example, U.S. Patent No. 5,750,373, and U.S. Patents No. 2005 / 0079574, U.S. Patent No. 2005 / 0119455, U.S. Patent No. 2005 / 0266000, U.S. Patent No. 2007 / 0117126, U.S. Patent No. 2007 / 0160598, U.S. Patent No. 2007 / 0237764, U.S. Patent No. 2007 / 0292936, and U.S. Patent No. 2009 / 0002360.

[0141] Antibody screening can be performed using assays that measure binding to a target polypeptide and / or assays that measure the antibody's ability to block specific interactions. An example of a binding assay is an ELISA that uses a fusion protein of the target polypeptide immobilized on a plate and a conjugated secondary antibody to detect the antibody bound to the target. An example of a blocking assay is a flow cytometry-based assay that measures the blockage of ligand proteins that bind to the target polypeptide. A fluorescently labeled secondary antibody is used to detect the amount of such ligand proteins that bind to the target polypeptide.

[0142] Antibodies can be isolated by screening a combinatorial library for antibodies having one or more desired activities. For example, various methods for preparing phage display libraries and screening such libraries for antibodies having desired binding properties are known in the art.

[0143] Antibodies or antibody fragments isolated from a human antibody library are considered human antibodies or human antibody fragments.

[0144] The antibody may be a full-length antibody. More specifically, the antibody may be an IgG isotype. More specifically, the antibody may be IgG1 or IgG4.

[0145] The constant region domain of an antibody, if present, may be selected in consideration of the proposed function of the antibody molecule, particularly any effector function that may be required. For example, the constant region domain may be a human IgA, IgD, IgE, IgG, or IgM domain. In particular, if the antibody molecule is intended for therapeutic use and antibody effector function is required, the human IgG constant region domain, especially the IgG1 and IgG3 isotypes, may be used. Alternatively, if the antibody molecule is intended for therapeutic purposes and antibody effector function is not required, the IgG2 and IgG4 isotypes may be used. It will be understood that sequence variants of these constant region domains may also be used. It will also be known to those skilled in the art that antibodies can undergo various posttranslational modifications. The type and extent of these modifications often depend on the host cell line and cell culture conditions used to express the antibody. Such modifications may include variations of glycosylation, methionine oxidation, diketopiperazine formation, aspartate isomerization, and asparagine deamidation. Frequent modifications involve the loss of carboxyl-terminal basic residues (such as lysine or arginine) due to the action of carboxypeptidases (as described in Harris, RJ, Journal of Chromatography 705:129-134, 1995). Therefore, the C-terminal lysine of the antibody heavy chain may be absent.

[0146] Alternatively, an antibody is an antigen-binding fragment.

[0147] For a review of specific antigen-binding fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, for example, Pluckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994), and also see International Publication No. 93 / 16185, U.S. Patent No. 5,571,894 and U.S. Patent No. 5,587,458. Fab and F(ab')2 fragments containing salvage receptor-binding epitope residues and having increased in vivo half-lives are disclosed in U.S. Patent No. 5,869,046.

[0148] Antigen-binding fragments and methods for producing them are well known in the art; see, for example, Verma et al., 1998, Journal of Immunological Methods, 216, 165-181; Adair and Lawson, 2005. Therapeutic antibodies. Drug Design Reviews-Online 2(3):209-217. The Fab-Fv format was first disclosed in International Publication No. 2009 / 040562, its disulfide-stabilized version Fab-dsFv was first disclosed in International Publication No. 2010 / 035012, and the TrYbe format was disclosed in International Publication No. 2015 / 197772.

[0149] Various techniques have been developed to produce antibody fragments. Such fragments can be induced via proteolytic digestion of intact antibodies (see, for example, Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)). However, antibody fragments can also be produced directly by recombinant host cells. For example, antibody fragments can be isolated from the antibody phage libraries mentioned above. Alternatively, Fab'-SH fragments can be directly recovered from Escherichia coli (E. coli) and chemically conjugated to form F(ab')2 fragments (Carter et al., Bio / Technology 10:163-167 (1992)).

[0150] The F(ab')2 fragment can be isolated directly from recombinant host cell cultures. The antibody may be a single-stranded Fv fragment (scFv), as described in International Publication No. 93 / 16185; U.S. Patent No. 5,571,894; and U.S. Patent No. 5,587,458. The antibody fragment may also be a “linear antibody,” as described, for example, in U.S. Patent No. 5,641,870. Such a linear antibody fragment may be monospecific or bispecific.

[0151] The antibody may be Fab, Fab', F(ab')2, Fv, dsFv, scFv, or dsscFv. The antibody may be a single-domain antibody or a nanobody, e.g., VH or VL or VHH or VNAR. The antibody may be a Fab or Fab' fragment described in International Publication Nos. 2011 / 117648, 2005 / 003169, 2005 / 003170, and 2005 / 003171.

[0152] Antibodies can be disulfide-stabilized single-strand variable fragments (dsscFv).

[0153] The disulfide bond between the variable domains VH and VL can be between two of the residues listed below. ·V H 37 + V L 95, see, for example, Protein Science 6,781-788 Zhu et al(1997); ·V H 44 + V L 100, see, for example, Weatherill et al., Protein Engineering, Design & Selection, 25(321-329), 2012; ·V H 44 + V L 105, see, for example, J Biochem.118,825-831 Luo et al(1995); ·V H 45 + V L 87, see, for example, Protein Science 6,781-788 Zhu et al(1997); ·V H 55 + V L 101, see, for example, FEBS Letters 377 135-139 Young et al(1995); ·V H 100 + V L 50, see, for example, Biochemistry 29 1362-1367 Glockshuber et al(1990); ·V H 100b + V L 49, see, for example, Biochemistry 29 1362-1367 Glockshuber et al(1990); ·V H 98 + V L For 46, see, for example, Protein Science 6,781-788 Zhu et al(1997); ·V H 101 + V L 46, see, for example, Protein Science 6,781-788 Zhu et al(1997); ·VH 105+V L 43. For example, see Proc.Natl.Acad.Sci.USA Vol.90 pp.7538-7542 Brinkmann et al (1993); or Proteins 19,35-47 Jung et al (1994). ·V H 106+V L 57. See, for example, FEBS Letters 377 135-139 Young et al (1995). and includes one or more corresponding positions in a pair of variable regions located within the molecule.

[0154] A disulfide bond may be formed between positions VH44 and VL100.

[0155] The antigen-binding fragments described herein may also be characterized as monoclonal, chimeric, humanized, fully human, multispecific, bispecific, etc., and discussions of these terms will be understood by those skilled in the art to relate to such fragments.

[0156] Multispecific antibodies that bind to IL22 and IL13 The present invention provides a multispecific antibody comprising at least two antigen-binding domains, wherein at least one antigen-binding domain binds to IL13 ("IL13-binding domain") and at least one antigen-binding domain binds to IL22 ("IL22-binding domain"). In particular, such antigen-binding domains specifically bind to their corresponding targets.

[0157] Examples of multispecific antibodies intended for use in connection with this disclosure include bivalent, trivalent, or tetravalent antibodies, Bis-scFv, diabodies, triabodies, tetrabodies, bibodies, and tribodies (see, for example, Holliger and Hudson, 2005, Nature Biotech 23(9):1126-1136; Schoonjans et al. 2001, Biomolecular Engineering, 17(6), 193-202).

[0158] In one embodiment, a multispecific antibody is a bispecific antibody. In one embodiment, the antibody contains two antigen-binding domains, one of which binds to IL13 and the other to IL22, i.e., each binding domain is monovalent for each antigen. In one embodiment, the antibody is a tetravalent bispecific antibody, i.e., the antibody contains four antigen-binding domains, for example, two of which bind to IL13 and the other two bind to IL22. In one embodiment, the antibody is a trivalent bispecific antibody.

[0159] In one embodiment, the multispecific antibody is a triplicate antibody.

[0160] The multispecific antibody of the present invention may be a multiparatopic antibody.

[0161] In one embodiment, each binding domain is monovalent. Preferably, each binding domain contains two antibody variable domains. More preferably, each binding domain contains one or fewer VH and one VL.

[0162] More specifically, the binding domains that bind to IL13 and IL22 are selected independently from Fab, scFv, Fv, dsFv, and dsscFv.

[0163] Various different multispecific antibody formats are known in the art. Although various classifications have been proposed, multispecific IgG antibody formats generally include bispecific IgG, IgG adducts, multispecific (e.g., bispecific) antibody fragments, multispecific (e.g., bispecific) fusion proteins, and multispecific (e.g., bispecific) antibody conjugates, as described, for example, Spiess et al., Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 67(2015):95-106.

[0164] Techniques for producing bispecific antibodies include, but are not limited to, CrossMab technology (Klein et al. Engineering therapeutic bispecific antibodies using CrossMab technology, Methods 154(2019)21-31), Knobs-in-holes engineering (e.g., International Publication No. 1996027011, International Publication No. 1998050431), DuoBody technology (e.g., International Publication No. 2011131746), and Azymetric technology (e.g., International Publication No. 2012058768). Further techniques for producing bispecific antibodies are described, for example, in Godar et al., 2018, Therapeutic bispecific antibody formats: a patent applications review (1994-2017), Expert Opinion on Therapeutic Patents, 28:3, 251-276. Bispecific antibodies include, in particular, CrossMab antibodies, DAF (two-in-one), DAF (four-in-one), DutaMab, DT-IgG, Knobs-in-holes common LC, Knobs-in-holes assembly, charge pair, Fab arm exchange, SEEDbody, Triomab, LUZ-Y, Fcab, κλ-body, and orthogonal Fab.

[0165] Additive IgG classically refers to full-length IgG manipulated by adding additional antigen-binding fragments to the N-terminus and / or C-terminus of the heavy and / or light chains of IgG. Examples of such additional antigen-binding fragments include sdAb antibodies (e.g., VH or VL), Fv, scFv, dsscFv, Fab, and scFab. The added IgG antibody formats include, for example, DVD-IgG, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgC(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, Zybody, and DVI-IgG (four-in-one), as described in Spiess et al., Mol Immunol. 67(2015):95-106.

[0166] Multispecific antibodies include, for example, nanobody, nanobody-HSA, BiTE, diabody, DART, TandAb, scDiabody, sc-Diabody-CH3, Diabody-CH3, Triple Body, Miniantibody, minibody, TriBi minibody, scFv-CH3 KIH, Fab-scFv, scFv-CH-CL-scFv, F(ab')2, F(ab')2-scFv2, scFv-KIH, Fab-scFv-Fc, tetravalent HCAb, scDiabody-Fc, Diabody-Fc, Tandem scFv-Fc; and intrabody, as described in Spiess et al., Mol Immunol. 67(2015):95-106.

[0167] Examples of multispecific fusion proteins include Dock and Lock, ImmTAC, HSabody, scDiabody-HSA, and Tandem scFv-Toxin.

[0168] Examples of multispecific antibody conjugates include IgG-IgG; Cov-X-body; and scFv1-PEG-scFv2.

[0169] Further multispecific antibody formats are described, for example, in Brinkmann and Kontermann, mAbs, 9:2, 182-212 (2017), such as tandem scFv, triplets, Fab-VHH, taFv-Fc, scFv4-Ig, scFv2-Fcab, and scFv4-IgG. Biobodies, tribodies, and methods for producing them are disclosed, for example, in International Publication No. 99 / 37791.

[0170] A preferred multispecific antibody for use in the present invention comprises a Fab linked to two scFv or dsscFv, where each scFv or dsscFv binds to the same or different targets (for example, one scFv or dsscFv that binds to a therapeutic target and another scFv or dsscFv that extends the half-life by binding to albumin, for example). Such a multispecific antibody is described in International Publication No. 2015 / 197772. In a preferred embodiment, the multispecific antibody comprises a Fab that binds to human IL22 linked to two scFv or dsscFv, where one scFv or dsscFv binds to IL13 and the other scFv or dsscFv binds to albumin. Another preferred antibody for use with the fragment of the present invention includes Fab linked to just one scFv or dsscFv, as described, for example, in International Publication No. 2013 / 068571 and Dave et al., Mabs, 8(7)1319-1335 (2016).

[0171] Another preferred multispecific antibody for use in the present invention is a knob-into-hole antibody ("KiH"). Generally, such a technique involves introducing a projection ("knob") at the interface of a first polypeptide (e.g., a first CH3 domain in the first antibody heavy chain) and introducing a corresponding cavity ("hole") at the interface of a second polypeptide (e.g., a second CH3 domain in the second antibody heavy chain), thereby allowing the projection to be positioned within the cavity to assist in the formation of a bispecific antibody. The projection is constructed by replacing a small amino acid side chain from the interface of the first polypeptide (e.g., a first CH3 domain in the first antibody heavy chain) with a larger side chain (e.g., arginine, phenylalanine, tyrosine, or tryptophan). Compensatory cavities of the same or similar size as the protrusions are created at the interface of the second polypeptide (e.g., the second CH3 domain in the second antibody heavy chain) by replacing larger amino acid side chains with smaller amino acid side chains (e.g., alanine, serine, valine, or threonine). The protrusions and cavities can be created by modifying the nucleic acid encoding the polypeptide, for example, by site-directed mutagenesis or peptide synthesis. Further details regarding the "knobs-into-holes" technology are described, for example, in U.S. Patent No. 5,731,168; U.S. Patent No. 7,695,936; International Publication No. 2009 / 089004; U.S. Patent Application Publication No. 2009 / 0182127; Marvin md Z u, Acta Pharmacologica Sincia (2005) 26(6):649-658; Kontermann Acta Pharmacologica Sincia (2005) 26:1-9; Ridgway et al, Prot Eng 9,617-621 (1996); and Carter, J Immunol Meth 248,7-15 (2001).

[0172] Antibodies that bind to albumin The high specificity and affinity of antibodies make them ideal diagnostic and therapeutic agents, particularly for modulating protein-protein interactions. However, antibodies can suffer from increased clearance rates from serum, especially if they lack the Fc domain that confers longevity in vivo (Medasan et al., 1997, J.Immunol. 158:2211-2217).

[0173] Methods for improving the half-life of antibodies are known. One approach has been to conjugate the fragment to a polymer molecule. Thus, the short cyclic half-life of the Fab',F(ab')2 fragment in animals has been improved by conjugation to polyethylene glycol (PEG; see, e.g., International Publications 98 / 25791, 99 / 64460, and 98 / 37200). Another approach has been to modify the antibody fragment by conjugation to a drug that interacts with the FcRn receptor (see, e.g., International Publication 97 / 34631). Another approach to extending the half-life was to use polypeptides that bind to serum albumin (e.g., Smith et al., 2001, Bioconjugate Chem. 12:750-756; European Patent No. 0486525; U.S. Patent No. 6267964; International Publication No. 04 / 001064; International Publication No. 02 / 076489; and International Publication No. 01 / 45746).

[0174] Serum albumin is a protein abundant in both vascular and extravascular compartments, and its half-life in humans is approximately 19 days (Peters, 1985, Adv Protein Chem. 37:161-245). This is similar to the half-life of IgG1, which is approximately 21 days (Waldeman & Strober, 1969, Progr. Allergy, 13:1-110).

[0175] Antiserum albumin-binding monovariable domains are described, along with their use as conjugates to increase the half-life of drugs including NCE (chemical entity) drugs, proteins, and peptides. See, for example, Holt et al., Protein Engineering, Design & Selection, vol 21, 5, pp283-288, International Publication No. 04003019, International Publication No. 2008 / 096158, International Publication No. 05118642, International Publication No. 2006 / 0591056, and International Publication No. 2011 / 006915. Their use in other antiserum albumin antibody and multispecific antibody formats is described in International Publication No. 2009 / 040562, International Publication No. 2010 / 035012, and International Publication No. 2011 / 086091. In particular, the inventors previously described an improved humanized anti-albumin antibody in International Publication No. 2013 / 068571.

[0176] In some embodiments, the multispecific antibodies of the present invention are engineered to bind to human serum albumin (e.g., containing an albumin-binding domain) to extend their in vivo serum half-lives and result in an improved pharmacokinetic profile.

[0177] Humanized antibodies, human antibodies, and chimeric antibodies, and methods for producing such antibodies The antibodies of the present invention may be, but are not limited to, humanized antibodies, fully human antibodies, or chimeric antibodies.

[0178] In one embodiment, the antibody is humanized. More specifically, the antibody is a chimeric, human, or humanized antibody.

[0179] In certain embodiments, the antibodies provided herein are chimeric antibodies. Examples of chimeric antibodies are described, for example, in U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984). In one example, a chimeric antibody includes a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, e.g., a monkey) and a human constant region. In further examples, a chimeric antibody is a “class-switching” antibody in which the class or subclass is changed from the class or subclass of the parent antibody. A chimeric antibody includes its antigen-binding fragment.

[0180] In one embodiment, the antibody is a humanized antibody.

[0181] Humanized antibodies may optionally further contain one or more framework residues derived from the non-human species from which the CDR originates. It will be understood that only the specificity-determining residues of the CDR may be replaced, rather than the entire CDR (see, for example, Kashmiri et al., 2005, Methods, 36, 25-34).

[0182] Preferably, the humanized antibody according to the present invention has a variable domain comprising a human receptor framework region and one or more CDRs, and optionally further comprising one or more donor framework residues.

[0183] Therefore, in one embodiment, a humanized antibody is provided in which the variable domain includes a human receptor framework region and a non-human donor CDR.

[0184] When a CDR or specificity-determining residue is grafted, any suitable receptor variable region framework sequence may be used, taking into account the class / type of the donor antibody from which the CDR originates, including mouse, primate, and human framework regions.

[0185] Examples of human frameworks that may be used in the present invention include KOL, NEWM, REI, EU, TUR, TEI, LAY, and POM (Kabat et al.). For example, KOL and NEWM can be used in the heavy chain, REI in the light chain, and EU, LAY, and POM can be used in both the heavy and light chains. Alternatively, human germline sequences may be used, which are available at www.imgt.org. In embodiments, the receptor framework is the IGHV1-69 human germline, the IGKV1D-13 human germline, the IGHV3-66 human germline, the IGKV1-12 human germline, the IGKV1-39 human germline, and / or the IGHV4-31 human germline. In embodiments, the human framework contains 1-5, 1-4, 1-3, or 1-2 donor antibody amino acid residues.

[0186] In the humanized antibody of the present invention, the receptor heavy chain and light chain do not necessarily have to originate from the same antibody, and may optionally include a composite chain having framework regions derived from different chains.

[0187] In certain embodiments, the antibodies provided herein are human antibodies. Human antibodies can be produced using various techniques known in the art.

[0188] Human antibodies include a “product” of a particular germline sequence or a heavy or light chain variable region or a full-length heavy or light chain “derived” therefrom, if the variable region or full-length chain of the antibody is obtained from a system using human germline immunoglobulin genes. Such systems include immunizing transgenic mice possessing human immunoglobulin genes with the antigen of interest, or screening a human immunoglobulin gene library presented on phages with the antigen of interest. A “product” of a human germline immunoglobulin sequence or a human antibody “derived” therefrom, or a fragment thereof, can be identified in this way by comparing the amino acid sequence of the human antibody with the amino acid sequence of the human germline immunoglobulin and selecting the human germline immunoglobulin sequence that is most closely sequenced to the human antibody sequence (i.e., maximum % identity). A “product” of a particular human germline immunoglobulin sequence or a human antibody “derived” therefrom may include amino acid differences compared to the germline sequence, for example, due to the intentional introduction of naturally occurring somatic mutations or site-directed mutations. However, selected human antibodies typically contain amino acid residues that identify a human antibody as human, such that the amino acid sequence encoded by the human germline immunoglobulin gene is at least 90% identical to the amino acid sequence encoded by the human germline immunoglobulin gene when compared to the germline immunoglobulin amino acid sequence of another species (e.g., mouse germline sequence). In specific cases, a human antibody may be at least 60%, 70%, 80%, 90%, or at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene. Typically, a human antibody derived from a particular human germline sequence will show a difference of 10 or fewer amino acids from the amino acid sequence encoded by the human germline immunoglobulin gene. In specific cases, a human antibody may show a difference of 5 or fewer amino acids from the amino acid sequence encoded by the germline immunoglobulin gene, or even 4, 3, 2, or 1 or fewer amino acids.

[0189] antigen-binding domain and its sequence The antigen-binding domain generally contains six CDRs, three of which are derived from the heavy chain and three from the light chain. In one embodiment, the CDRs are within a framework and together form a variable region. Thus, in one embodiment, the antigen-specific binding domain includes a light chain variable region and a heavy chain variable region.

[0190] In the context of the antibodies of this invention, three types of antigen-binding domains are mentioned: IL22-binding domains, IL13-binding domains, and albumin-binding domains.

[0191] Table 3. Summary of sequences of IL22 and IL13 antigen-binding domains (bd) [Table 3]

[0192] In one embodiment, the multispecific antibody is CDR-L1 containing sequence number 8, CDR-L2 containing sequence number 9, and CDR-L3 containing sequence number 10 A light chain variable region including, CDR-H1 containing sequence number 11, CDR-H2 containing Sequence ID No. 12, and CDR-H3 containing sequence number 13 It includes a heavy chain variable region and an antigen-binding domain that binds to IL22.

[0193] In another embodiment, the multispecific antibody is CDR-L1 containing sequence number 70, CDR-L2 containing sequence number 71, and CDR-L3 containing sequence number 72 A light chain variable region including, CDR-H1 containing sequence number 73, CDR-H2 containing Sequence ID 74, and CDR-H3 containing sequence number 75 It includes a heavy chain variable region and an antigen-binding domain that binds to IL22.

[0194] In one embodiment, the multispecific antibody is CDR-L1 containing sequence number 22, CDR-L2 containing Sequence ID No. 23, and CDR-L3 containing Sequence ID No. 24 Including a light chain variable region, CDR-H1 containing sequence number 25, CDR-H2 containing Sequence ID No. 26, and CDR-H3 containing sequence number 27 It includes a heavy chain variable region and an antigen-binding domain that binds to IL13.

[0195] In one embodiment, the antigen-binding domain that binds to IL22 includes a light chain variable region containing the sequence shown in SEQ ID NO: 14 and a heavy chain variable region containing the sequence shown in SEQ ID NO: 16.

[0196] Alternatively, the antigen-binding domain that binds to IL22 includes a light chain variable region containing the sequence shown in SEQ ID NO: 76 and a heavy chain variable region containing the sequence shown in SEQ ID NO: 78.

[0197] In one embodiment, the antigen-binding domain that binds to IL13 includes a light chain variable region containing the sequence shown in SEQ ID NO: 28 and a heavy chain variable region containing the sequence shown in SEQ ID NO: 29.

[0198] In an alternative embodiment, the antigen-binding domain that binds to IL13 includes a light chain variable region containing the sequence shown in SEQ ID NO: 32 and a heavy chain variable region containing the sequence shown in SEQ ID NO: 33.

[0199] In one embodiment, the antigen-binding domain that binds to IL13 is an scFv containing the sequence shown in SEQ ID NO: 36, or a dsscFv containing the sequence shown in SEQ ID NO: 38.

[0200] In one embodiment, the antigen-binding domain that binds to IL22 is a Fab comprising a light chain comprising the sequence set forth in SEQ ID NO: 18 and a heavy chain comprising the sequence set forth in SEQ ID NO: 20.

[0201] Alternatively, in one embodiment, an alternative antigen-binding domain that binds to IL22 is a Fab comprising a light chain comprising the sequence set forth in SEQ ID NO: 80 and a heavy chain comprising the sequence set forth in SEQ ID NO: 82.

[0202] In one embodiment, the present invention a CDR-L1 comprising SEQ ID NO: 8, a CDR-L2 comprising SEQ ID NO: 9, and a CDR-L3 comprising SEQ ID NO: 10 a light chain variable region comprising one or more of the foregoing, and a CDR-H1 comprising SEQ ID NO: 11, a CDR-H2 comprising SEQ ID NO: 12, and a CDR-H3 comprising SEQ ID NO: 13 a heavy chain variable region comprising one or more of the foregoing, and an antigen-binding domain that binds to IL22, a CDR-L1 comprising SEQ ID NO: 22, a CDR-L2 comprising SEQ ID NO: 23, and a CDR-L3 comprising SEQ ID NO: 24 a light chain variable region comprising one or more of the foregoing, and a CDR-H1 comprising SEQ ID NO: 25, a CDR-H2 comprising SEQ ID NO: 26, and a CDR-H3 comprising SEQ ID NO: 27 a heavy chain variable region comprising one or more of the foregoing, and an antigen-binding domain that binds to IL13, and provides a multispecific antibody.

[0203] Preferably, both antigen-binding domains comprise at least one CDR-H3 comprising the sequences provided above.

[0204] In one embodiment, the present invention a CDR-L1 comprising SEQ ID NO: 8, CDR-L2 containing sequence number 9, and CDR-L3 containing sequence number 10 A light chain variable region including, CDR-H1 containing sequence number 11, CDR-H2 containing Sequence ID No. 12, and CDR-H3 containing sequence number 13 A heavy chain variable region including, and an antigen-binding domain that binds to IL22, CDR-L1 containing sequence number 22, CDR-L2 containing Sequence ID No. 23, and CDR-L3 containing Sequence ID No. 24 A light chain variable region including, CDR-H1 containing sequence number 25, CDR-H2 containing Sequence ID No. 26, and CDR-H3 containing sequence number 27 A heavy chain variable region including, and an antigen-binding domain that binds to IL13, This provides multispecific antibodies, including those mentioned above.

[0205] Alternatively, the present invention is CDR-L1 containing sequence number 70, CDR-L2 containing sequence number 71, and CDR-L3 containing sequence number 72 A light chain variable region including, CDR-H1 containing sequence number 73, CDR-H2 containing Sequence ID 74, and CDR-H3 containing sequence number 75 A heavy chain variable region including, and an antigen-binding domain that binds to IL22, CDR-L1 containing sequence number 22, CDR-L2 containing Sequence ID No. 23, and CDR-L3 containing Sequence ID No. 24 A light chain variable region including, CDR-H1 containing sequence number 25, CDR-H2 containing Sequence ID No. 26, and CDR-H3 containing sequence number 27 A heavy chain variable region comprising, and an antigen-binding domain that binds to IL13 and comprises A multispecific antibody is provided that comprises

[0206] In one embodiment, the present invention A CDR-L1 comprising SEQ ID NO: 8 or SEQ ID NO: 70, A CDR-L2 comprising SEQ ID NO: 9 or SEQ ID NO: 71, and A CDR-L3 comprising SEQ ID NO: 10 or SEQ ID NO: 72 A light chain variable region comprising, and A CDR-H1 comprising SEQ ID NO: 11 or SEQ ID NO: 73, A CDR-H2 comprising SEQ ID NO: 12 or SEQ ID NO: 74, and A CDR-H3 comprising SEQ ID NO: 13 or SEQ ID NO: 75 A heavy chain variable region comprising, and an antigen-binding domain that binds to IL22 and comprises A CDR-L1 comprising SEQ ID NO: 22, A CDR-L2 comprising SEQ ID NO: 23, and A CDR-L3 comprising SEQ ID NO: 24 A light chain variable region comprising, and A CDR-H1 comprising SEQ ID NO: 25, A CDR-H2 comprising SEQ ID NO: 26, and A CDR-H3 comprising SEQ ID NO: 27 A heavy chain variable region comprising, and an antigen-binding domain that binds to IL13 and comprises <000​​​​​​​​​​​​​​​​​​​

[0208] In certain embodiments, the present invention is (i) an antigen-binding domain that binds to IL22, wherein the antigen-binding domain is A light chain containing the sequence shown in Sequence ID No. 18, and A Fab containing a heavy chain with the sequence shown in Sequence ID No. 20, comprising an antigen-binding domain that binds to IL22, (ii) an antigen-binding domain that binds to IL13, wherein the antigen-binding domain is scFv containing the sequence indicated by sequence number 36, or dsscFv containing the sequence shown in Sequence ID No. 38, an antigen-binding domain that binds to IL13, This provides multispecific antibodies, including those mentioned above.

[0209] Multispecific antibody format The present invention also provides multispecific antibodies that bind to IL13 and IL22. a) Equation (I): V H -CH1-(CH 2)s -(CH 3)t -X-(V1) p (I) The polypeptide chain and b) Formula (II): (V3) r -ZV L -C L -Y-(V2) q (II) A polypeptide chain and, including or consisting thereof, During the ceremony, V H This represents the heavy chain variable domain; CH1 represents domain 1 of the heavy chain constant region; CH2 represents domain 2 of the heavy chain constant region; CH3 represents domain 3 of the heavy chain constant region; X represents a linker or connector; V1 represents dsscFv, dsFv, scFv, VH, VL, or VHH; V3 represents dsscFv, dsFv, scFv, VH, VL, or VHH; Z represents a linker or bond; V L This represents the light chain variable domain; C L This represents a domain derived from the light chain constant region, such as Ckappa; Y represents a linker or bond; V2 represents dsscFv, dsFv, scFv, VH, VL, or VHH; p represents either 0 or 1; q represents either 0 or 1; r represents either 0 or 1; 's' represents either 0 or 1; t represents either 0 or 1; In the equation, if p is 0, X does not exist; if q is 0, Y does not exist; if r is 0, Z does not exist; and In the equation, if q is 0, then r is 1, and if r is 0, then q is 1; and In the formula, both q and r are 1, and one of V2 and V3 is V L In that case, only one of V2 or V3 is V L That is the case.

[0210] In one embodiment, the polypeptide chain of formula (I) includes an A protein-binding domain, while the polypeptide chain of formula (II) does not bind to the A protein.

[0211] In one embodiment, when s is 0 and t is 0, the multispecific antibodies according to this disclosure are provided as dimers of heavy chains and light chains of formulas (I) and (II), respectively, and V H -CH1 section is V L -C L Together with the portion, it forms a functional Fab or Fab' fragment.

[0212] In one embodiment, when s is 1 and t is 1, the multispecific antibody according to the present disclosure is provided as a dimer of two heavy chains and two light chains of formulas (I) and (II), respectively, wherein the two heavy chains are linked by interchain interactions, particularly at the CH2-CH3 level, and the V of each heavy chain H -The CH1 portion is V of each light chain L -C L Together with the parts, they form a functional Fab or Fab' fragment. In such embodiments, two V H -CH1-CH2-CH3 section consists of two V L -C L Together with the portion, it forms a functional full-length antibody. In such embodiments, the full-length antibody may include a functional Fc region.

[0213] V H represents a heavy chain variable domain. In one embodiment, V H It is humanized. In one embodiment, V H It is completely human.

[0214] V L represents a light chain variable domain. In one embodiment, V L It is humanized. In one embodiment, V L It is completely human.

[0215] Generally, V H and V L These together form an antigen-binding domain. In one embodiment, V H and V L These organisms form congeners. In one example, the congeners cooperatively bind to the antigen.

[0216] The variable regions used in this disclosure will generally be derived from antibodies that can be produced by any method known in the art.

[0217] V H and V LThe variable region used in the present invention as described herein may be from any suitable source, for example, a fully human or humanized one.

[0218] In one embodiment, V H and V L The binding domain formed by this process is specific to the first antigen.

[0219] In one embodiment, the binding domain of V1 is specific to the second antigen.

[0220] In one embodiment, the binding domain of V2 is specific to a second or third antigen.

[0221] In one embodiment, the binding domain of V3 is specific to a third or fourth antigen.

[0222] In one embodiment, V H -V L If present, each of V1, V2, and V3 binds separately to its respective antigen.

[0223] In one embodiment, the CH1 domain is a naturally occurring domain 1 or a derivative thereof derived from the antibody heavy chain. In one embodiment, the CH2 domain is a naturally occurring domain 2 or a derivative thereof derived from the antibody heavy chain. In one embodiment, the CH3 domain is a naturally occurring domain 3 or a derivative thereof derived from the antibody heavy chain.

[0224] In one embodiment, C in the light chain L The fragment is a constant kappa sequence or a derivative thereof. In one embodiment, C in the light chain L A fragment is a stationary lambda sequence or a derivative thereof.

[0225] As used herein, derivatives of naturally occurring domains are intended to mean that at least one amino acid in the naturally occurring sequence has been substituted or deleted in order to optimize the properties of the domain, for example, by eliminating undesirable properties, but the characteristic properties of the domain are retained. In one embodiment, a derivative of a naturally occurring domain contains 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid substitutions or deletions compared to the naturally occurring sequence.

[0226] In one embodiment, one or more natural or manipulated interchain (i.e., between light and heavy chains) disulfide bonds are present in the functional Fab or Fab' fragment.

[0227] In one embodiment, CH1 and C in the polypeptide chains of formulas (I) and (II) L A "natural" disulfide bond exists between them.

[0228] When the CL domain is derived from either kappa or lambda, the native position of the cysteine-forming bond is 214 in human cKappa and cLambda (Kabat numbering, 4th edition, 1987).

[0229] The exact location of the disulfide bond forming cysteine ​​in CH1 depends on the specific domain actually used. For example, in human gamma-1, the native location of the disulfide bond is at position 233 (Kabat numbering). The locations of the cysteine-forming bonds in other human isotypes such as gamma-2, 3, 4, IgM, and IgD are known, for example, position 127 for human IgM, IgE, IgG2, IgG3, and IgG4, and position 128 in the heavy chain of human IgD and IgA2B.

[0230] Depending on the case, the V of polypeptides of formulas I and II H and V L A disulfide bond may exist between them.

[0231] In one embodiment, the multispecific antibody according to this disclosure comprises CH1 and C L It has a disulfide bond between it and the naturally occurring one at a position equivalent to or corresponding to that of a naturally occurring bond.

[0232] In one embodiment, a steady-state region including CH1 and C L These constant regions have disulfide bonds at positions that do not exist naturally. This can be manipulated in the molecule by introducing cysteine(s) at the desired one or more positions into the amino acid chain. This unnatural disulfide bond is CH1 and C L In addition to, or as a substitute for, the naturally occurring disulfide bonds between them. The cysteine(s) at the natural position can be replaced by amino acids such as serine that cannot form disulfide crosslinks.

[0233] The introduction of manipulated cysteine ​​can be carried out using any method known in the art. These methods include, but are not limited to, PCR extension duplication mutagenesis, site-directed mutagenesis, or cassette mutagenesis (see, in general, Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY, 1989; Ausbel et al., Current Protocols in Molecular Biology, Greene Publishing & Wiley-Interscience, NY, 1993). Site-directed mutagenesis kits, such as the QuikChange® site-directed mutagenesis kit (Stratagene, La Jolla, CA), are commercially available. Cassette mutagenesis can be carried out based on Wells et al., 1985, Gene, 34:315-323. Alternatively, mutants can be produced by annealing, ligation and PCR amplification, and whole gene synthesis by cloning of duplicate oligonucleotides.

[0234] In one embodiment, CH1 and C L Disulfide bonds between the molecules are completely absent, and for example, the interchain cysteine ​​may be replaced with another amino acid such as serine. Thus, in one embodiment, there are no interchain disulfide bonds in the functional Fab fragment of the molecule. Disclosures such as International Publication 2005 / 003170, incorporated herein by reference, describe methods for providing Fab fragments without interchain disulfide bonds.

[0235] Preferred antibody formats for use in the present invention include, for example, IgG and Fab, in which a complete IgG or Fab fragment is manipulated by adding at least one additional antigen-binding domain (e.g., one, two, three, or four further antigen-binding domains), such as a single-domain antibody (e.g., VH or VL, or VHH), scFv, dsscFv, or dsFv to the N-terminus and / or C-terminus of the light chain of the IgG or Fab, and optionally to the heavy chain of the IgG or Fab, respectively, as described in International Publication Nos. 2009 / 040562, 2010035012, 2011 / 030107, 2011 / 061492, 2011 / 061246, and 2011 / 086091, for example, a single-domain antibody (e.g., VH or VL, or VHH), scFv, dsscFv, or dsFv to the N-terminus and / or C-terminus of the light chain of the IgG or Fab, and optionally to the heavy chain of the IgG or Fab. In particular, the Fab-Fv format was first disclosed in International Publication No. 2009 / 040562, and its disulfide-stabilized version, Fab-dsFv, was first disclosed in International Publication No. 2010 / 035012. Single-linker Fab-dsFv, which is linked to Fab via a single linker between the VL or VH domain of Fv and the C-terminus of the LC of Fab, was first disclosed in International Publication No. 2014 / 096390, incorporated herein by reference. Additive IgG, including full-length IgG manipulated by adding dsFv to the C-terminus of the light chain (and optionally to the heavy chain) of IgG, was first disclosed in International Publication No. 2015 / 197789, incorporated herein by reference.

[0236] Another preferred antibody format for use in the present invention comprises a Fab linked to two scFv or dsscFv, each scFv or dsscFv binding to the same or different targets (for example, one scFv or dsscFv binding to a therapeutic target and another scFv or dsscFv extending the half-life by binding to albumin, for example). Such antibody fragments are described in International Publication 2015 / 197772. Another preferred antibody for use in the fragments of the present invention comprises a Fab linked to just one scFv or dsscFv, as described in International Publication 2013 / 068571 and Dave et al., 2016, Mab, 8(7) 1319-1335, which are incorporated herein by reference.

[0237] If present, V1 represents dsscFv, dsFv, scFv, VH, VL, or VHH, for example, dsscFv, dsFv, or scFv.

[0238] If present, V2 represents dsscFv, dsFv, scFv, VH, VL, or VHH, for example, dsscFv, dsFv, or scFv.

[0239] If present, V3 represents dsscFv, dsFv, scFv, VH, VL, or VHH, for example, dsscFv, dsFv, or scFv.

[0240] If both V2 and V3 exist, only one of them can represent VL.

[0241] In one embodiment, if V1 and / or V2 and / or V3 are dsFv or dsscFv, the disulfide bond between the variable domains VH and VL of V1 and / or V2 and / or V3 lies between two of the residues listed below (Kabat numbering is used in the following list unless otherwise indicated in context). When Kabat numbering is referenced, the relevant reference is Kabat et al., 1991 (5th edition, Bethesda, Md.) in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA.

[0242] In one embodiment, the disulfide bond is located at a position selected from the group consisting of the following: ·V H 37+V L 95. For example, see Protein Science 6, 781-788 Zhu et al (1997); ·V H 44+V L 100, for example; see Weatherill et al., Protein Engineering, Design & Selection, 25(321-329), 2012; ·V H 44+V L 105, see, for example, J Biochem. 118, 825-831 Luo et al (1995); ·V H 45+V L 87. For example, see Protein Science 6, 781-788 Zhu et al (1997); ·V H 55+V L 101, see, for example, FEBS Letters 377 135-139 Young et al (1995); ·V H 100+V L50. See, for example, Biochemistry 29 1362-1367 Glockshuber et al (1990); ·V H 100b + V L 49. See, for example, Biochemistry 29 1362-1367 Glockshuber et al (1990); ·V H 98 + V L For 46, see, for example, Protein Science 6,781-788 Zhu et al (1997); ·V H 101 + V L 46. See, for example, Protein Science 6,781-788 Zhu et al (1997); ·V H 105 + V L 43. See, for example, Proc. Natl. Acad. Sci. USA Vol.90 pp.7538-7542 Brinkmann et al (1993); or Proteins 19,35-47 Jung et al (1994); ·V H 106 + V L 57. See, for example, FEBS Letters 377 135-139 Young et al (1995) and one or more positions corresponding thereto in the variable region pairs located within the molecule.

[0243] In one embodiment, the disulfide bond is at position V H between position 44 and position V L 100.

[0244] The above amino acid pairs are at positions that promote substitution by cysteine so as to be able to form a disulfide bond. Cysteine can be engineered to these desired positions by known techniques. Thus, in one embodiment, the engineered cysteine according to the present disclosure refers to the case where the naturally occurring residue at a given amino acid position is substituted with a cysteine residue.

[0245] The introduction of manipulated cysteine ​​can be carried out using any method known in the art. These methods include, but are not limited to, PCR extension duplication mutagenesis, site-directed mutagenesis, or cassette mutagenesis (see, in general, Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY, 1989; Ausbel et al., Current Protocols in Molecular Biology, Greene Publishing & Wiley-Interscience, NY, 1993). Site-directed mutagenesis kits, such as the QuikChange® site-directed mutagenesis kit (Stratagen, La Jolla, CA), are commercially available. Cassette mutagenesis can be carried out based on Wells et al., 1985, Gene, 34:315-323. Alternatively, mutants can be produced by annealing, ligation and PCR amplification, and whole gene synthesis by cloning of duplicate oligonucleotides.

[0246] Therefore, in one embodiment, when V1 and / or V2 and / or V3 are dsFv or dsscFv, the variable domains VH and VL of V1 and / or V2 and / or V3 may be linked by a disulfide bond between two cysteine ​​residues, and the positions of the cysteine ​​residue pairs are selected from the group consisting of VH37 and VL95, VH44 and VL100, VH44 and VL105, VH45 and VL87, VH100 and VL50, VH100b and VL49, VH98 and VL46, VH101 and VL46, VH105 and VL43 and VH106 and VL57.

[0247] In one embodiment, when V1 and / or V2 and / or V3 are dsFv or dsscFv, the variable domains VH and VL of V1 and / or V2 and / or V3 may be linked by a disulfide bond between two cysteine ​​residues outside the CDR, one in VH and one in VL, and the positions of the cysteine ​​residue pairs are selected from the group consisting of VH37 and VL95, VH44 and VL100, VH44 and VL105, VH45 and VL87, VH100 and VL50, VH98 and VL46, VH105 and VL43 and VH106 and VL57.

[0248] In one embodiment, if V1 is dsFv or dsscFv, the variable domains VH and VL of V1 are linked by a disulfide bond between two manipulated cysteine ​​residues, one at position VH44 and the other at position VL100. In one embodiment, if V2 is dsFv or dsscFv, the variable domains VH and VL of V2 are linked by a disulfide bond between two manipulated cysteine ​​residues, one at position VH44 and the other at position VL100. In one embodiment, if V3 is dsFv or dsscFv, the variable domains VH and VL of V3 are linked by a disulfide bond between two manipulated cysteine ​​residues, one at position VH44 and the other at position VL100.

[0249] In one embodiment, if V1 is dsscFv, dsFv, or scFv, the VH domain of V1 is bound to X.

[0250] In one embodiment, if V1 is dsscFv, dsFv, or scFv, the VL domain of V1 is bound to X.

[0251] In one embodiment, when V2 is dsscFv, dsFv, or scFv, the VH domain of V2 is bound to Y.

[0252] In one embodiment, when V2 is dsscFv, dsFv, or scFv, the VL domain of V2 is bound to Y.

[0253] In one embodiment, if V3 is dsscFv, dsFv, or scFv, the VH domain of V3 is bound to Z.

[0254] In one embodiment, if V3 is dsscFv, dsFv, or scFv, the VL domain of V3 is bound to Z.

[0255] Those skilled in the art will understand that if V1 and / or V2 and / or V3 represent dsFv, the multispecific antibody contains a third polypeptide encoding a corresponding free VH or VL domain that is not bound to X, Y, or Z. When V1 and V2, V2 and V3, or V1, V2, and V3 are dsFv, the "free variable domain" (i.e., the domain linked to the rest of the polypeptide via a disulfide bond) is common to both chains. Thus, while the actual variable domains fused to or linked to the polypeptide via X, Y, or Z may differ in each polypeptide chain, the free variable domains paired with them are generally identical to one another.

[0256] In some embodiments, p is 1. In some embodiments, p is 0. In some embodiments, q is 1. In some embodiments, q is 0 and r is 1. In some embodiments, r is 1. In some embodiments, q is 1 and r is 0. In some embodiments, q is 1 and r is 1. In some embodiments, s is 1. In some embodiments, s is 0. In some embodiments, t is 1. In some embodiments, t is 0. In some embodiments, s is 1 and t is 1. In some embodiments, s is 0 and t is 0.

[0257] In one embodiment, p is 1, q is 1, r is 0, s is 0, t is 0, and both V1 and V2 represent dsscFv.

[0258] Thus, in one aspect, provided is a multispecific antibody that binds to IL22 and IL13, a) a polypeptide chain of formula (Ia): V H -CH1-X-V1 (Ia) and b) a polypeptide chain of formula (IIa): V L -C L -Y-V2 (IIa) comprising or consisting of, wherein V H represents a heavy chain variable domain; CH1 represents domain 1 of the heavy chain constant region; X represents a linker or a binding moiety; Y represents a linker or a binding moiety; V1 represents an scFv, dsscFv, or dsFv; V L represents a light chain variable domain; C L represents a domain derived from the light chain constant region, e.g., Ckappa; V2 represents an scFv, dsscFv or dsFv; wherein at least one of V1 or V2 is a dsscFv or dsFv, a multispecific antibody.

[0259] In one embodiment, the polypeptide chain of formula (Ia) comprises an A protein binding domain, and the polypeptide chain of formula (IIa) does not bind to A protein.

[0260] In such embodiments, V2 does not bind to protein A; that is, the scFv, dsscFv, or dsFv of V2 does not contain a protein A binding domain. In one embodiment, V2, i.e., the scFv, dsscFv, or dsFv of V2, contains a VH1 domain. In another embodiment, V2, i.e., the scFv, dsscFv, or dsFv of V2, contains a VH3 domain that does not bind to protein A. In one embodiment, V2, i.e., the scFv, dsscFv, or dsFv of V2, contains a VH2 domain. In one embodiment, V2, i.e., the scFv, dsscFv, or dsFv of V2, contains a VH4 domain. In one embodiment, V2, i.e., the scFv, dsscFv, or dsFv of V2, contains a VH5 domain. In one embodiment, V2, i.e., the scFv, dsscFv, or dsFv of V2, contains a VH6 domain. In one embodiment, the polypeptide chain of formula (Ia) is V H Or it contains only one A protein-binding domain present in V1. In one embodiment, the polypeptide chain of formula (Ia) contains only one A protein-binding domain present in V1. In another embodiment, the polypeptide chain of formula (Ia) each contains V H It also contains two A protein-binding domains present in V1.

[0261] In another embodiment, p is 0, q is 1, r is 0, s is 1, t is 1, and V2 is dsscFv. Therefore, in one embodiment, what is provided is a multispecific antibody that binds to IL22 and IL13, a) Equation (Ib): V H -CH1-CH2-CH3(Ib) The polypeptide chain and b) Equation (IIb): V L -C L -Y-V2(IIb) A polypeptide chain and, including or consisting thereof, During the ceremony, V H This represents the heavy chain variable domain; CH1 represents domain 1 of the heavy chain constant region; CH2 represents domain 2 of the heavy chain constant region; CH3 represents domain 3 of the heavy chain constant region; Y represents a linker or bond; V L This represents the light chain variable domain; C L This represents a domain derived from the light chain constant region, such as Ckappa; V2 is a multispecific antibody representing dsscFv.

[0262] In one embodiment, the polypeptide chain of formula (Ib) includes an A protein-binding domain, while the polypeptide chain of formula (IIb) does not bind to the A protein.

[0263] In such embodiments, V2 does not bind to protein A, i.e., the dsscFv of V2 does not contain a protein A binding domain. In one embodiment, V2, i.e., the dsscFv of V2, contains a VH1 domain. In another embodiment, V2, i.e., the dsscFv of V2, contains a VH3 domain that does not bind to protein A. In one embodiment, the polypeptide chain of formula (Ib) is V H Alternatively, it may contain only one A protein-binding domain located at CH2-CH3. In another embodiment, the polypeptide chain of formula (Ib) is V H It also contains two A protein-binding domains located at CH2-CH3.

[0264] In another embodiment, p is 0, q is 1, r is 0, s is 1, t is 1, and V2 is dsFv. Therefore, in one embodiment, a multispecific antibody that binds to IL22 and IL13 is provided. a) Equation (Ic): V H -CH1-CH2-CH3(Ic) The polypeptide chain and b) Formula (IIc): V L -C L -Y-V2(IIc) A polypeptide chain and, including or consisting thereof, During the ceremony, V H This represents the heavy chain variable domain; CH1 represents domain 1 of the heavy chain constant region; CH2 represents domain 2 of the heavy chain constant region; CH3 represents domain 3 of the heavy chain constant region; Y represents a linker or bond; V L This represents the light chain variable domain; C L This represents a domain derived from the light chain constant region, such as Ckappa; V2 is a multispecific antibody representing dsFv.

[0265] In one embodiment, the polypeptide chain of formula (Ic) includes an A protein-binding domain, while the polypeptide chain of formula (IIc) does not bind to the A protein.

[0266] In such embodiments, V2, i.e., the dsFv of V2, does not bind to protein A. In one embodiment, the polypeptide chain of formula (Ic) is V H Alternatively, it contains a single A protein-binding domain located at CH2-CH3. In another embodiment, the polypeptide chain of formula (Ic) is V H It also contains two A protein-binding domains located at CH2-CH3.

[0267] In another embodiment, p is 0, q is 0, r is 1, s is 1, t is 1, and V3 is dsscFv.

[0268] Therefore, in one embodiment, what is provided is a multispecific antibody that binds to IL22 and IL13, a) Equation (Id): V H -CH1-CH2-CH3(Id) The polypeptide chain and b) Formula (IId): V3-ZV L-C L (IId) A polypeptide chain and, including or consisting thereof, During the ceremony, V H This represents the heavy chain variable domain; CH1 represents domain 1 of the heavy chain constant region; CH2 represents domain 2 of the heavy chain constant region; CH3 represents domain 3 of the heavy chain constant region; Z represents a linker or bond; V L This represents the light chain variable domain; C L This represents a domain derived from the light chain constant region, such as Ckappa; V3 is a multispecific antibody representing dsscFv.

[0269] In one embodiment, the polypeptide chain of formula (Id) includes an A protein-binding domain, while the polypeptide chain of formula (IId) does not bind to the A protein.

[0270] In such embodiments, V3, i.e., dsscFv of V3, does not bind to protein A. In one embodiment, the polypeptide chain of formula (Id) is V H Alternatively, it contains a single A protein-binding domain located at CH2-CH3. In another embodiment, the polypeptide chain of formula (Id) is V H It also contains two A protein-binding domains located at CH2-CH3.

[0271] In one embodiment of the multispecific antibody of the present invention, V L and V H It contains an antigen-binding domain that binds to IL22, V2 contains an antigen-binding domain that binds to IL13.

[0272] In another embodiment of the multispecific antibody of the present invention, V L and V HIt contains an antigen-binding domain that binds to IL22, V1 contains an antigen-binding domain that binds to serum albumin. V2 contains an antigen-binding domain that binds to IL13.

[0273] Table 4. Summary of sequences of IL22, IL13, and albumin antigen-binding domains. [Table 4]

[0274] In one embodiment, V L teeth, CDR-L1 containing sequence number 8, CDR-L2 containing sequence number 9, and Includes CDR-L3 containing sequence number 10, and V H teeth, CDR-H1 containing sequence number 11, CDR-H2 containing Sequence ID No. 12, and Includes CDR-H3 containing sequence number 13.

[0275] In one embodiment, V1 is CDR-L1 containing sequence number 40, CDR-L2 containing sequence number 41, and CDR-L3 containing Sequence ID No. 42 A light chain variable region including, CDR-H1 containing sequence number 43, CDR-H2 containing Sequence ID 44, and CDR-H3 containing sequence number 45 A heavy chain variable region including and including.

[0276] In one embodiment, V2 is CDR-L1 containing sequence number 22, CDR-L2 containing Sequence ID No. 23, and CDR-L3 containing Sequence ID No. 24 A light chain variable region including, CDR-H1 containing sequence number 25, CDR-H2 containing Sequence ID No. 26, and CDR-H3 containing sequence number 27 A heavy chain variable region including and including.

[0277] In one embodiment, V L This includes the sequence shown in sequence number 14, V H This includes the sequence shown in sequence number 16.

[0278] In one embodiment, V1 includes a light chain variable region containing the sequence shown in sequence number 46, and a heavy chain variable region containing the sequence shown in sequence number 47.

[0279] In an alternative embodiment, V1 includes a light chain variable region containing the sequence shown in SEQ ID NO: 50 and a heavy chain variable region containing the sequence shown in SEQ ID NO: 51.

[0280] In one embodiment, the light chain variable region and the heavy chain variable region of V1 are connected by a linker, the linker including the arrangement shown in sequence number 69.

[0281] In one embodiment, V1 is an scFv containing the sequence shown in sequence number 54, or a dsscFv containing the sequence shown in sequence number 56.

[0282] In one embodiment, V2 includes a light chain variable region containing the sequence shown in sequence number 28 and a heavy chain variable region containing the sequence shown in sequence number 29.

[0283] In an alternative embodiment, V2 includes a light chain variable region containing the sequence shown in SEQ ID NO: 28 or 32, and a heavy chain variable region containing the sequence shown in SEQ ID NO: 29 or 33.

[0284] In one embodiment, the light chain variable region and the heavy chain variable region of V2 are connected by a linker, the linker having the arrangement shown in sequence number 67.

[0285] In one embodiment, V2 is an scFv containing the sequence shown in sequence number 36, or a dsscFv containing the sequence shown in sequence number 38.

[0286] In one embodiment, X is a linker containing the sequence shown in sequence number 68.

[0287] In one embodiment, Y is a linker containing the sequence shown in sequence number 66.

[0288] In one embodiment, the polypeptide chain of formula (Ia) includes the sequence shown in SEQ ID NO: 58 or SEQ ID NO: 60.

[0289] In one embodiment, the polypeptide chain of formula (IIa) includes the sequence shown in SEQ ID NO: 62 or SEQ ID NO: 64.

[0290] In one embodiment, the polypeptide chain of formula (Ia) includes the sequence shown in SEQ ID NO: 60, and the polypeptide chain of formula (IIa) includes the sequence shown in SEQ ID NO: 64. Knobs-in-holes bi-specific format

[0291] In one embodiment, the present invention provides a multispecific antibody that binds to IL22 and IL13, comprising at least two polypeptides, each polypeptide comprising a CH3 domain ("CH3 polypeptide").

[0292] Knobs-in-holes technology relies on modifying the interface between two CH3 domains of two CH3 polypeptides, for example, the two heavy chains of an antibody. A bulky residue is introduced into the CH3 domain of one CH3 polypeptide, forming a protrusion ("knob"), and a cavity (or "hole") is formed in the second CH3 polypeptide that can accommodate this bulky residue. Thus, manipulating knob and hole mutations at the interface of two CH3 polypeptides facilitates the interaction between the first and second CH3 polypeptides.

[0293] A "projection" is constructed by replacing a small amino acid side chain from the interface of the first CH3 polypeptide with a larger side chain (e.g., tyrosine or tryptophan). Compensatory "cavities" of the same or similar size as the projection are created on the interface of the second CH3 polypeptide, sometimes by replacing a larger amino acid side chain with a smaller one (e.g., alanine or threonine). If a properly positioned and sized projection or cavity exists at the interface of either the first or second CH3 polypeptide, the corresponding cavity or projection only needs to be manipulated at the adjacent interface, respectively.

[0294] The resulting heterodimer Fc region can be further stabilized by the introduction / formation of artificial disulfide crosslinks. Disulfide bonds that do not exist naturally are constructed by substituting naturally occurring amino acids on the first CH3 polypeptide with free thiol-containing residues such as cysteine, so that a free thiol interacts with another free thiol-containing residue on the second CH3 polypeptide to form a disulfide bond between the first and second CH3 polypeptides.

[0295] The following substitutions, which result in appropriately separated cysteine ​​residues for forming new intrachain disulfide bonds in the individual heavy chains of the Fc region of subclass IgG1 IgG antibodies, have been found to increase heterodimerization: Y349C on one chain and S354C on the other; Y349C on one chain and E356C on the other; Y349C on one chain and E357C on the other; L351C on one chain and S354C on the other; T394C on one chain and E397C on the other; or D399C on one chain and K392C on the other (residue numbering according to the Kabat EU index numbering system).

[0296] In one embodiment, the CH3 polypeptide is the heavy chain of the antibody. In one embodiment, the multispecific antibody is a bispecific full-length immunoglobulin (Ig), e.g., IgG, containing two heavy chains, where at least one CH3 domain of the two heavy chains is manipulated using the Knobs-in-holes technique, and each heavy chain, paired with a light chain, forms an antigen-binding domain. In such embodiments, each antigen-binding domain formed by the pair of heavy and light chains binds to distinct epitopes on the same or different antigens. A heavy chain manipulated to introduce a knob may be called a “knob chain.” A heavy chain manipulated to introduce a complementary pore may be called a “hole chain.”

[0297] In one embodiment, the multispecific antibody of the present invention includes one of the knob and hole mutation (substitution) combinations listed in Table 5 (residue numbering by the EU Index Numbering System). Alternatively, the knob and hole mutation can be introduced into one heavy chain, and the complementary knob and hole mutation can be introduced into a second heavy chain.

[0298] Table 5. Exemplary knob and hole mutations (substitutions). Numbering follows EU conventions. [Table 5]

[0299] In one embodiment, the antibody for use in the present invention comprises knob substitutions T366W and Y349C (i.e., knob chains) in the heavy chain and hole substitutions T366S, L368A, Y407V and E356C (i.e., hole chains) in the secondary heavy chain.

[0300] Mutations can be introduced into the constant domains of the heavy or light chain by methods well known in the art, for example, by site-directed mutagenesis.

[0301] In one embodiment, the light chains of a bispecific antibody are identical to each other, with the first heavy chain and first light chain forming a binding domain that binds to a first antigen, and the second heavy chain and second light chain forming a binding domain that binds to a different antigen. In such embodiments, host cells can be co-transfected with one or more vectors containing nucleic acids encoding a whole heavy chain, a knob heavy chain, and a common light chain. A method for preparing a bispecific antibody containing two common light chains is described, for example, in U.S. Patent No. 9409989.

[0302] In another embodiment, a multispecific antibody manipulated with the Knobs-in-holes technique contains two different light chains.

[0303] Methods for preparing bispecific antibodies manipulated by knobs-in-holes technology, comprising two antibody heavy chains and two different light chains, where each heavy chain pairs with a light chain to form a different antigen-binding domain, are described, for example, in International Publication No. 11133886, International Publication No. 2013 / 055958, and International Publication No. 2015 / 171822.

[0304] More specifically, the present invention relates to a multispecific antibody that binds to IL22 and IL13, a) Equation (III): VH1-CH1-CH2-CH3(III) The polypeptide chain and b) Formula (IV): VL1-C L (IV) The polypeptide chain and c) Formula (V): VH2-CH1-CH2-CH3(V) The polypeptide chain and d) Equation (VI): VL2-C L (VI) A polypeptide chain and, including or consisting thereof, During the ceremony, VH1 and VH2 represent heavy chain variable domains; CH1 represents domain 1 of the heavy chain constant region; CH2 represents domain 2 of the heavy chain constant region; CH3 represents domain 3 of the heavy chain constant region; VL1 and VL1 represent light chain variable domains; C L This represents a domain derived from the light chain constant region, such as Ckappa; In the formula, VH1 and VL1 include an IL22 binding domain, VH2 and VL2 include an IL13 binding domain, and the CH3 domain of the polypeptides of formulas III and V includes one or more substitutions listed in Table 5, thereby providing a multispecific antibody.

[0305] In one embodiment, the antibody of the present invention comprises a knob-substituted T366W (i.e., polypeptide of formula III or V) in the heavy chain and a hole-substituted T366S, L368A, or Y407V (i.e., polypeptides of formula V or III, respectively) in the secondary heavy chain.

[0306] In one embodiment, VL1 is CDR-L1 containing sequence number 8, CDR-L2 containing sequence number 9, and Includes CDR-L3 containing sequence number 10, Furthermore, VH1 is, CDR-H1 containing sequence number 11, CDR-H2 containing Sequence ID No. 12, and Includes CDR-H3 containing sequence number 13.

[0307] In one embodiment, VL2 is CDR-L1 containing sequence number 22, CDR-L2 containing Sequence ID No. 23, and Includes CDR-L3 containing Sequence ID No. 24, Furthermore, VH2 is, CDR-H1 containing sequence number 25, CDR-H2 containing Sequence ID No. 26, and Includes CDR-H3 containing sequence number 27.

[0308] In one embodiment, the polypeptide chain of formula (III) includes the sequence shown in sequence number 144, the polypeptide chain of formula (IV) includes the sequence shown in sequence number 142, the polypeptide chain of formula (V) includes the sequence shown in sequence number 152, and the polypeptide chain of formula (VI) includes the sequence shown in sequence number 148.

[0309] In one embodiment, the polypeptide chain of formula (III) includes the sequence shown in sequence number 146, the polypeptide chain of formula (IV) includes the sequence shown in sequence number 142, the polypeptide chain of formula (V) includes the sequence shown in sequence number 150, and the polypeptide chain of formula (VI) includes the sequence shown in sequence number 148. Functional properties of antibodies

[0310] The multispecific antibody according to the present invention comprises at least two antigen-binding domains, one of which binds to IL13 and the second antigen-binding domain binds to IL22. More specifically, such a multispecific antibody can bind to human and cynomolgus monkey IL22 and IL13.

[0311] The composition according to the present invention comprises an antibody containing an antigen-binding domain that binds to IL22, and an antibody containing an antigen-binding domain that binds to IL13. More specifically, the antigen-binding domain that binds to IL22 can bind to human and cynomolgus monkey IL22, and the antigen-binding domain that binds to IL13 can bind to human and cynomolgus monkey IL13.

[0312] The IL13 binding domain is i. It binds to IL13, preventing the binding of IL13Rα1, and consequently blocking subsequent interactions with IL4R; or ii. It binds to IL13 in a way that allows it to bind to IL13Rα1, but prevents the recruitment of IL4R to the complex.

[0313] The IL22 binding domain is i. To bind to IL22 and prevent IL22 from binding to IL22R1; or ii. It binds to IL22, but enables IL22R1 to bind to IL22.

[0314] Preferably, the antibodies are specific to those antigens.

[0315] The properties described herein with respect to antigen-binding domains also apply to antibodies, including multispecific antibodies containing those domains.

[0316] The antibody of the present invention is a neutralizing antibody.

[0317] Preferably, the IL22-binding domain neutralizes one or more IL22 activities. In particular, the IL22-binding domain can neutralize IL22 bound to IL22 receptor 1 (IL22R1). The IL22-binding domain binds to IL22 and inhibits the binding of IL22 to IL22-binding proteins (IL22RA2 or IL22BP). Preferably, the IL22-binding domain can neutralize IL22 bound to IL22 receptor 1 (IL22R1) and IL22-binding proteins (IL22RA2).

[0318] The IL22 binding domain binds to the same region on IL22 as IL22R1. In one particular embodiment of the IL22 binding domain, the present invention provides an IL22 binding domain that binds to a region on IL22 such that the binding sterically blocks the interaction between IL22 and IL22R1.

[0319] In one embodiment, the IL22-binding domain according to the present invention binds to IL22 that is not bound to an IL22-binding protein ("free IL22"). In another embodiment, the IL22-binding domain binds to IL22 and prevents IL22 from binding to an IL22-binding protein.

[0320] Preferably, the IL13-binding domain neutralizes one or more IL13 activities. The IL13-binding domain also inhibits the interaction between IL13 and IL13R-alpha-1 and IL13R-alpha-2. The IL13-binding domain binds to IL13 and prevents the binding of IL13R-α1, and as a result, also blocks the binding of IL-4R. In one example, the IL13-binding domain binds to IL13 and blocks the interaction between IL13 and IL13R-alpha-1 and / or IL13R-alpha-2. Inhibition of IL13 binding to IL13R-alpha-1 prevents the formation of the IL13 / IL13R-alpha-1 / IL4R-alpha receptor complex. In one example, the IL13-binding domain allows IL13 to bind to IL13R-alpha-1 but blocks the binding of IL4R-alpha, preventing the formation of the receptor complex.

[0321] In one embodiment, the IL22-binding domain has a stronger binding affinity to IL22 compared to IL22R1. This is characterized by a dissociation constant (KD) at IL22 that is at least 10 times higher than that of IL22R1 or IL22BP. Specifically, this is measured using BIACore technique.

[0322] The IL22-binding domain binds to IL22 with sufficient affinity and specificity. In certain embodiments, the IL22-binding domain is present in concentrations of approximately 1 μM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, or 0.001 nM (e.g., 10 -8 M or less, for example, 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 The IL22-binding domain according to the present invention binds to human IL22 with a KD of less than 100 pM.

[0323] In certain embodiments, the IL22 binding domain is approximately 1 μM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, or 0.001 nM (e.g., 10 -8 M or less, for example, 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 The IL22-binding domain binds to cynomolgus monkey IL22 with any one of the KD values ​​(M), including any range between these values. In one embodiment, the IL22-binding domain binds to cynomolgus monkey IL22 with a KD of less than 100 pM.

[0324] In certain embodiments, the IL13 binding domain is approximately 1 μM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, or 0.001 nM (e.g., 10 -8 M or less, for example, 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 The IL13-binding domain according to the present invention binds to human IL13 with a KD of less than 100 pM.

[0325] In certain embodiments, the IL13 binding domain is approximately 1 μM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, or 0.001 nM (e.g., 10 -8 M or less, for example, 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 The IL13-binding domain binds to cynomolgus monkey IL13 with any one of the KD values ​​(M), including any range between these values. In one embodiment, the IL13-binding domain binds to cynomolgus monkey IL13 with a KD of less than 250 pM.

[0326] Those skilled in the art will understand that the KD value can vary depending on the antibody format and overall structure. For example, the KD of the antigen-binding domain can vary in the context of multispecific antibodies.

[0327] The multispecific antibodies and compositions of the present invention can also inhibit IL-10 release in cells.

[0328] As demonstrated by previous examples, the IL22-binding domain can inhibit the proliferation and differentiation of IL22-mediated keratinocytes.

[0329] The multispecific antibody of the present invention exhibits dose-dependent inhibition of the IL13 biomarker (eotaxin-3) and the IL22-dependent biomarker (S100A7).

[0330] The multispecific antibody of the present invention can simultaneously bind to either human or cynomolgus monkey IL22 and IL13. In one embodiment, the multispecific antibody includes an additional antigen-binding domain that binds to albumin and can simultaneously bind to either human or cynomolgus monkey IL22, IL13 and albumin.

[0331] Therefore, the multispecific antibodies of the present invention act in a manner similar to compositions containing antibodies that bind to IL13 and antibodies that bind to IL22.

[0332] The affinity of an antibody, and the degree to which it inhibits binding, can be determined by those skilled in the art using conventional techniques, such as those described in Scatchard et al. (Ann.KY.Acad.Sci.51:660-672 (1949)), or by surface plasmon resonance (SPR) using systems such as BIAcore. In surface plasmon resonance, the target molecule is immobilized on a solid phase and exposed to a ligand in a mobile phase moving along a flow cell. When the ligand binds to the immobilized target, the local refractive index changes, changing the SPR angle, which can be monitored in real time by detecting the change in the intensity of the reflected light. By analyzing the rate of change of the SPR signal, the apparent rate constants of the association and dissociation phases of the binding reaction can be obtained. The ratio of these values ​​gives the apparent equilibrium constant (affinity) (see, for example, Wolff et al., Cancer Res.53:2560-65 (1993)). Epitopes and antibodies that bind to the same epitope

[0333] The antibody may compete for or bind to the same epitopes as defined above with respect to the light chain, heavy chain, light chain variable region (LCVR), heavy chain variable region (HCVR), or CDR sequence for binding to IL22 and / or IL13.

[0334] The antibody may compete for binding to IL22 with or bind to the same epitope as the multispecific antibody containing the combination of CDR-L1 / CDR-L2 / CDR-L3 / CDR-H1 / CDR-H2 / CDR-H3 sequences of SEQ ID NOs. 8 / 9 / 10 / 11 / 12 / 13.

[0335] The antibody may compete for binding to IL13 with multispecific antibodies containing combinations of CDR-L1 / CDR-L2 / CDR-L3 / CDR-H1 / CDR-H2 / CDR-H3 sequences of SEQ ID NOs. 22 / 23 / 24 / 25 / 26 / 27, or it may bind to the same epitope a.

[0336] The antibodies may compete for binding to serum albumin with multispecific antibodies containing combinations of CDR-L1 / CDR-L2 / CDR-L3 / CDR-H1 / CDR-H2 / CDR-H3 sequences of SEQ ID NOs. 40 / 41 / 42 / 43 / 44 / 45, or they may bind to the same epitopes.

[0337] The antibody may compete for binding to IL22 with or bind to the same epitope as the multispecific antibody containing the LCVR and HCVR sequence pairs of SEQ ID NOs. 14 / 16 or 76 / 78. The antibody may compete for binding to IL22 with or bind to the same epitope as the Fab containing a light chain with the sequence shown in SEQ ID NOs. 18 and a heavy chain with the sequence shown in SEQ ID NOs. 20.

[0338] Therefore, in one embodiment, the IL22-binding domain binds to an epitope on IL22, the epitope containing one or more residues of the polypeptide VRLIGEKLFHGVSM (SEQ ID NO: 155) corresponding to residues 72-85 of the amino acid sequence of IL22 as defined by SEQ ID NO: 1. More specifically, the antibody binds to at least one, at least two, at least three, at least five, at least eight, at least ten, or all of the residues selected from residues 72-85 of the amino acid sequence of IL22 as defined by SEQ ID NO: 1. More specifically, the IL22-binding domain binds to the polypeptide VRLIGEKLFHGVSM (SEQ ID NO: 155) corresponding to residues 72-85 of the amino acid sequence of IL22 as defined by SEQ ID NO: 1.

[0339] In one embodiment, the IL22-binding domain binds to an epitope on IL22, the epitope comprising at least one, at least two, at least three, at least five, at least eight, at least ten, or all of the residues selected from the list consisting of Gln48, Glu77, Phe80, His81, Gly82, Val83, Ser84, Met85, Arg88, Leu169, Met172, Ser173, Arg175, Asn176, and Ile179 of human IL22 (SEQ ID NO: 1) as measured at a contact distance of less than 4 Å. More specifically, the IL22-binding domain binds to an epitope on IL22, which, when determined by a contact distance of less than 5 Å between the antibody and IL22, includes at least one, at least two, at least three, at least five, at least eight, at least ten, or all of the residues selected from the list consisting of Lys44, Phe47, Gln48, Ile75, Gly76, Glu77, Phe80, His81, Gly82, Val83, Ser84, Met85, Ser86, Arg88, Leu169, Met172, Ser173, Arg175, Asn176, and Ile179 of human IL22 (SEQ ID NO: 1).

[0340] In particular, the antibody may compete for binding to IL22 with or bind to the same epitopes as antibodies containing the heavy and light chain residues listed in Table 6 or 7 below. More specifically, the antibody contains a CDR-H3 sequence containing the residues defined in Table 7 and preferably binds to the epitopes on IL22 as defined above. More specifically, the antibody of the present invention contains CDR-H1, CDR-H2, and CDR-H3 residues as defined in Table 6 or 7 and binds to the epitopes on IL22 as defined above.

[0341] Table 6. Amino acids (11041) of the light and heavy chains of the IL22-binding domain of the present invention involved in interaction with IL22, where the contact distance between the antibody and IL22 is 4 Å or less. The positions of the residues correspond to SEQ ID NO: 14 for the light chain and SEQ ID NO: 16 for the heavy chain (sequential numbering). [Table 6]

[0342] Table 7. Amino acids (11041) of the light and heavy chains of the IL22-binding domain of the present invention involved in interaction with IL22, where the contact distance between the antibody and IL22 is 5 Å or less. The positions of the residues correspond to SEQ ID NO: 14 for the light chain and SEQ ID NO: 16 for the heavy chain (sequential numbering). [Table 7]

[0343] More specifically, the multispecific antibody of the present invention binds to an epitope on human IL22 as defined above, and the antibody prevents IL22 from binding to IL22R1 and IL22RA2. More specifically, the light chain of the antibody sterically prevents the binding of IL22R1 to IL22.

[0344] The epitopes can be identified in combination with any of the antibodies provided by the present invention by any suitable binding site mapping method known in the art. Examples of such methods include screening peptides of various lengths derived from the full-length target protein for binding to the antibodies of the present invention, and identifying fragments that can specifically bind to the antibody containing the sequence of the epitope recognized by the antibody. The target peptides can be produced synthetically. The peptides that bind to the antibody can be identified, for example, by mass spectrometry. In another example, the epitopes to which the antibodies of the present invention bind can be identified using NMR spectroscopy or X-ray crystallography. Typically, when epitope determination is performed by X-ray crystallography, amino acid residues of the antigen within 4 Å of the CDR are considered to be the amino acid residue portion of the epitope. Once identified, the epitopes can be used to prepare fragments that bind to the antibodies of the present invention and, if necessary, can be used as immunogens to obtain further antibodies that bind to the same epitope.

[0345] In one embodiment, the antibody epitope is determined by X-ray crystallography.

[0346] Whether an antibody binds to the same epitope as the reference antibody, or competes for binding with the reference antibody, can be easily determined using routine methods known in the art. For example, to determine whether a test antibody binds to the same epitope as the reference antibody of the present invention, the reference antibody is bound to a protein or peptide under saturated conditions. The ability of the test antibody to bind to the protein or peptide is then evaluated. If the test antibody can bind to the protein or peptide after saturated binding with the reference antibody, it can be concluded that the test antibody binds to a different epitope than the reference antibody. On the other hand, if the test antibody cannot bind to the protein or peptide after saturated binding with the reference antibody, then either the test antibody can bind to the same epitope as the one bound by the reference antibody of the present invention, or the reference antibody causes a conformational change of the antigen, and therefore prevents the binding of the test antibody.

[0347] To determine whether an antibody competes for binding with a reference antibody, the above binding methodology is performed in two different experimental settings. In the first setting, the reference antibody is bound to the antigen under saturated conditions, and then the binding of the test antibody to the antigen is evaluated. In the second setting, the test antibody is bound to the antigen under saturated conditions, and then the binding of the reference antibody to the protein / peptide is evaluated. If, in both experimental settings, only the first (saturated) antibody can bind to the protein / peptide, it can be concluded that the test antibody and the reference antibody compete for binding to the antigen. As will be understood by those skilled in the art, an antibody that competes for binding with a reference antibody does not necessarily bind to the same epitope as the reference antibody, but can sterically block the binding of the reference antibody by binding to an overlapping or adjacent epitope, or can cause a conformational change that results in a lack of binding.

[0348] Two antibodies bind to the same or overlapping epitopes if each competitively inhibits (blocks) the other's binding to the antigen. If several amino acid mutations that reduce or eliminate the binding of one antibody also reduce or eliminate the binding of the other, the two antibodies have overlapping epitopes.

[0349] Alternatively, if all essentially the amino acid mutations in the antigen that reduce or eliminate the binding of one antibody also reduce or eliminate the binding of the other antibody, then the two antibodies have the same epitope.

[0350] Next, further routine experiments (e.g., peptide mutation and binding analysis) can be performed to confirm whether the observed lack of binding of the test antibody is actually due to binding to the same antigenic region as the reference antibody, or whether steric blockage (or another phenomenon) is the cause of the observed lack of binding. These types of experiments can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art.

[0351] Antibody variants In certain embodiments, antibody variants having one or more amino acid substitutions, insertions, and / or deletions are provided. CDRs and FRs are examples of sites of interest for substitutional mutagenesis. Amino acid substitutions can be introduced into the antibody of interest and screened for desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.

[0352] In certain embodiments, amino acid sequence variants of antibodies described herein are intended. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of antibodies can be prepared by introducing appropriate modifications to the nucleotide sequence encoding the protein, or by peptide synthesis. Such modifications include, for example, deletions from and / or insertions of residues and / or substitutions of residues within the amino acid sequence of the antibody (e.g., within one or more CDR and / or framework sequences, or within VH and / or VL domains). Any combination of deletions, insertions, and substitutions can be performed to arrive at the final construct, as long as the final construct has the desired properties.

[0353] In certain embodiments of the variant VH and VL sequences provided herein, each HVR is either unchanged or contains one, two, or three or fewer amino acid substitutions. IL22 binding domain variant

[0354] It will be understood that one or more amino acid substitutions, additions, and / or deletions can be made to the CDR of the IL22-binding domain provided by the present invention without significantly altering the ability of the antibody to bind to IL22 and attenuate IL22 activity. The effects of any amino acid substitution, addition, and / or deletion can be readily tested by those skilled in the art, for example, by elucidating the IL22 binding and inhibition of the interaction between IL22 and its receptor IL22R1 and IL22-binding proteins using the methods described herein, particularly the methods illustrated in the examples.

[0355] As a result, in certain embodiments of the IL22-binding domain variant VH and VL sequences, each CDR contains one, two, or three or fewer amino acid substitutions, such amino acid substitutions are conserved, and the IL22-binding domain retains its binding properties to IL22 and blocks the binding of IL22 to IL22R1 and IL22-binding proteins.

[0356] Accordingly, in one embodiment, the -IL22-binding domain includes a CDR such that one or more amino acids in one or more CDRs are substituted with another amino acid, for example, a similar amino acid as defined below herein, as shown in Sequence ID No. 8 / 9 / 10 / 11 / 12 / 13.

[0357] In one embodiment, the -IL22-binding domain includes a light chain variable domain containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in Sequence ID No. 14, and a heavy chain variable domain containing a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity with the sequence shown in Sequence ID No. 16.

[0358] In the embodiments, one or more amino acid substitutions in one or more CDRs replace free cysteine ​​residues or modify potential asparagine deamide sites. In the embodiments, one or more amino acid substitutions in one or more CDRs modify potential aspartic acid isomerization sites. In the embodiments, one or more amino acid substitutions in one or more CDRs remove potential DP hydrolysis sites. In the embodiments of the IL22-binding domain, one or more amino acid substitutions in one or more CDRs replace free cysteine ​​residues or modify potential asparagine deamide sites. In the embodiments, one or more amino acid substitutions in one or more CDRs modify potential aspartic acid isomerization sites. In the embodiments of the IL22-binding domain, one or more amino acid substitutions in one or more CDRs remove potential DP hydrolysis sites.

[0359] In this embodiment, with respect to CDR-L3 (sequence number 10), the substitution is C91S or C91V;N95D;S96A; or a combination thereof; with respect to CDR-H2 (sequence number 12), the substitution is D54E, G55A, or a combination thereof; with respect to CDR-H3 (sequence number 13), the substitution is D107E, or a combination of the listed substitutions; the position in the light chain is determined by sequence number 14, and the position in the heavy chain is determined by sequence number 16.

[0360] In one embodiment, the antibody of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the sequence shown in SEQ ID NO: 14, with one or more residues at positions 91, 95 and / or 96 substituted with another amino acid, and the heavy chain variable region comprises the sequence shown in SEQ ID NO: 16, with one or more residues at positions 54, 55 and / or 107 substituted with another amino acid.

[0361] In some embodiments, the IL22 binding domain is a Fab comprising a light chain containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in Sequence ID No. 18, and / or a heavy chain containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in Sequence ID No. 20.

[0362] In some embodiments, the IL22 binding domain includes CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 sequences, each including sequence numbers 8, 9, 10, 11, 12, and 13, respectively, and the remaining portions of the light chain variable region and heavy chain variable region have at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with sequence numbers 14 and 16, respectively.

[0363] IL13 binding domain variant It will also be understood that one or more amino acid substitutions, additions, and / or deletions may be made to the CDR of the IL13-binding domain provided by the present invention without significantly altering the antibody's ability to bind to IL13 and neutralize IL13 activity. The effects of any amino acid substitution, addition, and / or deletion can be readily tested by those skilled in the art to determine IL13 binding to IL13R-alpha-1 and IL13R-alpha-2.

[0364] As a result, in certain embodiments of the IL13-binding domain variant VH and VL sequences, each CDR contains one, two, or three or fewer amino acid substitutions, such amino acid substitutions are conserved, and the IL13-binding domain retains its binding properties to IL13, blocking IL13 binding to IL13R-alpha-1 and IL13R-alpha-2, preventing binding to IL13R-alpha-1, and blocking binding to IL-4R.

[0365] Accordingly, in one embodiment, the -IL13-binding domain includes a CDR defined by the sequence shown in SEQ ID NOs. 22 / 23 / 24 / 25 / 26 / 27, in which one or more amino acids in one or more CDRs are substituted with another amino acid, for example, a similar amino acid as defined herein below.

[0366] In some embodiments, the IL13 binding domain includes a light chain variable region containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in Sequence ID No. 28, and / or a heavy chain variable region containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in Sequence ID No. 29.

[0367] In some embodiments, the IL13 binding domain includes a light chain variable region containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in Sequence ID No. 32, and / or a heavy chain variable region containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in Sequence ID No. 33.

[0368] In some embodiments, the IL13 binding domain is an scFv containing a sequence that has at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in SEQ ID NO: 36, or a dsscFv containing a sequence that has at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in SEQ ID NO: 38.

[0369] In some embodiments, the IL13 binding domain includes CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 sequences, each including sequence numbers 22, 23, 24, 25, 26, and 27, respectively, and the remaining portions of the light chain variable region and the heavy chain variable region have at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with sequence numbers 28 and 29, respectively.

[0370] In some embodiments, the IL13 binding domain includes CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 sequences, respectively, including SEQ ID NOs. 22, 23, 24, 25, 26, and 27, and the remaining portions of the light chain variable region and the heavy chain variable region have at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with SEQ ID NOs. 32 and 33, respectively.

[0371] Albumin-binding domain variant In one embodiment, the albumin-binding domain comprises a CDR defined by the sequence shown in SEQ ID NOs. 40 / 41 / 42 / 43 / 44 / 45, in which one or more amino acids in one or more CDRs are substituted with other amino acids, such as similar amino acids as defined herein.

[0372] In some embodiments, the albumin-binding domain includes a light chain variable region containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in Sequence ID No. 46, and / or a heavy chain variable region containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in Sequence ID No. 47.

[0373] In some embodiments, the albumin-binding domain includes a light chain variable region containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in Sequence ID No. 50, and / or a heavy chain variable region containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in Sequence ID No. 51.

[0374] In some embodiments, the antialbumin-binding domain is an scFv containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in SEQ ID NO: 54, or a dsscFv containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in SEQ ID NO: 56. In some embodiments, the albumin-binding domain comprises CDR-L1 / CDR-L2 / CDR-L3 / CDR-H1 / CDR-H2 / CDR-H3 sequences, each including sequence numbers 40 / 41 / 42 / 43 / 44 / 45, and the remaining portions of the light chain variable region and heavy chain variable region have at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with sequence numbers 46 and 47, respectively. In some embodiments, the albumin-binding domain comprises CDR-L1 / CDR-L2 / CDR-L3 / CDR-H1 / CDR-H2 / CDR-H3 sequences, each including sequence numbers 40 / 41 / 42 / 43 / 44 / 45, and the remaining portions of the light chain variable region and heavy chain variable region have at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with sequence numbers 50 and 51, respectively.

[0375] Multispecific antibody mutants In certain embodiments, substitutions, insertions, or deletions may occur within one or more CDRs, provided that such changes do not substantially reduce the antibody's ability to bind to IL22 and IL13. For example, conservative modifications that do not substantially reduce binding affinity can be made within a CDR. Such changes may be outside a CDR. In certain embodiments of the variant VH and VL sequences, each CDR is either unchanged or contains one, two, or three or fewer amino acid substitutions.

[0376] Accordingly, the present invention provides a multispecific antibody comprising a CDR defined by the sequences shown in SEQ ID NOs: 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, and 27, wherein one or more amino acids in one or more CDRs are substituted with another amino acid, for example, a similar amino acid as defined below herein.

[0377] Furthermore, the present invention provides a multispecific antibody comprising a CDR defined by the sequences shown in SEQ ID NOs: 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, 27, 40, 41, 42, 43, 44, 45, wherein one or more amino acids in one or more CDRs are substituted with another amino acid, for example, a similar amino acid as defined below herein.

[0378] In one embodiment, the CDR of the multispecific antibody includes a sequence that has at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in SEQ ID NOs. 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, and 27, while retaining the ability to bind to IL13 and IL22.

[0379] In one embodiment, V L This includes a sequence that has at least 70%, 80%, 90%, 95%, or 98% identity or similarity to the sequence shown in Sequence ID No. 14, and V H This includes a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity to the sequence shown in Sequence ID No. 16.

[0380] In one embodiment, V1 includes a light chain variable region containing a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity with the sequence shown in Sequence ID No. 46, and / or a heavy chain variable region containing a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity with the sequence shown in Sequence ID No. 47.

[0381] In one embodiment, V1 includes a light chain variable region containing a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity with the sequence shown in Sequence ID No. 50, and / or a heavy chain variable region containing a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity with the sequence shown in Sequence ID No. 51.

[0382] In one embodiment, the light chain variable region and heavy chain variable region of V1 of formula (I), (Ia), (Ib), (Ic), or (Id) are linked by a linker, the linker comprising a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in sequence number 69.

[0383] In one embodiment, V1 is an scFv containing a sequence that has at least 70%, 80%, 90%, 95%, or 98% identity or similarity to the sequence shown in sequence number 54, or a dsscFv containing a sequence that has at least 70%, 80%, 90%, 95%, or 98% identity or similarity to the sequence shown in sequence number 56.

[0384] In one embodiment, V2 includes a light chain variable region containing a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity with the sequence shown in Sequence ID No. 28, and / or a heavy chain variable region containing a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity with the sequence shown in Sequence ID No. 29.

[0385] In one embodiment, V2 includes a light chain variable region containing a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity with the sequence shown in Sequence ID No. 32, and / or a heavy chain variable region containing a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity with the sequence shown in Sequence ID No. 33.

[0386] In one embodiment, the light chain variable region and the heavy chain variable region of V2 are linked by a linker, the linker containing a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in Sequence ID No. 67.

[0387] In one embodiment, V2 is an scFv containing a sequence that has at least 70%, 80%, 90%, 95%, or 98% identity or similarity to the sequence shown in sequence number 36, or a dsscFv containing a sequence that has at least 70%, 80%, 90%, 95%, or 98% identity or similarity to the sequence shown in sequence number 38.

[0388] In one embodiment, X in formula I, Ia, Ib, Ic, or Id is a linker containing a sequence that has at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in sequence number 68.

[0389] In one embodiment, Y is a linker that includes a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in sequence number 66.

[0390] In one embodiment, the polypeptide chain of formula (Ia) includes a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in SEQ ID NO: 58 or SEQ ID NO: 58 or 60.

[0391] In one embodiment, the polypeptide chain of formula (IIa) includes a sequence having at least 70%, 80%, 90%, 95%, or 98% identity or similarity to the sequence shown in SEQ ID NO: 62 or SEQ ID NO: 64.

[0392] In one embodiment, the polypeptide chain of formula (Ia) includes a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in sequence number 58, and the polypeptide chain of formula (IIa) includes a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity to the sequence shown in sequence number 62.

[0393] In one embodiment, the polypeptide chain of formula (Ia) includes a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in sequence number 60, and the polypeptide chain of formula (IIa) includes a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequence shown in sequence number 64.

[0394] In some embodiments, the multispecific antibody comprises a CDR defined by the sequences shown in SEQ ID NOs: 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, 27, 40, 41, 42, 43, 44, 45, a heavy chain variable region and a light chain variable region defined by the sequences provided herein, wherein the remaining parts of the polypeptide chains of formulas (Ia) and (IIa) outside the variable regions have at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequences provided herein.

[0395] In some embodiments, the multispecific antibody comprises a CDR defined by the sequences shown in SEQ ID NOs: 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, and 27, a heavy chain variable region and a light chain variable region defined by the sequences provided herein, wherein the remaining portions of the polypeptide chains of formulas (III), (IV), (V), and (VI) outside the variable regions have at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity or similarity with the sequences provided herein.

[0396] Sequence identity and similarity The degree of identity and similarity between sequences can be easily calculated. "Sequence Identity %" (or "Sequence Similarity %") is calculated by (1) comparing two optimally aligned sequences across a comparison window (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window, etc.), (2) determining the number of positions containing the same (or similar) amino acids to obtain the number of matching positions (e.g., the same amino acid is present in both sequences, similar amino acids are present in both sequences), (3) dividing the number of matching positions by the total number of positions within the comparison window (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window), and (4) multiplying the result by 100 to obtain the Sequence Identity % or Sequence Similarity %.

[0397] Methods for aligning sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be achieved, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), the homology matching algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), the similarity search method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis), or by manual alignment and visual inspection (see, for example, Current Protocols in Molecular Biology, Ausubel et al., eds. 1995 supplement).

[0398] Preferred examples of algorithms suitable for determining sequence identity percentages and sequence similarity percentages include the BLAST and BLAST2.0 algorithms described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). Polypeptide sequences can also be compared using FASTA with default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignment and sequence identity percentage of the best overlap region between the query sequence and the search sequence.

[0399] In certain embodiments, substitutions, insertions, or deletions may occur within one or more CDRs, provided that such changes do not substantially reduce the antibody's ability to bind to the target.

[0400] For example, conservative modifications can be made in the CDR that do not substantially reduce binding affinity. Such modifications can be made outside the antigen contact residue in the CDR.

[0401] Conservative substitutions, along with more substantial "exemplary substitutions," are shown in Table 8.

[0402] Table 8. Examples of amino acid substitutions [Table 8]

[0403] Substantial modification of the biological properties of antibody variants can be achieved by selecting substitutions that have a significantly different effect on the structure of the polypeptide backbone in the substitution region, the molecular charge or hydrophobicity at the target site, or the maintenance of the side chain bulk. Amino acids can be grouped according to the similarity of their side chain properties (ALLehninger, Biochemistry second ed., pp. 73-75, Worth Publishers, New York (1975)).

[0404] One type of substitution mutant involves substituting one or more CDR region residues of the parent antibody (humanized antibody or human antibody). Generally, the resulting mutant(s) selected for further study have altered specific biological properties (e.g., increased affinity, decreased immunogenicity) compared to the parent antibody, and / or substantially retain specific biological properties of the parent antibody. Exemplary substitution mutants are affinity-mature antibodies, which can be readily generated using affinity maturation techniques, for example, phage display-based techniques. Briefly, one or more CDR residues are mutated, the mutant antibody is presented on a phage, and it is screened for specific biological activity (e.g., binding affinity).

[0405] For example, to improve antibody affinity, modifications (e.g., substitutions) can be made to the CDR. Such modifications may be made at HVR "hotspots," i.e., residues encoded by codons that are frequently mutated during the somatic cell maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and / or residues that come into contact with the antigen, and the resulting mutant VH or VL is tested for binding affinity. Affinity maturation by secondary library construction and re-selection from secondary libraries is described, for example, in Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by one of various methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-specific mutagenesis). A secondary library is then constructed. Next, the library is screened to identify any antibody variant with the desired affinity.

[0406] One method that can be used to identify antibody residues or regions that may be targets for mutagenesis is alanine scanning mutagenesis (Cunningham and Wells (1989) Science, 244:1081-1085). In this method, residues or a number of target residues are identified and substituted with alanine to determine whether the interaction between the antibody and the antigen is affected. Alternatively, the X-ray structure of the antigen-antibody complex can be used to identify the contact points between the antibody and its antigen. Mutants can then be screened to determine whether they possess the desired properties.

[0407] Steady-state region mutant In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby creating an Fc region variant. The Fc region variant may include a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) that includes amino acid modifications (e.g., substitutions) at one or more amino acid positions.

[0408] Specific antibody variants exhibiting improved or reduced binding to FcR are described. (See, for example, U.S. Patent No. 6,737,056; International Publication No. 2004 / 056312; and Shields et al., J. Biol. Chem. 9(2):6591-6604(2001)).

[0409] Antibodies with increased half-life and improved binding to the neonatal Fc receptor (FcRn) are described in U.S. Patent No. 2005 / 0014934. These antibodies contain an Fc region having one or more substitutions that improve the binding of the Fc region to FcRn.

[0410] In certain embodiments, the antibody variant includes an Fc region having one or more amino acid substitutions that improve ADCC, for example, substitutions at positions 298, 333 and / or 334 of the Fc region (residue EU numbering).

[0411] Antibodies with reduced effector function include those in which one or more of the Fc region residues 234, 235, 237, 238, 265, 269, 270, 297, 327, and 329 are substituted (see, for example, U.S. Patent No. 6,737,056). Such Fc variants include those having substitutions in two or more of the amino acid positions 265, 269, 270, 297, and 327, where the amino acid residues are numbered according to the EU numbering system.

[0412] In vitro and / or in vivo cytotoxic assays can be performed to confirm the reduction / depletion of CDC and / or ADCC activity. For example, an Fc receptor (FcR) binding assay can be performed to ensure that an antibody lacks FcγR binding (and therefore likely lacks ADCC activity) but retains FcRn binding ability. Primary cells, which mediate ADCC and NK cells, express only FcγRIII, while monocytes express FcRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays for evaluating the ADCC activity of the molecule of interest are described in U.S. Patents 5,500,362 and 5,821,337. Alternatively, or in addition, the ADCC activity of the molecule of interest can be evaluated in vivo, for example, in animal models, such as those disclosed in Clynes et al. Proc. Nat l Acad. Sci. USA 95:652-656 (1998). A Clq binding assay can also be performed to confirm that the antibody cannot bind to Clq and therefore lacks CDC activity. See, for example, the Clq and C3c binding ELISAs in International Publication Nos. 2006 / 029879 and International Publication Nos. 2005 / 100402. To evaluate complement activation, a CDC assay can be performed (see, for example, Gazzano-Santoro et al, J.Immunol.Methods 202:163 (1996); Cragg, MS et al, Blood 101:1045-1052 (2003); and Cragg, MS and MI Glennie, Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance / half-life determination can also be performed using methods known in the art (see, for example, Petkova, S B et al, Int l.Immunol. 18(12):1759-1769 (2006)).

[0413] The constant region domain of the antibody molecule of the present invention, if present, may be selected in consideration of the proposed function of the antibody molecule, particularly any effector function that may be required. For example, the constant region domain may be a human IgA, IgD, IgE, IgG, or IgM domain. In particular, if the antibody molecule is intended for therapeutic use and antibody effector function is required, human IgG constant region domains, especially IgG1 and IgG3 isotypes, may be used. Alternatively, if the antibody molecule is intended for therapeutic purposes and antibody effector function is not required, IgG2 and IgG4 isotypes may be used. It will be understood that sequence variants of these constant region domains may also be used.

[0414] Glycosylated mutants In certain embodiments, the antibodies provided herein are modified to increase or decrease the degree to which the antibody is glycosylated. The addition or deletion of glycosylation sites to an antibody can be conveniently achieved by modifying the amino acid sequence so that one or more glycosylation sites are created or removed.

[0415] Effector molecules If desired, the antibody may be conjugated to one or more effector molecules. In one embodiment, the antibody is not bound to an effector molecule.

[0416] It will be understood that the effector molecule may comprise a single effector molecule or two or more such molecules linked to form a single portion capable of binding to the multispecific antibody of the present invention. If it is desirable to obtain an antibody linked to the effector molecule, this may be prepared by standard chemical or recombinant DNA procedures in which an antibody fragment is linked to the effector molecule directly or via a coupling agent. Techniques for conjugating such effector molecules to antibodies are well known in the art (see Hellstrom et al., Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., 1987, pp. 623-53; Thorpe et al., 1982, Immunol. Rev., 62:119-58 and Dubowchik et al., 1999, Pharmacology and Therapeutics, 83, 67-123). Specific chemical procedures include, for example, those described in International Publications 93 / 06231, 92 / 22583, 89 / 00195, 89 / 01476, and 03 / 031581. Alternatively, if the effector molecule is a protein or polypeptide, linkage can be achieved using recombinant DNA procedures, for example, as described in International Publication 86 / 01533 and European Patent 0392745.

[0417] Examples of effector molecules include cytotoxic or cytotoxic agents, including any drug that is harmful to cells (e.g., cytotoxic). Examples include combrestatin, drastatin, epothilone, staurosporine, meitansinoid, spongstatin, rhizoxin, halichondrin, loridine, hemiasterin, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracinedione, mitoxantrone, mitramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin, as well as their analogs or homologs.

[0418] Effector molecules also include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechloretamine, thioepachlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C and cis-dichlorodiamine platinum(II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mitramycin, anthramycin (AMC), calicheamicin or duocalmycin), and antimitotic agents (e.g., vincristine and vinblastine).

[0419] Other effector molecules include chelated radionuclides such as 111In and 90Y, Lu177, bismuth-213, californium-252, iridium-192, and tungsten-188 / rhenium-188; or, but are not limited to, drugs such as alkylphosphocholines, topoisomerase I inhibitors, taxoids, and suramin.

[0420] Other effector molecules include proteins, peptides, and enzymes. The enzymes of interest include, but are not limited to, proteolytic enzymes, hydrolases, lyases, isomerases, and transferases. The proteins, polypeptides, and peptides of interest include, but are not limited to, immunoglobulins, toxins, e.g., abrin, lysine A, Pseudomonas exotoxin, or diphtheria toxin, proteins, e.g., insulin, tumor necrosis factor, α-interferon, β-interferon, nerve growth factor, platelet-derived growth factor, or tissue plasminogen activator, thrombotic agents or anti-angiogenic agents, e.g., angiostatin or endostatin, or biological response modifiers, e.g., lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), nerve growth factor (NGF), or other growth factors and immunoglobulins.

[0421] Other effector molecules may include, for example, detectable substances useful for diagnostics. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent substances, luminescent substances, bioluminescent substances, radionuclides, positron-emitting metals (for use in positron emission tomography), and non-radioactive paramagnetic metal ions. For metal ions that can be conjugated to antibodies for use as diagnostic agents, see generally U.S. Patent No. 4,741,900. Suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; suitable prosthetic groups include streptavidin, avidin, and biotin; suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, and phycoerythrin; suitable luminescent materials include luminol; suitable bioluminescent materials include luciferase, luciferin, and aequorin; and suitable radionuclides include 125I, 131I, 111In, and 99Tc.

[0422] In another example, effector molecules may increase the half-life of an antibody in vivo and / or decrease its immunogenicity and / or enhance the delivery of the antibody across the epithelial barrier to the immune system. Examples of suitable effector molecules of this type include polymers, albumins, albumin-binding proteins, or albumin-binding compounds such as those described in International Publication No. 2005 / 117984.

[0423] If the effector molecule is a polymer, it can generally be a synthetic or naturally occurring polymer, such as optionally substituted linear or branched polyalkylene, polyalkene, or polyoxyalkylene polymer, or a branched or unbranched polysaccharide, such as a homo or heteropolysaccharide.

[0424] Specific optional substituents that may be present on the above synthetic polymer include one or more hydroxy, methyl, or methoxy groups.

[0425] Specific examples of synthetic polymers include substituted or branched linear or branched poly(ethylene glycol), poly(propylene glycol), poly(vinyl alcohol), or derivatives thereof, particularly substituted or branched poly(ethylene glycol), such as methoxypoly(ethylene glycol) or derivatives thereof.

[0426] Specific examples of naturally occurring polymers include lactose, amylose, dextran, glycogen, or their derivatives.

[0427] In one embodiment, the polymer is albumin or a fragment thereof, for example, human serum albumin or a fragment thereof.

[0428] The size of the polymer can be varied as desired, but generally, the average molecular weight range is 500 Da to 50,000 Da, e.g., 5,000 to 40,000 Da, e.g., 20,000 to 40,000 Da. The polymer size may be selected based in particular on the intended use of the product, e.g., its ability to localize to specific tissues such as tumors or its ability to extend the circulating half-life (see Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545 for a review). For example, if the product is intended to leave the circulation and penetrate tissues for use in the treatment of tumors, it may be advantageous to use a low molecular weight polymer, for example, with a molecular weight of about 5,000 Da. For applications where the product remains in circulation, it may be advantageous to use a high molecular weight polymer, for example, with a molecular weight in the range of 20,000 Da to 40,000 Da.

[0429] Suitable polymers include polyalkylene polymers, such as poly(ethylene glycol) or especially methoxypoly(ethylene glycol) or its derivatives, particularly those having a molecular weight in the range of about 15,000 Da to about 40,000 Da.

[0430] In one example, the antibody is bound to a poly(ethylene glycol) (PEG) moiety. In a particular embodiment, the antigen-binding fragment and PEG molecule according to the present invention may be bound via any available amino acid side chain or terminal amino acid functional group located in the antibody fragment, such as any free amino, imino, thiol, hydroxyl, or carboxyl group. Such amino acids may be naturally present in the antibody fragment or may be engineered into the fragment using recombinant DNA methods (see, for example, U.S. Patent No. 5,219,996; U.S. Patent No. 5,667,425; International Publication No. 98 / 25971; International Publication No. 2008 / 038024). In one example, the antibody molecule of the present invention is a modified Fab fragment, where the modification is the addition of one or more amino acids to the C-terminus of its heavy chain to enable the binding of an effector molecule. Preferably, the additional amino acids form a modified hinge region containing one or more cysteine ​​residues to which the effector molecule can be bound. Multiple sites can be used to bind two or more PEG molecules.

[0431] Suitablely, the PEG molecule is covalently bonded via a thiol group on at least one cysteine ​​residue located in the antibody fragment. Each polymer molecule bound to the modified antibody fragment may also be covalently bonded to a sulfur atom of a cysteine ​​residue located in the fragment. The covalent bond is generally a disulfide bond, or more specifically, a sulfur-carbon bond. When a thiol group is used as a bonding site, appropriately activated effector molecules, such as maleimide and thiol-selective derivatives such as cysteine ​​derivatives, can be used. The activated polymer can be used as a starting material in the preparation of the polymer-modified antibody fragment described above. The activated polymer can be any polymer containing a thiol-reactive group, such as an α-halocarboxylic acid or ester, e.g., iodoacetamide, imide, e.g., maleimide, vinyl sulfone, or disulfide. Such starting materials may be commercially available (e.g., from Nektar, formerly Shearwater Polymers Inc., Huntsville, AL, USA) or prepared from commercially available starting materials using conventional chemical procedures. Certain PEG molecules include 20K methoxy-PEG-amine (Nektar, formerly available from Shearwater; Rapp Polymere; and SunBio) and M-PEG-SPA (Nektar, formerly available from Shearwater).

[0432] In one embodiment, the antibody comprises a modified Fab fragment, Fab' fragment, or diFab, which is PEGylated, i.e., PEG (poly(ethyleneglycol)) covalently bonded thereto, according to a method disclosed, for example, in European Patent No. 0948544 or European Patent No. 1090037 ["Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications", 1992, J. Milton Harris (ed), Plenum Press, New York; "Poly(ethyleneglycol) Chemistry and Biological Applications", 1997, J. Milton Harris and S. Zalipsky (eds), American Chemical Society, Washington DC and "Bioconjugation Protein Coupling Techniques for the Biomedical Sciences", 1998, M. Aslam and A. Dent, Grove Publishers, New York; see also Chapman, A. 2002, Advanced Drug Delivery Reviews 2002, 54:531-545]. In one example, PEG is bound to a cysteine ​​within the hinge region. In another example, the PEG-modified Fab fragment has a maleimide group covalently bonded to a single thiol group within the modified hinge region. Lysine residues may also be covalently bonded to the maleimide group, and each amine group on the lysine residue may be bonded to a methoxypoly(ethylene glycol) polymer having a molecular weight of approximately 20,000 Da. Therefore, the total molecular weight of PEG bonded to the Fab fragment may be approximately 40,000 Da.

[0433] In one embodiment, the present invention provides an antibody molecule comprising a modified Fab' fragment having a modified hinge region at the C-terminus of its heavy chain, to which an effector molecule is bound. Preferably, the effector molecule is PEG and is bound using the method described in International Publication Nos. 98 / 25971 and 2004072116 or International Publication Nos. 2007 / 003898. The effector molecule may be bound to the antibody fragment using the method described in International Patent Application Publication Nos. 2005 / 003169, 2005 / 003170 and 2005 / 003171.

[0434] In one embodiment, the antibody is not bound to the effector molecule.

[0435] Polynucleotides and vectors The present invention also provides isolated polynucleotides encoding antibodies or components thereof according to the present invention. Isolated polynucleotides according to the present invention may include, for example, synthetic DNA, cDNA, genomic DNA, or any combination thereof, produced by chemical treatment.

[0436] Table 9. Amino acid sequences of the antibodies of the present invention and their corresponding nucleic acid sequences. [Table 9]

[0437] Examples of preferred sequences are provided herein. Accordingly, in one embodiment, the present invention provides isolated polynucleotides encoding an antibody, an antigen-binding domain, or a portion thereof, comprising one or more sequences shown in SEQ ID NOs: 15, 17, 19, 21, 30, 31, 34, 35, 37, 39, 48, 49, 52, 53, 55, 57, 59, 61, 63, 65, 143, 145, 147, 149, 151, 153, 77, 79, 81, 83.

[0438] In one embodiment, the present invention provides isolated polynucleotides encoding the multispecific antibodies of the present invention, comprising the sequences shown in SEQ ID NOs. 59, 61, 63, and 65.

[0439] In one embodiment, the present invention provides isolated polynucleotides encoding the multispecific antibodies of the present invention, which include sequences shown in SEQ ID NOs: 143, 145, 147, 149, 151, and 153.

[0440] The present invention also provides cloning or expression vectors comprising one or more polynucleotides described herein. For example, a cloning or expression vector according to the present invention comprises one or more isolated polynucleotides comprising sequences selected from SEQ ID NOs: 15, 17, 19, 21, 30, 31, 34, 35, 37, 39, 48, 49, 52, 53, 55, 57, 59, 61, 63, 65, 143, 145, 147, 149, 151, 153, 77, 79, 81, 83.

[0441] DNA sequences encoding the antibody or its antigen-binding fragment of the present invention can be prepared using standard molecular biology techniques. The desired DNA sequence can be fully or partially synthesized using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques may be used as needed.

[0442] General methods for constructing vectors, transfection methods, and culture methods are well known to those skilled in the art. For further information, see “Current Protocols in Molecular Biology”, 1999, FMAusubel (ed), Wiley Interscience, New York and the Maniatis Manual produced by Cold Spring Harbor Publishing.

[0443] Host cells for the production of multispecific antibodies Also provided are host cells comprising one or more isolated polynucleotide sequences according to the present invention, or one or more cloning or expression vectors comprising one or more isolated polynucleotide sequences encoding the antibody or its antigen-binding fragment according to the present invention. Any suitable host cell / vector system can be used for the expression of the polynucleotide sequences encoding the antibody or its antigen-binding fragment according to the present invention. Bacteria, e.g., Escherichia coli (E. coli), and other microbial systems may be used, or eukaryotes, e.g., mammals, host cell expression systems may be used. Suitable mammalian host cells include CHO, myeloma, or hybridoma cells.

[0444] In further embodiments, host cells comprising such nucleic acids or vectors are provided. In one such embodiment, the host cell comprises (1) a vector comprising nucleic acids encoding an amino acid sequence comprising an amino acid sequence comprising an amino acid sequence comprising an amino acid sequence comprising an amino acid sequence comprising an anti-IL13 antibody VL and an amino acid sequence comprising an anti-IL13 antibody VH, or (2) a first vector comprising nucleic acids encoding an amino acid sequence comprising an anti-IL22 antibody VL and a second vector comprising nucleic acids encoding an amino acid sequence comprising an anti-IL22 antibody VH (e.g., transformed by them). In one embodiment, the host cell is a eukaryotic cell, e.g., Chinese hamster ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, the host cell is a prokaryotic cell, e.g., Escherichia coli (E. coli) cell. In one embodiment, a method for producing an anti-X antibody is provided, comprising culturing a host cell comprising the nucleic acid encoding the above antibody under conditions suitable for antibody expression, and optionally recovering the antibody from the host cell (or host cell culture medium).

[0445] Host cells suitable for cloning or expressing antibodies or vectors encoding their components include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, especially when glycosylation and Fc effector function are not required. For the expression of antibody fragments and polypeptides in bacteria, see, for example, U.S. Patents 5,648,237, 5,789,199, and 5,840,523 (see, for example, Charlton, Methods in Molecular Biology, Vol. 248, BKCLo, ed., Humana Press, Totowa, NJ, 2003, pp. 245-254). After expression, antibodies can be isolated and further purified.

[0446] Eukaryotic microorganisms such as fungi or yeasts are suitable cloning and / or expression hosts for antibody-encoding vectors, including "humanized" fungal and yeast strains whose glycosylation pathways result in the production of antibodies with a partial or complete human glycosylation pattern. (Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006)).

[0447] Suitable types of Chinese hamster ovary (CHO cells) for use in the present invention may include CHO and CHO-K1 cells, including dhfr-CHO cells such as CHO-DG44 cells and CHO-DXB11 cells, which can be used with a DHFR-selectable marker, or CHOK1-SV cells, which can be used with a glutamine synthetase-selectable marker. Other cell types used for antibody expression include lymphocyte cell lines, such as NS0 myeloma cells and SP2 cells, and COS cells. Host cells can be stably transformed or transfected with isolated polynucleotide sequences or expression vectors according to the present invention.

[0448] A Protein Protein A is a 42 kDa surface protein first found in the cell wall of the bacterium Staphylococcus aureus. Protein A is widely used for the detection, quantification, and purification of immunoglobulins. Protein A has been reported to bind to the Fab moiety derived from VH3 family antibodies and to the Fc gamma region of the constant region of IgG (between the CH2 and CH3 domains). The crystal structure of the complex formed by Protein A and Fab is described, for example, in Graille et al., 2000, PNAS, 97(10):5399-5404. In the context of this disclosure, Protein A encompasses the native Protein A and any of its variants or derivatives, as long as the Protein A variant or derivative retains the ability to bind to the VH3 domain and / or the Fc gamma domain.

[0449] The polypeptide chain of formula (I) of the present invention comprises an A protein-binding domain. In one embodiment, the polypeptide chain of formula (I) comprises one, two, or three A protein-binding domains.

[0450] The A protein-binding domain may refer to the VH3 domain or a portion of the VH3 domain that binds to the A protein, i.e., the A protein-binding interface. The portion of the VH3 domain that binds to the A protein does not contain the CDR of the VH3 domain; i.e., the A protein-binding interface of VH3 does not contain the CDR. Therefore, it will be understood that the A protein-binding domain does not compete with the antigen-binding domain disclosed in this application.

[0451] In one embodiment, the polypeptide chain of formula (I) is V H and / or includes the A protein-binding domain present in CH2-CH3 and / or V1. In one embodiment, the polypeptide chain of formula (I) is V H and / or CH2-CH3 and / or V1 contain 1, 2, or 3 A protein-binding domains. In one embodiment, the polypeptide chain of formula (I) is V HOr it contains only one A protein-binding domain present in V1. In one embodiment, s is 0, t is 0, and the polypeptide chain of formula (I) is V H Or it contains only one A protein-binding domain present in V1. In one embodiment, the polypeptide chain of formula (I) is V H It contains only one A protein-binding domain. In one embodiment, s is 0, t is 0, p is 0, and the polypeptide chain of formula (I) is V H It contains only one A protein-binding domain present in it. In one embodiment, the polypeptide chain of formula (I) contains only one A protein-binding domain present in V1. In one embodiment, s is 0, t is 0, p is 1, and the polypeptide chain of formula (I) contains only one A protein-binding domain present in V1.

[0452] In one embodiment, the polypeptide chain of formula (I) contains two A protein-binding domains. In another embodiment, the polypeptide chain of formula (I) contains two A protein-binding domains located at VH and CH2-CH3, respectively. In yet another embodiment, the polypeptide chain of formula (I) contains V H and V1 contains two A protein-binding domains. In another embodiment, the polypeptide chain of formula (I) contains two A protein-binding domains located at CH2-CH3 and V1, respectively.

[0453] In one embodiment, the polypeptide chain of formula (I) comprises three A protein-binding domains, each of which is V H It is present in CH2-CH3 and V1.

[0454] Natural A proteins can interact with the constant region of IgG, particularly the Fc gamma region. More specifically, A proteins can interact with the binding domain between CH2 and CH3. In one embodiment, when s is 1 and t is 1, both CH2 and CH3 are naturally occurring domains of the IgG class.

[0455] In some embodiments, the A protein-binding domain(s) may include or consist of a VH3 domain or a variant thereof that binds to the A protein. In some embodiments, the A protein-binding domain(s) may include or consist of a naturally occurring VH3 domain. In some embodiments, the variant of the VH3 domain that binds to the A protein is a variant of a naturally occurring VH3 domain, and the naturally occurring VH3 domain is unable to bind to the A protein.

[0456] The polypeptide chain of formula (II) of this disclosure does not bind to protein A. In one embodiment, the binding domain of V2 does not bind to protein A. In one embodiment, the binding domain of V3 does not bind to protein A. In one embodiment, neither V2 nor V3 binds to protein A.

[0457] In some embodiments, V2 and / or V3 include or consist of VH1 and / or VH2 and / or VH4 and / or VH5 and / or VH6, but do not include the VH3 domain. In some embodiments, V2 and / or V3 include or consist of a VH3 domain or variant thereof that does not bind to protein A. In some embodiments, V2 and / or V3 include or consist of a naturally occurring VH3 domain that cannot bind to protein A. In some embodiments, the variant of the VH3 domain that does not bind to protein A is a variant of naturally occurring VH3, and the naturally occurring VH3 domain can bind to protein A.

[0458] Human VH3 germline genes and VH3 domains (or frameworks) are well-characterized. While many naturally occurring VH3 domains are capable of binding to A protein, certain naturally occurring VH3 domains are not (Roben et al., 1995, J Immunol. 154(12):6437-6445).

[0459] VH3 domains for use in this disclosure can be obtained by several methods. In one embodiment, the VH3 domains for use in this disclosure are naturally occurring VH3 domains selected for their ability or inability to bind to protein A, depending on their position within polypeptides (I) and / or (II) of this disclosure. For example, a panel of antibodies may be generated against an antigen of interest by immunization of non-human animals and then humanized, and the humanized antibodies may be screened and selected against, for example, a protein A affinity column based on their ability or non-binding to protein A via the humanized VH3 domain. Alternatively, an antibody library may be screened using display techniques (e.g., phage display, yeast display, ribosome display, bacterial display, mammalian cell surface display, mRNA display, DNA display) to select antibodies containing VH3 domains that bind via a protein A binding interface that does not contain CDRs or bind to protein A.

[0460] Alternatively, the VH3 domain for use in this disclosure is a naturally occurring variant of VH3. In one embodiment, the VH3 variant comprises a naturally occurring VH3 sequence capable of binding to protein A, further comprising at least one amino acid mutation that causes it to lose its ability to bind to protein A. In one embodiment, the VH3 variant that binds to protein A comprises a naturally occurring VH3 sequence that is incapable of binding to protein A, further comprising at least one amino acid mutation. In such embodiments, the mutation(s) are involved in the VH3 domain gaining the ability to bind to protein A, i.e., the mutation(s) contribute to the creation of a protein A binding domain that was not naturally present.

[0461] In one embodiment, the VH3 variant contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid mutations. In one embodiment, the VH3 variant contains mutations at positions 15, 17, 19, 57, 59, 64, 65, 66, 68, 70, 81, or 82 on VH3, with numbering according to Kabat, as described, for example, Graille et al., 2000, PNAS, 97(10):5399-5404. The mutations may be substitutions, deletions, or insertions. In one embodiment, the VH3 variant contains substitutions at positions 15, 17, 19, 57, 59, 64, 65, 66, 68, 70, 81, or 82 on VH3, with numbering according to Kabat.

[0462] Naturally occurring VH1, VH2, VH4, VH5, and VH6 do not bind to protein A. In one embodiment, the VH domain that does not bind to protein A is VH1. In one embodiment, the VH domain that does not bind to protein A is VH2. In one embodiment, the VH domain that does not bind to protein A is VH4. In one embodiment, the VH domain that does not bind to protein A is VH5. In one embodiment, the VH domain that does not bind to protein A is VH6.

[0463] Production of multispecific antibodies There are several approaches to producing multispecific antibodies, particularly bispecific antibodies. Morrison et al. (Coloma and Morrison 1997, Nat Biotechnol. 15, 159-163) described the fusion of single-strand variable fragments (scFv) to whole antibodies, such as IgG. Schoonjans et al., 2000, Journal of Immunology, 165, 7050-7057 described the fusion of scFv and antibody Fab fragments. International Publication No. 2015 / 197772 describes the fusion of disulfide-stabilized scFv (dsscFv) and Fab fragments.

[0464] Standard approaches described in the prior art involve the expression of at least two polypeptides in host cells, each encoding the heavy chain (HC) or light chain (LC) or antibody fragment, e.g., Fab, of the entire antibody, and additional antigen-binding fragments of the antibody can be fused to the N-terminal and / or C-terminal positions of the heavy and / or light chains. When attempting to recombinatively produce such multispecific antibodies by expressing two polypeptides (expressing one light chain and one heavy chain to form additional Fab) or four polypeptides (expressing two light chains and two heavy chains to form additional IgG), it is usually necessary to express the light chains in excess of the heavy chains to ensure proper folding of the heavy chains during assembly with the corresponding light chains. In particular, CH1 (domain 1 of the heavy chain constant region) is prevented from folding on its own by the BIP protein, which can be substituted by the corresponding LC. Therefore, the correct folding of CH1 / HC depends on the availability of its corresponding LC (Lee et al., 1999, Molecular Biology of the Cell, Vol. 10, 2209-2219).

[0465] Methods for expressing multispecific antibodies may result in the production of light chains in excess of heavy chains, which remain in the host cell sample. These excess light chains tend to form dimeric complexes (or "LC dimers") with the desired multispecific antibody, which are byproducts of the production method, and are particularly monomeric, thus requiring purification.

[0466] Importantly, the technical problems associated with the formation of light chain dimers, particularly when fused to further antigen-binding fragments at the N-terminus and / or C-terminus, have not been identified to date. Commonly used analytical methods do not allow for the detection and quantification of these added LC dimers within the heterogeneous products of the production method. This can introduce significant bias when estimating the amount of the product using standard analytical methods.

[0467] Therefore, there is a need to improve multispecific antibodies and their production methods, which would allow for the easy and efficient isolation and removal of LC dimers in the earliest steps of the production process, thereby improving the yield of the target protein for therapeutic use, i.e., multispecific antibodies, particularly the monomeric form of the protein.

[0468] The multispecific antibodies of the present invention have been manipulated to provide improved multispecific antibodies with equivalent functionality and stability, while increasing the yield of the "multispecific antibody" material, particularly monomers, obtained after purification, especially after a one-step purification including A protein affinity chromatography.

[0469] Advantageously, the multispecific antibodies of this disclosure can be purified more efficiently by an improved purification method than those commonly used in the prior art, particularly by involving fewer steps, which is cost- and time-efficient on an industrial scale. In particular, the multispecific antibodies of this disclosure maximize the amount of the target protein (i.e., the correct multispecific antibody format) obtained after a one-step purification method including A protein affinity chromatography, thereby simultaneously purifying the target multispecific antibody and removing the adducted LC dimer. Advantageously, the method for producing and purifying the multispecific antibodies of this disclosure does not require additional purification steps, particularly adducted LC dimers, to capture excess free unbound light chains.

[0470] The present invention provides a method for producing a multispecific antibody or antigen-binding domain according to the present invention, comprising culturing host cells according to the present invention under conditions suitable for producing a multispecific antibody or antigen-binding domain according to the present invention, and isolating the multispecific antibody or antigen-binding domain.

[0471] A multispecific antibody or antigen-binding domain may contain only heavy chain or light chain polypeptides, in which case only the heavy chain or light chain polypeptide coding sequence needs to be used to transfect host cells. For the production of antibodies or antigen-binding domains containing both heavy and light chains, a cell line can be transfected with two vectors: a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide. Alternatively, a single vector containing sequences encoding both light and heavy chain polypeptides may be used.

[0472] Therefore, a method is provided for culturing host cells to express a multispecific antibody or antigen-binding domain, isolating the latter, and optionally purifying it, to provide the isolated multispecific antibody or antigen-binding domain. In one embodiment, the method further includes the step of conjugating an effector molecule to the isolated antibody or fragment.

[0473] The present invention also provides a method for producing an antibody according to the present invention, comprising culturing a host cell containing the vector of the present invention under conditions suitable for eliciting protein expression from DNA encoding the antibody molecule of the present invention, and isolating the antibody molecule.

[0474] Antibody molecules may contain only heavy chain or light chain polypeptides, in which case only the heavy chain or light chain polypeptide coding sequence needs to be used to transfect host cells. For the production of products containing both heavy and light chains, cell lines can be transfected with two vectors: a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide. Alternatively, a single vector containing sequences encoding both light and heavy chain polypeptides may be used.

[0475] The antibodies and antigen-binding fragments according to the present invention are expressed at favorable levels from host cells. Therefore, the properties of the antibodies and / or fragments are optimized and appear to be useful for commercial processing.

[0476] purified antibody In one embodiment, a purified antibody, such as a humanized antibody, and in particular the antibody according to the present invention, is provided that is substantially purified from endotoxin and / or host cell protein or DNA, and in particular does not contain or substantially contains endotoxin and / or host cell protein or DNA.

[0477] "Substantially endotoxin-free" generally refers to an endotoxin content of 1 EU or less per 1 mg of antibody product, for example, 0.5 or 0.1 EU per 1 mg of product.

[0478] "Substantially free of host cell proteins or DNA" generally means, where necessary, that the host cell protein and / or DNA content is 400 μg or less per 1 mg of antibody product, for example, 100 μg / mg or less, and particularly 20 μg / mg.

[0479] In vitro and ex vivo use of multispecific antibodies The present invention also provides an in vitro or ex vivo method for inhibiting IL22-induced STAT3 phosphorylation, comprising contacting keratinocyte cells with the multispecific antibody of the present invention and incubating them. Any keratinocyte cells and their derivatives, including HaCaT cells, can be used.

[0480] The present invention further provides an in vitro or ex vivo method for inhibiting IL-22-induced IL-10 release, comprising contacting epithelial cells with an antibody containing an IL-22-binding domain according to the present invention and incubating them. More specifically, COLO205 cells can be used.

[0481] Also provided is an in vitro or ex vivo method for inhibiting IL22-induced S100A7 release, comprising contacting keratinocytes with an antibody containing the IL22-binding domain according to the present invention and incubating them.

[0482] Also provided is an in vitro or ex vivo method for inhibiting IL22-induced epidermal thickening associated with abnormal keratinocyte differentiation and parakeratosis, comprising contacting and incubating a reconstituted epithelium consisting of keratinocytes and dermal fibroblasts with the antibody according to the present invention. In particular, abnormal keratinocyte proliferation and differentiation demonstrated by IL22-induced epidermal thickening and parakeratosis are inhibited.

[0483] Cells are generally incubated for a sufficient time for antibodies or their antigen-binding fragments to bind to their targets and produce a biological effect.

[0484] Methods involving multispecific antibodies may be used to achieve biological effects such as those described in the examples herein.

[0485] Therapeutic use of multispecific antibodies The multispecific antibodies, formulations thereof, or pharmaceutical compositions of the present invention may be administered for prophylactic and / or therapeutic purposes.

[0486] The present invention provides a multispecific antibody or a pharmaceutical composition thereof for use as a pharmaceutical.

[0487] In prophylactic use, a multispecific antibody, formulation, or composition is administered to a subject at risk of any disorder or condition as described herein in an amount sufficient to prevent or reduce the subsequent effects of one or more of the conditions or symptoms thereof.

[0488] For therapeutic purposes, multispecific antibodies are administered to subjects already suffering from the disorders or conditions described herein in amounts sufficient to cure, alleviate, or partially cessate one or more of the conditions or symptoms thereof. Such therapeutic treatment may result in a reduction in the severity of disease symptoms or an increase in the frequency or duration of asymptomatic periods.

[0489] The subject being treated may be an animal. Preferably, the pharmaceutical composition according to the present invention is suitable for administration to human subjects.

[0490] The present invention provides a method for treating a disorder or condition described herein in a subject that requires treatment of such disorder or condition, the method comprising administering a multispecific antibody according to the present invention to the subject. The multispecific antibody is administered in a therapeutically effective dose.

[0491] The present invention also provides multispecific antibodies for use in the treatment of disorders or conditions as described herein.

[0492] Therapeutic use of antibody combinations that bind to IL22 and IL13 The present invention also provides the therapeutic use of a combination of an antibody that binds to IL-13 and an antibody that binds to IL-22. Such a combination may be in the form of a composition containing an antibody that binds to IL-13 and a composition containing an antibody that binds to IL-22, or in the form of two separate antibodies.

[0493] Antibody combinations, compositions, formulations thereof, or pharmaceutical compositions thereof may be administered for prophylactic and / or therapeutic purposes.

[0494] In prophylactic applications, antibodies, formulations, or combinations thereof are administered to subjects at risk of any disorder or condition as described herein in an amount sufficient to prevent or reduce the subsequent effects of one or more of the conditions or symptoms thereof.

[0495] For therapeutic purposes, antibodies are administered to subjects already suffering from the disorders or conditions described herein in amounts sufficient to cure, alleviate, or partially cessate one or more of the conditions or symptoms thereof. Such therapeutic treatment may result in a reduction in the severity of disease symptoms or an increase in the frequency or duration of asymptomatic periods.

[0496] The subject being treated may be an animal. Preferably, the pharmaceutical composition containing the antibody combination is suitable for administration to human subjects.

[0497] The present invention provides a method for treating a disorder or condition described herein in a subject requiring such treatment, the method comprising administering a combination of an antibody that binds to IL-13 and an antibody that binds to IL-22 to the subject. Such antibodies are administered in a therapeutically effective dose.

[0498] The present invention provides a method for treating a disorder or condition described herein in a subject requiring such treatment, the method comprising administering to the subject a composition comprising an antibody that binds to IL13 and an antibody that binds to IL22. Such antibodies are administered in a therapeutically effective dose.

[0499] The combination reduces skin barrier dysfunction and / or parakeratosis and / or the release of antimicrobial peptides.

[0500] In relation to the combination, anti-IL13 antibodies and anti-IL22 antibodies can be administered simultaneously or subsequently.

[0501] The present invention also provides a combination of an antibody that binds to IL13 and an antibody that binds to IL22 for use in treating the disorders or conditions described herein.

[0502] The present invention also provides compositions comprising antibodies that bind to IL13 and antibodies that bind to IL22 for use in treating the disorders or conditions described herein.

[0503] Each antibody in the combination or composition can be independently selected from full-length antibodies, Fab, scFv, Fv, dsFv, and dsscFv as described above.

[0504] Each antibody in the combination can be independently selected from monoclonal, humanized, human, and chimeric forms.

[0505] Indications for treatment The multispecific antibodies, combinations, and compositions of the present invention may be used in the treatment, prevention, or improvement of inflammatory skin conditions associated with IL22, IL22R1, IL13, or IL13RA1 activity; for example, any condition arising entirely or partially from signaling mediated by IL22R1, IL13RA1, IL-13R2, and / or IL-22BP.

[0506] IL22 is primarily produced by lymphoid cells such as T helper 1 (Th1), Th17, and Th22 cells, γδT cells, natural killer (NK) cells, and innate lymphoid cells (ILCs) 3, as well as non-lymphoid cells such as fibroblasts, neutrophils, macrophages, and mast cells. High levels of IL22 have been found in human psoriatic plaques (Boniface et al., Clin Exp Immunol. 150:407-415 (2007)), and the involvement of this cytokine in the pathogenesis of psoriasis has been demonstrated in a mouse model of skin inflammation (Van Belle et al. J Immunol. January 1;188(1):462-9 (2012)). Ligands such as IL22, which transmit signals via IL22R1, are involved in many diseases, and since IL22R1 is expressed on skin and epithelial cells, important diseases affecting the skin and epithelium are those that affect the skin and epithelium. IL-13 is a multifaceted cytokine involved in immune response states, such as atopic dermatitis, asthma, allergies, and inflammatory responses. The role of IL-13 in immune responses is facilitated by its influence on cellular signaling pathways. IL-13 has been shown to play a role in epidermal thickening.

[0507] The antibodies and compositions of the present invention can be used to treat inflammatory skin conditions. In certain embodiments, the inflammatory skin condition is selected from psoriasis, psoriatic arthritis, contact dermatitis, chronic hand eczema, or atopic dermatitis. More specifically, the inflammatory skin disease is atopic dermatitis.

[0508] In particular, as demonstrated by the present invention, the antibodies and compositions of the present invention inhibit abnormal keratinocyte differentiation and epidermal thickening associated with parakeratosis in subjects diagnosed with inflammatory skin conditions.

[0509] As a result, the present invention provides a method for attenuating impaired skin barrier function and / or parakeratosis and / or the release of cytokines and / or antimicrobial peptides, such as S100A7, in subjects diagnosed with inflammatory skin diseases, the method comprising administering the antibody provided in the present invention to the subject.

[0510] In yet another embodiment, the present invention provides antibodies for use in reducing epidermal thickening, impaired skin barrier function, and / or parakeratosis, and / or the release of cytokines and / or antimicrobial peptides, such as S100A7, and / or eotaxin-3, in subjects diagnosed with inflammatory skin diseases.

[0511] In yet another embodiment, the present invention provides the use of antibodies of the present invention for producing pharmaceuticals to reduce epidermal thickening, impaired skin barrier function, and / or parakeratosis, and / or the release of cytokines and / or antimicrobial peptides, such as S100A7, in subjects diagnosed with inflammatory skin diseases.

[0512] In particular, such a reduction in skin barrier function is achieved by decreasing abnormal IL22-mediated keratinocyte proliferation and differentiation.

[0513] Diagnostic use of antibodies Furthermore, part of the present invention involves the use of antibodies as diagnostic activators or in diagnostic assays for diagnosing inflammatory skin diseases, for example.

[0514] Diagnosis may preferably be performed on a biological sample. “Biological sample” encompasses various sample types obtained from an individual and can be used in a diagnostic assay or monitoring assay. The definition includes blood such as cerebrospinal fluid, plasma, and serum, as well as other liquid samples of biological origin such as urine and saliva, solid tissue samples such as biopsy specimens or tissue cultures, or cells and their offspring derived therefrom. This definition also includes samples that have been manipulated in any way after their procurement, for example, by treatment with reagents, solubilization, or concentration of specific components such as polynucleotides.

[0515] Diagnostic tests may preferably be performed on biological samples that have not come into contact with the human or animal body. Such diagnostic tests are also called in vitro tests. In vitro diagnostic tests may rely on in vitro methods to detect markers in biological samples obtained from individuals.

[0516] Pharmaceutical compositions and diagnostic compositions Antibodies or compositions of antibodies may be provided as pharmaceutical compositions. Pharmaceutical compositions are usually sterile and typically contain pharmaceutically acceptable carriers and / or adjuvants. The pharmaceutical compositions of the present invention may further contain pharmaceutically acceptable adjuvants and / or carriers.

[0517] Since the antibodies of the present invention are useful in the treatment, diagnosis and / or prevention of disorders or conditions as described herein, the present invention also provides pharmaceutical compositions or diagnostic compositions comprising the antibodies according to the present invention or their antigen-binding fragments in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents.

[0518] In particular, the antibody or its antigen-binding fragment is provided as a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients, diluents, or carriers.

[0519] These compositions may contain, in addition to the therapeutic active ingredient(s), pharmaceutically acceptable excipients, carriers, diluents, buffers, stabilizers, or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.

[0520] The present invention also provides compositions comprising a pharmaceutical formulation comprising an antibody, or a polynucleotide comprising a sequence encoding such an antibody. In certain embodiments, the composition comprises one or more antibodies bound to IL13 and IL22, or one or more polynucleotides comprising a sequence encoding one or more antibodies bound to IL13 and IL22. These compositions may further comprise a suitable carrier known in the art, such as an adjuvant comprising a pharmaceutically acceptable excipient and / or buffer.

[0521] The antibody pharmaceutical compositions described herein are prepared by mixing such antibodies having a desired purity with one or more pharmaceutically acceptable carriers in the form of lyophilized formulations or aqueous solutions.

[0522] Examples of the above technologies and protocols can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.

[0523] Pharmacochemically acceptable carriers are generally non-toxic to the recipient at the doses and concentrations used and are not limited to buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; alkylparabens, e.g., methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); and low molecular weight (less than approximately 10 residues). Examples of pharmaceutically acceptable carriers as used herein include polypeptides; proteins, e.g., serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, e.g., polyvinylpyrrolidone; amino acids, e.g., glycine, glutamine, asparagine, histidine, arginine, lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; chelating agents, e.g., EDTA; sugars, e.g., sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, e.g., sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers as used herein include interstitial drug dispersants, e.g., soluble neutral-active hyaluronidase glycoproteins (sHASEGP), e.g., human soluble PH-20 hyaluronidase glycoprotein, e.g., rHuPH20 (HYLENEX®, Baxter International, Inc.). Specific exemplary sHASEGPs, including rHuPH20, and methods of use are described in U.S. Patent Applications Publications 2005 / 0260186 and 2006 / 0104968. In one embodiment, sHASEGP is combined with one or more additional glycosaminoglycans, such as chondroitinase.

[0524] An example of a lyophilized antibody preparation is described in U.S. Patent No. 6,267,958. Aqueous antibody preparations include those described in U.S. Patent No. 6,171,586 and International Publication No. 2006 / 044908, the latter of which contains histidine-acetate buffer.

[0525] The active ingredient may be encapsulated in microcapsules (e.g., hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules, respectively) prepared by coacervation technology or interfacial polymerization, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules), or in macroemulsions. Such techniques are described in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0526] A sustained-release preparation may be prepared. A suitable example of a sustained-release preparation is a semipermeable matrix of a solid hydrophobic polymer containing an antibody, the matrix being in the form of a molded article, such as a film or microcapsule.

[0527] Preparations used for in vivo administration are generally sterile. Sterilization can be easily achieved, for example, by filtration using a sterile filtration membrane.

[0528] An example of a lyophilized antibody preparation is described in U.S. Patent No. 6,267,958. Aqueous antibody preparations include those described in U.S. Patent No. 6,171,586 and International Publication No. 2006 / 044908.

[0529] The pharmaceutical composition of the present invention may comprise one or more pharmaceutically acceptable salts.

[0530] Pharmaceutically acceptable carriers include aqueous carriers or diluents. Suitable aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, buffer water, and physiological saline. Other examples of carriers include ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. In many cases, it is desirable to include an isotonic agent, such as sugar, polyhydric alcohol, such as mannitol, sorbitol, or sodium chloride, in the composition.

[0531] Pharmaceutical compositions typically must be sterile and stable under manufacturing and storage conditions. Compositions can be formulated as solutions, microemulsions, liposomes, or other ordered structures suitable for high drug concentrations.

[0532] In one embodiment, the antibody or its antigen-binding fragment according to the present invention is the sole active ingredient. In another embodiment, the antibody or its antigen-binding fragment according to the present invention is combined with one or more additional active ingredients. Alternatively, a pharmaceutical composition comprising the antibody or its antigen-binding fragment according to the present invention as the sole active ingredient can be administered individually to a patient (for example, simultaneously, sequentially, or separately) in combination with other drugs, medications, or hormones.

[0533] The exact properties of the carrier or other materials may depend on the route of administration, e.g., oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, and intraperitoneal routes. For example, a solid oral form may contain, along with the active substance, diluents such as lactose, dextrose, saccharose, cellulose, corn starch, or potato starch; lubricants such as silica, talc, stearic acid, magnesium stearate, or calcium stearate, and / or polyethylene glycol; binders such as starch, gum arabic, gelatin, methylcellulose, carboxymethylcellulose, or polyvinylpyrrolidone; disaggregating agents such as starch, alginic acid, alginate, or sodium starch glycolate; foaming mixtures; dyes; sweeteners; wetting agents such as lecithin, polysorbate, or lauryl sulfate, and generally non-toxic and pharmacologically inert substances used in pharmaceutical formulations. Such pharmaceutical preparations can be manufactured by known methods, for example, by mixing, granulation, tableting, sugar coating, or film coating processes.

[0534] Oral formulations include commonly used excipients such as pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained-release formulations, or powders, and contain 10% to 95%, preferably 25% to 70%, of the active ingredient. If the pharmaceutical composition is lyophilized, the lyophilized material may be reconstituted before administration (e.g., into a suspension). Reconstitution is preferably carried out in a buffer solution.

[0535] The solution for intravenous administration or infusion may contain, for example, sterile water as a carrier, or preferably in the form of sterile aqueous isotonic saline.

[0536] Preferably, the pharmaceutical composition or diagnostic composition contains a humanized antibody according to the present invention.

[0537] Therapeutic effective dose and dosage Antibodies and pharmaceutical compositions can be appropriately administered to patients to identify the required therapeutically effective dose. For any antibody, the therapeutically effective dose can first be estimated using a cell culture assay or an animal model, usually rodents, rabbits, dogs, pigs, or primates. Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes of administration in humans.

[0538] The precise therapeutically effective dose for human subjects will depend on the severity of the disease state, the subject's general health status, age, weight, and sex, diet, time and frequency of administration, possible drug combinations, sensitivity to response, and tolerance / response to treatment. Compositions may be conveniently provided in unit dose forms containing a predetermined amount of the activator of this disclosure per dose. Dose ranges and regimens for any of the embodiments described herein include, but are not limited to, doses in the range of 1 mg to 1000 mg unit doses.

[0539] The appropriate dosage of the antibody / modulator or pharmaceutical composition of the present invention can be determined by those skilled in the art. The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention may be varied to obtain an amount of the active ingredient that is not toxic to the patient and is effective in achieving the desired therapeutic response for a particular patient, composition, and mode of administration. The selected dosage level depends on various pharmacokinetic factors, including the activity of the particular composition of the present invention used, the route of administration, the time of administration, the excretion rate of the particular compound used, the duration of treatment, other drugs, compounds and / or materials used in combination with the particular composition used, the age, sex, weight, condition, overall health and prior medical history of the patient being treated, and similar factors well known in the medical field.

[0540] An appropriate dose may range, for example, from approximately 0.01 μg / kg to approximately 1000 mg / kg body weight of the patient being treated, typically from approximately 0.1 μg / kg to approximately 100 mg / kg body weight.

[0541] The administration regimen may be adjusted to provide the optimal desired response (e.g., therapeutic response). For example, a single dose may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the urgency of the treatment situation. As used herein, the administration unit form refers to a physically distinct unit suitable as a unit dose for the subject being treated, each unit containing a predetermined amount of the active compound calculated to produce the desired therapeutic effect in relation to the required pharmaceutical carrier.

[0542] Administration of pharmaceutical compositions or preparations Antibodies or preparations or compositions thereof may be administered for prophylactic and / or therapeutic purposes.

[0543] Antibodies or pharmaceutical compositions may be administered via one or more routes of administration using one or more of the various methods known in the art. As will be understood by those skilled in the art, the route of administration and / or mode of administration will vary depending on the desired outcome. Examples of routes of administration for the compounds or pharmaceutical compositions of the present invention include intravenous, intramuscular, intradermal, intraocular, intraperitoneal, subcutaneous, spinal, or other parenteral administration routes, for example, by injection or infusion. Alternatively, the antibodies / modifiers or pharmaceutical compositions of the present invention may be administered via parenteral routes such as topical, epidermal, or mucosal administration routes. The antibodies / modifiers or pharmaceutical compositions of the present invention may be for oral administration.

[0544] Suitable forms for administration include those suitable for intravenous, inhalable, or subcutaneous parenteral administration, such as by injection or infusion, such as by bolus injection or continuous infusion. If the product is for injection or infusion, it may take the form of a suspension, solution, or emulsion in an oily or aqueous vehicle and may contain additional agents such as suspending agents, preservatives, stabilizers, and / or dispersants. Alternatively, the antibody or its antigen-binding fragment according to the present invention may be in a dry form for reconstitution with a suitable sterile solution before use. A solid form suitable for dissolution in a liquid vehicle or suspension in a liquid vehicle before injection can also be prepared.

[0545] Once formulated, the compositions of the present invention can be administered directly to a target. Therefore, the use of antibodies or their antigen-binding fragments according to the present invention for the manufacture of pharmaceuticals is provided herein.

[0546] Products and Kits This disclosure also provides a kit and instructions for use comprising the antibody of the present invention. The kit may further comprise one or more additional reagents, such as additional therapeutic or prophylactic agents as discussed above.

[0547] This invention provides for the use of multispecific antibodies or pharmaceutical compositions thereof according to the present invention for the manufacture of pharmaceuticals.

[0548] The present invention also provides the use of the multispecific antibodies of the present invention for manufacturing pharmaceuticals for treating disorders or conditions as described herein.

[0549] The present invention also provides the use of a combination of an antibody that binds to IL22 and an antibody that binds to IL13, or a pharmaceutical composition thereof, for manufacturing a pharmaceutical for treating the disorders or conditions described herein.

[0550] The present invention also provides the use of a composition comprising an antibody that binds to IL22 and an antibody that binds to IL13, or a pharmaceutical composition thereof, for the manufacture of a pharmaceutical for treating a disorder or condition as described herein.

[0551] In certain embodiments, the product or kit includes a container containing one or more antibodies of the present invention or compositions described herein. In certain embodiments, the product or kit includes a container containing nucleic acids(s) or compositions encoding one (or more) antibodies described herein. In some embodiments, the kit includes cells or cell lines that produce antibodies described herein.

[0552] In certain embodiments, the product or kit includes a container and a label or accompanying information on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container may be formed from a variety of materials such as glass or plastic. The container may hold the composition, either by itself or in combination with another composition effective for treatment, prevention and / or diagnosis, and may have a sterile access port. At least one agent in the composition is the antibody of the present invention. The label or accompanying information indicates that the composition is used for the treatment of inflammatory skin conditions, more specifically atopic dermatitis.

[0553] It should be noted that the above embodiments are illustrative and not limiting to the present invention, and that those skilled in the art can design many alternative embodiments without departing from the scope of the claims.

[0554] Tables 10-17 show the sequences included in the present invention.

[0555] Table 10. Sequences of IL22, IL13, and albumin-related proteins [Table 10]

[0556] Table 11. CDRs and IL13 / IL22 TrYbe sequences of the IL13-binding domain, IL22-binding domain, and albumin-binding domain. [Table 11-1] [Table 11-2] [Table 11-3] [Table 11-4] [Table 11-5] [Table 11-6] [Table 11-7] [Table 11-8] [Table 11-9]

[0557] Table 12.11070 IL22 binding domain sequence [Table 12-1] [Table 12-2]

[0558] Table 13. Other 11041 sequences (IL22 binding domains) [Table 13-1] [Table 13-2] [Table 13-3]

[0559] Table 14. Other 11070 sequences (IL22 binding domains) [Table 14]

[0560] Table 15. Other IL13-binding domain sequences [Table 15]

[0561] Table 16 Human receptor framework used in IL22 binding domains [Table 16]

[0562] Table 17. Sequence of IL / IL22 bispecific KiH molecules [Table 17-1] [Table 17-2] [Table 17-3] [Table 17-4]

[0563] example Example 1: Preparation and selection of the therapeutic anti-IL13 antibody CA650 Rats were immunized with either purified human IL-13 (Peprotech) or rat fibroblasts expressing human IL-13 (expressing approximately 1 μg / ml in the culture supernatant), or in some cases, a combination of both. After 3–6 injections, the animals were sacrificed and PBMCs, spleen, bone marrow, and lymph nodes were collected. Serum was monitored for binding to human IL-13 by ELISA and for its ability to neutralize hIL-13 in the HEK-293 IL13R-STAT-6 reporter cell assay (HEK-Blue assay, Invivogen).

[0564] B cell cultures were prepared, and the supernatant was initially screened for their ability to bind to hIL13 in a bead-based assay in the Applied Biosystems FMAT assay. This was a homogeneous assay using biotinylated human IL13 coated on streptavidin beads and a goat anti-rat Fc-Cy5 conjugate as a reveal agent. Positive results from this assay were then advanced to the HEK-293 IL13R-STAT-6 reporter cell assay (HEK-Blue assay, Invivogen) to identify the neutralizing agent. The neutralizing supernatant was then profiled with Biacore to estimate the offrate and characterize the mode of action of the neutralization. Neutralizations were classified as either Bin 1 or Bin 2. Bin 1 represents an antibody that binds to human IL13, prevents the binding of IL13Rα1, and consequently also blocks the binding of IL-4R. Bin 2 represents an antibody that binds to human IL13 in a way that allows binding to IL13Rα1 but prevents the recruitment of IL-4R to the complex. I selected antibody Bin 1.

[0565] In primary FMAT screening from a total of 27 × 100 plate SLAM experiments, approximately 7500 IL13-specific positories were identified. 800 wells demonstrated neutralization in the HEK-blue assay. 170 wells contained the Bin 1 antibody with the desirable Biacore profile, i.e., an off-rate of less than 5 × 10⁻⁴ s⁻¹. Variable region cloning was attempted from these 170 wells, and 160 successfully obtained fluorescence foci. 100 wells generated heavy chain variable region gene pairs and light chain variable region gene pairs after reverse transcription (RT)-PCR. These V-region genes were cloned as full-length mouse IgG1 antibodies and re-expressed in a HEK-293 transient expression system. Sequence analysis revealed the existence of 27 unique families of anti-human IL13 antibodies. Next, these recombinant antibodies were retested in cell-based assays for their ability to block recombinant hIL13 (derived from Escherichia coli (E. coli) and mammalian sources), recombinant mutant hIL13 (R130Q) (derived from Escherichia coli (E. coli)), naturally occurring wild-type and mutant hIL13 (derived from human donors), and cynomolgus monkey IL13 (derived from mammals). The recombinant antibodies were also tested in Biacore for their ability to bind mutant human IL13 (R130Q) and cynomolgus monkey IL13. Following this characterization, five antibody families met our criteria, namely, antibodies with a concentration of less than 100 pM, which represents minimal reduction in potency and affinity for all human and cynomolgus monkey IL13 preparations.

[0566] Based on neutralizing efficacy, affinity, and donor content in the humanized graft (see below), humanized CA650 was selected for further progression.

[0567] Example 2: Humanized CA650 antibody Antibody 650 was humanized by transplanting a CDR from the rat V region onto a human germline antibody V region framework. Numerous framework residues from the rat V region were also retained in the humanized sequence to restore antibody activity. These residues were selected using the protocol outlined by Adair et al. (1991) (Humanized antibodies. International Publication No. 91 / 09967). The alignment of the rat antibody (donor) V region sequence and the human germline (receptor) V region sequence, along with the designed humanized sequence, is shown in Figure 2 (Figure 2(A) light chain graft 650 and Figure 2(B) heavy chain graft 650). The CDRs grafted from the donor onto the receptor sequence are as defined by Kabat (Kabat et al., 1987), except for CDR-H1 (see Adair et al., 1991 Humanized antibodies. International Publication No. 91 / 09967), where the Chothia / Kabat combined definition is used.

[0568] The gene encoding the initial V region sequence was designed, constructed using an automated synthesis approach by Entelechon GmbH, and modified to generate grafted versions gL8 and gH9 by oligonucleotide-directed mutagenesis. The gL8 sequence was subcloned into the UCB Celltech human light chain expression vector pVhCK, which contains DNA encoding the human C-Kappa constant region (Km3 allotype). The gH9 sequence was subcloned into pVhg1Fab, which contains DNA encoding the human heavy chain gamma-1 CH1 constant region.

[0569] The human V region IGKV1-39 + JK2 J region (International Immunogenetics Information System® IMGT, http: / / www.imgt.org) was selected as the receptor for the antibody 650 light chain CDR. All light chain framework residues in graft gL8 are derived from human germline genes, with the exception of residues 58 and 71 (numbering follows Kabat), which retain the donor residues isoleucine (I58) and tyrosine (Y71), respectively. Retention of residues I58 and Y71 was essential for the full potency of the humanized antibody.

[0570] The human V region IGHV1-69+JH4 J region (IMGT, http: / / www.imgt.org) was selected as the receptor for the heavy chain CDR of antibody 650. All heavy chain framework residues in graft gH9 are derived from human germline genes, except for residues 67, 69, and 71 (see Sequence ID No. 29, numbered by Kabat and residues 68, 70, and 72) which retain the donor residues alanine (A67), phenylalanine (F69), and valine (V71), respectively. Retention of residues A67, F69, and V71 was essential for the full potency of the humanized antibody. The glutamine residue at position 1 of the human framework was substituted with glutamic acid (E1) to obtain homogeneous product expression and purification: the conversion of glutamine to pyroglutamate at the N-terminus of antibodies and antibody fragments has been widely reported. The final selected variable graft sequences, gL8 and gH9, are shown in Figure 2(A) and Figure 2(B), respectively (1539gL8gH9).

[0571] Figure 2 shows the CDR, heavily variable region, lightly variable region, and the amino acid and DNA sequences encoding the scFv and dsscFV formats of antibody 650.

[0572] Example 3: Preparation of anti-human albumin antibody 645 The production of anti-human albumin antibody 645 was previously described in International Publication No. 2013 / 068571. The amino acid and DNA sequences encoding the CDR, heavy and light variable regions, scFv and dsscFV formats of antibody 645 are listed in Table 11.

[0573] Example 4: Preparation and selection of therapeutic anti-IL22 antibodies 11041 and 11070 Numerous animals of different species (including mice, rats, and rabbits) were immunized with either purified, in-house-produced human IL-22 or commercially available human IL-22 (R&D systems). After 3–5 injections, the animals were sacrificed, and PBMCs, spleens, bone marrow, and lymph nodes were collected. Serum was monitored for binding to human and cynomolgus monkey IL-22 by ELISA.

[0574] In the case of 11041, memory B cell cultures were prepared, and the supernatant was initially screened for their ability to bind to human and cynomolgus monkey IL22 in a bead-based assay using the TTP Labtech Mirrorball system. This was a homogeneous multiplex assay using biotinylated human IL22 and biotinylated cynomolgus monkey IL22 coated on Sol-R streptavidin beads (TTP Labtech), along with a goat anti-rabbit Fc-FITC conjugate as a reveal agent.

[0575] In the primary mirrorball screening from a total of 12×(164-400) plate B culture experiment, approximately 4500 IL22-specific positive hits were identified. The positive supernatant from this assay was then further characterized as follows: • To confirm binding to IL-22 in humans and cynomolgus monkeys using ELISA, • Progression to IL22-dependent HACAT phosphoSTAT-3 HTRF cell assay (CisBio) to identify neutralizing agents, and • Profiling in BIAcore to estimate the off-rate and characterize the mode of neutralization.

[0576] Neutralization was classified into either Bin 1 or Bin 2. Bin 1 represents an antibody that binds to human IL22 and prevents the binding of IL22R1. Bin 2 represents an antibody that binds to human IL22 but allows the binding of IL22R1. Bin 1 antibodies were selected. Wells demonstrating neutralization in the phosphoSTAT-3 HTRF assay and / or wells with a desirable BIAcore profile were advanced for V-region retrieval using fluorescence focusing.

[0577] Bone marrow-derived plasma cells were also directly screened for their ability to bind to human IL-22 using fluorescence focusing (related to 11070). Here, B cells secreting IL-22-specific antibodies were collected on biotinylated human IL-22 immobilized on streptavidin beads using a reagent to elucidate goat anti-rat Fc-FITC conjugates. Approximately 300 direct foci were selected.

[0578] Following reverse transcription (RT) and PCR of selected cells, "transcriptional activity PCR" (TAP) products encoding the V region of the antibody were generated and used to transiently transfect HEK-293 cells. The resulting TAP supernatant containing the recombinant antibody was conjugated to human IL22 and cynomolgus monkey IL22, and its ability to block IL22R1 binding in BIAcore and neutralize IL22 in a HACAT phosphoSTAT-3 HTRF cell assay was tested.

[0579] Next, heavy and light chain variable region gene pairs from interesting TAP products were cloned as rabbit or mouse Fab antibodies and re-expressed in a HEK-293 transient expression system. A total of 131 V regions were cloned and sequenced. The recombinant cloned antibodies were then re-tested for their ability to conjugate human and cynomolgus monkey IL22, block IL22R1 binding in BIAcore, and neutralize IL22-dependent IL-10 release in a COLO205 IL-10 HTRF cell-based assay (CisBio). Following this characterization, two antibodies met the criteria, namely rabbit-derived 11041 and rat-derived 11070.

[0580] Based on neutralizing efficacy, affinity for both human IL22 and cynomolgus monkey IL22, donor content in humanized grafts (see below), and expression data, rabbit-derived 11041 was selected for further progression.

[0581] Example 5: Binding of rabbit 11041 Fab to human, cynomolgus monkey, and mouse IL22. The affinity of purified rabbit 11041 Fab for human, cynomolgus monkey, and mouse IL22 was evaluated using a Biacore T200 instrument (GE Healthcare) by capturing rabbit 11041 Fab with immobilized anti-rabbit IgG F(ab')2, followed by titration of IL22 from various sources. Affinipure goat anti-rabbit IgG-F(ab')2 fragment-specific (Jackson ImmunoResearch) was immobilized on a CM5 sensor tip via amine coupling chemistry to a capture level of approximately 5000 response units (RU). HBS-EP+ buffer (10 mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% surfactant P20, GE Healthcare) was used as the running buffer at a flow rate of 10 μL / min. 10 μL injection of 0.5 μg / mL of 11041 Fab was used for capture by the immobilized goat anti-rabbit Fab. Human IL-22, cyno IL-22, and mouse IL-22 were titrated at a flow rate of 30 μL / min against captured 11041 Fab (PB0006661) (at concentrations of 0 nM, 0.6 nM, 1.8 nM, 5.5 nM, 16.6 nM, and 50 nM) to evaluate their affinity. Blockade of human IL-22R1 was evaluated by injecting 100 nM IL-22 (at 30 μL / min for 180 seconds), followed by injection of human IL-22R1 (at 50 nM for 180 seconds).

[0582] Surfaces were generated by injecting 2 × 10 μL of 50 mM HCl and dispersed by injecting 10 μL of 5 mM NaOH at a flow rate of 10 μL / min. Background subtraction binding curves were analyzed using Biacore T200 evaluation software following a standard procedure. Kinetic parameters were determined from a fitting algorithm. The kinetic parameters for binding purified 11041 to human, cynomolgus monkey, and mouse IL22 are shown in Table 18.

[0583] Table 18. Kinetic parameters of rabbit 11041 binding to human, cynomolgus monkey, and mouse IL22. [Table 18]

[0584] Example 6: Humanization of 11041 Antibody 11041 was humanized by transplanting a CDR from the rabbit V region onto a human germline antibody V region framework. Numerous framework residues from the rabbit V region were also retained in the humanized sequence to restore antibody activity. These residues were selected using the protocol outlined by Adair et al. (1991) (International Publication No. 91 / 09967). The alignment of the rabbit antibody (donor) V region sequence and the human germline (receptor) V region sequence, along with the designed humanized sequence, is shown in Figures 4 and 5. The CDRs grafted from the donor onto the receptor sequence are as defined by Kabat (Kabat et al., 1987), except for CDR-H1 (see Adair et al., International Publication No. 91 / 09967), where the Chothia / Kabat combination definition is used.

[0585] The human V region IGKV1D-13 + IGKJ4 J region (IMGT, http: / / www.imgt.org / ) was selected as the receptor for the antibody 11041 light chain CDR. While all light chain framework residues in the humanized graft mutants are derived from human germline genes, residues from the group containing residues 2 and 3 (see SEQ ID NO: 99 gL1), which retain the donor residues valine (V2) and valine (V3), are absent, present in only one or two copies. In some humanized graft mutants, the unpaired / free cysteine ​​residue at position 91 of CDRL3 was removed by mutation to either valine (C91V) or serine (C91S): the free cysteine ​​residue may undergo post-translational modifications such as cysteinylation, which can contribute to covalent aggregation and reduced stability. Mutations in this residue resulted in unexpected 15- to 50-fold increases in binding affinity, as measured by surface plasmon resonance (Table 19, gL1gH1 (642 pM) compared to gL1(C91V)gH1 (41.9 pM) or gL1(C91S)gH1 (12.4 pM)). In several humanized graft mutants, the potential asparagine deamide site in CDRL3 was modified by substituting the asparagine residue at position 95 with aspartic acid (N95D) or by substituting the serine residue at position 96 with alanine (S96A). Modification of the deamide site by the S96A mutation significantly reduced the baseline level of deamide.

[0586] The human V region IGHV3-66+IGHJ4 J region (IMGT, http: / / www.imgt.org / ) was selected as the receptor for the heavy chain CDR of antibody 11041. Similar to many rabbit antibodies, the VH gene of antibody 11041 is shorter than that of the selected human receptor. When aligned with the human receptor sequence, framework 1 of the VH region of antibody 11041 lacks the N-terminal residues retained in the humanized antibody (Figure 4). Framework 3 of the 11041 rabbit VH region also lacks two residues in the loop between the beta-sheet chains D and E (75 and 76, referencing SEQ ID NO: 110 gH1): in the humanized graft variant, the gap is filled with the corresponding residues from the selected human receptor sequence (lysine 75, K75; asparagine 76, N76) (Figure 1). All heavy chain framework residues in the humanized graft mutants are derived from human germline genes, with the exception of residues 24, 48, 49, 73, and 78 (see SEQ ID NO: 110 gH1), which retain the donor residues valine (V24), isoleucine (I48), glycine (G49), serine (S73), and valine (V78), respectively. Retention of donor residues V24, I48, G49, and V78 was essential for maximal affinity binding to human IL22, as measured by surface plasmon resonance. In some humanized graft mutants, potential aspartate isomerization sites in CDRH2 were modified by substituting the aspartate residue at position 54 with glutamate (D54E) or by substituting the glycine residue at position 55 with alanine (G55A). In some humanized graft mutants, the potential hydrolysis site of CDRH3 was modified by substituting the aspartic acid residue at position 107 with glutamic acid (D107E).

[0587] Table 19. Binding affinity of different mutants generated [Table 19]

[0588] Example 7: Humanization of 11070 Antibody 11070 was humanized by transplanting a CDR from the rat V region into a human germline antibody V region framework. Numerous framework residues from the rat V region were also retained in the humanized sequence to restore antibody activity. These residues were selected using the protocol outlined by Adair et al. (1991) (International Publication No. 91 / 09967). Alignment of the rat antibody (donor) V region sequence with the human germline (receptor) V region sequence, along with the designed humanized sequence, is shown in Figures 5A and 5B. The CDRs grafted from the donor onto the receptor sequence are as defined by Kabat (Kabat et al., 1987), except for CDR-H1 (see Adair et al., International Publication No. 91 / 09967), where the Chothia / Kabat combination definition is used.

[0589] The human V region IGKV1-12 + IGKJ2 J region (IMGT, http: / / www.imgt.org / ) was selected as the receptor for the antibody 11070 light chain CDR. All light chain framework residues in the humanized graft mutants are derived from human germline genes, with the exception of one or more residues in the group containing residues 3, 44, 58, and 68 (see SEQ ID NO: 127 gL1), which retain the donor residues valine (V3), asparagine (N44), threonine (T58), and serine (S68), respectively. Retention of donor residue N44 was essential for maximum affinity binding to human IL22, as measured by surface plasmon resonance (Table 20).

[0590] The human V region IGHV4-31+IGHJ6 J region (IMGT, http: / / www.imgt.org / ) was selected as the receptor for the heavy chain CDR of antibody 11070. All heavy chain framework residues in the humanized graft mutants are derived from human germline genes, with the exception of one or more residues in the group containing residues 37, 41, 48, 67, 71, 76, and 78 (see SEQ ID NO: 128 gH1), which retain the donor residues valine (V37), serine (S41), methionine (M48), leucine (L67), arginine (R71), serine (S76), and valine (V78), respectively. The glutamine residue at position 1 of the human framework was substituted with glutamic acid (E1) to obtain homogeneous product expression and purification: the conversion of glutamine to pyroglutamate at the N-terminus of antibodies and antibody fragments has been widely reported. Retention of donor residues V37, L67, R71, and V78 was essential for maximum affinity binding to human IL-22, as measured by surface plasmon resonance (Table 20). In several humanized graft mutants, the potential asparagine deamide site in CDRH2 was modified by substituting the serine residue at position 61 with threonine (S61T).

[0591] Table 20: Binding affinity of different generated variants of the 11070 antibody. [Table 20]

[0592] Example 8: Cloning and creation of mutants Genes encoding variants of the heavy and light chain V region sequences were designed and constructed using an automated synthesis approach with ATUM (Newark, CA). Further variants of the heavy and light chain V regions were generated by modifying the VH and VK genes by oligonucleotide-directed mutagenesis, which in some cases included mutations within the CDR. For transient expression in mammalian cells, the humanized light chain V region gene was cloned into the UCB light chain expression vector pMhCK, which contains DNA encoding the human Kappa chain constant region (Km3 allotype). The humanized heavy chain V region gene was cloned into the UCB human gamma-1 Fab heavy chain expression vector pMhFabnh, which contains DNA encoding the human gamma-1 CH1 hinge domain. Co-transfection of the resulting heavy and light chain vectors into Expi293™ suspension cells resulted in the expression of humanized recombinant antibodies in human Fab format. We evaluated mutant humanized Fab antibodies against human IL22 compared to the parent antibody, their efficacy in in vitro assays, their biophysical properties, and their suitability for downstream processing.

[0593] Example 9: Binding characteristics of humanized 11041 Fab antibody Humanized samples were tested for 11,041 antibodies by capturing the sample on immobilized anti-human IgG-F(ab')2 and then titrating the captured surface with human IL22. The assay was performed using a Biacore 8K instrument (GE Healthcare), and Biomolecular Interaction Analysis (BIA) was performed using Biacore 8000 evaluation software. Affinpure goat anti-human IgG-F(ab')2 fragment-specific (Jackson ImmunoResearch) was immobilized on a CM5 sensor chip to a capture level of approximately 5,000 response units (RU) via amine coupling chemistry. HBS-EP+ buffer (10 mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% surfactant P20, GE Healthcare) was used as the running buffer at a flow rate of 10 μL / min. For capture with immobilized goat anti-human Fab IgG, a 10 μL injection of a humanized sample containing 0.5 μg / mL of 11041 antibody was used. Human IL22 (50 nM, 16.7 nM, 5.6 nM, 1.9 nM, and 617 pM) was titrated over the captured 11041 antibodies at a flow rate of 30 μL / min.

[0594] The surface was generated by injecting 2 × 10 μL of 50 mM HCl and scattered by injecting 5 μL of 5 mM NaOH at a flow rate of 10 μL / min. Background subtraction coupling curves were analyzed using Insight evaluation software following a standard procedure. Kinetic parameters were determined from the fitting algorithm. The IL22 affinity determined from a single experiment is shown in Table 21 and was shown to be less than 100 pM.

[0595] Table 21. Binding affinity between humanized 11041 Fab and IL22 [Table 21]

[0596] Example 10: Evaluation of blockade of the IL22BP binding site on IL22 by humanized 11041 antibody. Using surface plasmon resonance (Biacore T200), we evaluated whether 11041gL13gH14 Fab (as part of a bispecific antibody) or fezakinumab could block the IL22BP binding site of IL22.

[0597] A goat anti-human IgG Fab-specific antibody (Jackson ImmunoResearch) was immobilized on a CM5 Sensorchip to a level of approximately 6000 RU via an amine coupling chemical reaction.

[0598] Each analytical cycle consisted of capturing 11041gL13gH14 Fab or fezakinumab molecules on the anti-Fab surface, injecting 20 nM IL22 (prepared in-house), followed by an injection of 100 nM IL22BP, each at a rate of 30 μl / min for 180 seconds. At the end of each cycle, the surface was regenerated at a flow rate of 10 μl / min using a 60-second injection of 50 mM HCl, followed by a 30-second injection of 5 mM NaOH, and a final 60-second injection of 50 mM HCl. Background binding and drift were subtracted using a control cycle consisting of buffer capture or buffer analyte injection.

[0599] Table 22. IL22 and IL22BP binding response [Table 22]

[0600] When IL22 bound to surface-captured 11041gL13gH14 Fab, IL22BP was unable to bind to IL22. However, when IL22 bound to surface-captured fezakinumab, IL22BP was still able to bind to IL22. In conclusion, 11041gL13gH14 Fab (as part of a bispecific antibody) blocks the IL22BP binding site of IL22, but not fezakinumab.

[0601] Example 11: Purification of IL22 As described by Nagem et al [Nagem et al Structure. 2002 Aug;10(8):1051-62.], a his-tagged version of IL22 was largely purified. BL21(DE3) Escherichia coli strains were transformed by heat shock with an expression construct encoding his-tagged IL22.

[0602] The encoded protein sequence is as follows: MGSSHHHHHHSSGENLYFQGSQGGAAAPISSHCRLDKSNFQQPYITNRTFMLAKEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI(Sequence ID 3)

[0603] IL22 protein sequence after TEV cleavage (see below): GSQGGAAAPISSHCRLDKSNFQQPYITNRTFMLAKEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI(Sequence ID 4)

[0604] Cells were grown in the presence of 100 μg / ml ampicillin, and protein expression was induced by adding IPTG to a concentration of 1 mM when the cells reached an optical density of 1 (measured at 600 nM). After 4 hours, the cells were harvested by centrifugation. After cell lysis with a high-pressure cell homogenizer, inclusion bodies containing IL22 were collected by high-speed centrifugation. The inclusion bodies were washed with 50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, and 0.5% (w / v) DOC (pH 8), and then washed again with the same buffer without detergent. The washed inclusion bodies were solubilized overnight at 4°C in a buffer containing 50 mM MES, 10 mM EDTA, 1 mM DTT, and 8 M urea. Insoluble substances were separated by centrifugation, and IL22 from the soluble fraction was refolded to 0.1 mg / ml in 100 mM Tris-HCl, 2 mM EDTA, 0.5 M arginine, 1 mM reduced glutathione, and 0.1 mM oxidized glutathione by dilution, with a final pH of 8.0. After incubation at 4°C for 72 hours, the protein was concentrated and purified by size exclusion chromatography on a HiLoad 26 / 600 Superdex 75 pg column equilibrated with 25 mM MES pH 5.4 and 150 mM NaCl. The protein was then frozen at -80°C until further use.

[0605] The his tag was removed by incubating the IL22 protein and TEV protease overnight at 4°C. After diluting the protein in PBS containing 25 mM imidazole, the cleaved protein was passed through a 5 ml HisTrap® High Performance column (GE Healthcare) and collected by flow-through.

[0606] Example 12: HDX-MS of IL22 in the presence of 11041gL13gH14 Fab and 11070gL7gH16 Fab Hydrogen-deuterium exchange mass spectrometry (HDX-MS) was used for epitope mapping of IL22 in 11041gL13gH14 Fab and 11070gL7gH16 Fab.

[0607] Sample preparation and data acquisition For HDX-MS analysis, 30 μM IL22 was prepared as described in Example 11, and 30 μM IL22 was prepared by conjugating it with either 90 μM 11041 gL13 gH14 Fab or 11070 gL7 gH16 Fab, and incubated at 4°C for 1 hour. 4 μl of IL22, IL22 / 11041 gL13 gH14 Fab or IL22 / 11070 gL7 gH16 Fab was prepared. The Fab complex was diluted at 25°C in 57 μL of 10 mM phosphate in H2O (pH 7.0) or 10 mM phosphate in D2O (pD 7.0). The deuterated samples were then incubated at 25°C for 0.5, 2, 15, and 60 minutes. After the reaction, all samples were quenched at 1°C by mixing 1:1 with quench buffer (4 M guanidine hydrochloride, 250 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), 100 mM phosphate). The final pH of the mixture was 2.5. The mixture was then digested using a nanoAcquity HDX module (Waters The peptide was immediately injected into the corp. Peptide digestion was then performed online using an Enzymatic online digestion column (Waters) in 0.2% formic acid water at 20°C and a flow rate of 100 μL / min. Triple dilutions were performed at all deuterated points and with undeuterated controls, with blanks between each data point.

[0608] Next, the peptide fragments were captured using an Acquity BEH C18 1.7 μM VANGUARD chilled pre-column for 3 minutes. Next, the peptides were eluted into chilled Acquity UPLC BEH C18 1.7 μM 1.0 × 100 using the following gradient: 0 min, 5% B; 6 min, 35% B; 7 min, 40% B; 8 min, 95% B; 11 min, 5% B; 12 min, 95% B; 13 min, 5% B; 14 min, 95% B; 15 min, 5% B (A: 0.2% HCOOH in H2O, B: 0.2% HCOOH in acetonitrile). The peptide fragments were ionized by positive electrospray to a Synapt G2-Si mass spectrometer (Waters). Data acquisition was performed in ToF-only mode over the m / z range of 50–2000 Th using the MSe method (low collision energy, 4 V; high collision energy: ramp from 18 V to 40 V). Glu-1-fibrinopeptide B peptide was used for internal lock mass correction.

[0609] HDX-MS Data Processing MSE data from non-deuterated control samples of IL22, IL22 / 11041gL13gH14 Fab, or IL22 / 11070gL7gH16 Fab complexes were used for sequence identification using Waters Protein Lynx Global Server 2.5.1 (PLGS). Peptide searches were performed against a database containing only IL22 sequences, using a 500-count precursor intensity threshold and three matched product ions required for assignment. Ion accounting files from the three control samples were combined into a peptide list imported into Dynamx v3.0 software.

[0610] The peptides were further filtered using DynamX. The filtering parameters used were minimum and maximum peptide sequence lengths of 4 and 25, respectively; minimum intensity of 1000; minimum MS / MS product of 2; minimum product per amino acid of 0.2; and maximum MH+ error threshold of 10 ppm. The isotopic envelope resulting from deuterium uptake of each peptide at each time point was quantified using DynamX v3.0. Furthermore, all spectra were examined and visually checked to ensure accurate assignment of m / z peaks, and only peptides with a high signal-to-noise ratio were used for HDX-MS analysis.

[0611] Following manual filtration in Dynamx, statistical analysis and filtration were performed using Deuteros (https: / / academic.oup.com / bioinformatics / article / 35 / 17 / 3171 / 5288775) with statistical analysis published by Houde et al., 2011 (https: / / www.ncbi.nlm.nih.gov / pubmed / 21491437). Deuterium generated a Wood plot displaying the y-axis metric of peptide length, start and end residues, comprehensive coverage, and absolute uptake (Dalton units). This is the difference in uptake in the presence of ligand (binding) and apoform. The Wood plot initially applies confidence filtering to all peptides at each time point. Peptides with deuteration differences outside the selected confidence limits are not significant and are shown in light gray. Significant peptides are shown in dark gray and black. Results were filtered and epitopes identified using an in-house algorithm. The data presented is from after a 0.5-minute deuteration incubation.

[0612] IL22 coverage map HDX analysis of IL22 containing 11041gL13gH14 Fab and 11070gL7gH16 Fab was performed in a single experiment. A total coverage of 91.3% was obtained for HDX-MS experiments from 47 peptides. The peptide redundancy after filtering and analysis was 3.48.

[0613] IL22 HDX-MS in the presence of 11041gL13gH14 Fab Seven peptides (i.e., potential epitopes) were observed to show a statistically significant decrease in deuterium uptake upon antibody binding, six of which were consistent with the analysis (highlighted in black on the Wood plot in Figure 7, A): 72VRLIGEKLFHGVS84, 72VRLIGEKLFHGVSM85, 75IGEKLFHGVS84, 75IGEKLFHGVSM85, 76GEKLFHGVS84, and 80FHGVSM85. Increased deuterium uptake (i.e., potential conformational changes) was observed in three peptides: 101EEVLFPQSDRF111, 103VLFPQSDRFQPYM115, and 103VLFPQSDRFQPYMQE117. The 11041gL13gH14 Fab epitopes were projected onto the structure of IL22 (Figure 7, B). Other regions that are protected or deprotected during antibody binding due to conformational changes are highlighted in dark gray.

[0614] In conclusion, the protected region representing the epitope region of 11041gL13gH14 Fab is residues 72-85 (VRLIGEKLFHGVSM).

[0615] IL22 HDX-MS in the presence of 11070gL7gH16 Fab Four peptides (i.e., potential epitopes) were observed to show a statistically significant decrease in deuterium uptake upon antibody binding, three of which were consistent with SPEED analysis (highlighted in black on the Wood plot in Figure 8, A): 72VRLIGEKLFHGVSM85, 75IGEKLFHGVSM85, and 80FHGVSM85. Increased deuterium uptake (i.e., potential conformational changes) was observed in two peptides: 43DKSNFQQPYITNRTFM58 and 105FPQSDRFQPYMQE117. The 11070gL7gH16 Fab epitope was projected onto the structure of IL22 (Figure 8, B). Other regions protected or deprotected upon antibody binding due to conformational changes are highlighted in dark gray.

[0616] In conclusion, the protected region representing the epitope region of 11070gL7gH16 Fab is residues 72-85 (VRLIGEKLFHGVSM). [Table 23]

[0617] Example 13: Purification and structural analysis of the IL22 / 11041gL13gH14 complex IL22 was purified as described in Example 11.

[0618] The cleaved IL22 was mixed with 11041 g L13 g H14 Fab and purified by size exclusion chromatography on a HiLoad® 26 / 600 Superdex® 75 pg column (GE Healthcare) equilibrated with 10 mM Tris pH 7.4 and 150 mM NaCl.

[0619] The IL22 / 11041gL13gH14 Fab complex was concentrated to 10.1 mg / ml. The crystallization conditions for the complex were identified using several commercially available crystallization screens. These were performed in a sitting drop format using a Swissci 96-well 2-droplet MRC crystallization plate (supplied from Molecular Dimensions, catalog no. MD11-00-100). First, the reservoir was filled with 75 μL of each crystallization condition from the screen using a Microlab STAR liquid processing system (Hamilton). Then, 300 nL of the IL22 / Fab complex and 300 nL of the reservoir solution were dispensed into the wells of the crystallization plate using a Mosquito liquid handler (TTP LabTech). The initial crystallization conditions were identified as condition 59 of the Nextal Tubes JCSG+ screening (Qiagen catalog number: 130720), containing 0.16 M calcium acetate hexahydrate, 0.08 M sodium cacodylate pH 6.5, 14.4% PEG8000, and 20% glycerol. This condition is further referred to as JCSG+59. Optimized crystals were obtained by adding 0.01 M yttrium(III) chloride hexahydrate, found in the additive screening (Hampton Research catalog number HR2-138), to JCSG+59 supplied from Molecular Dimensions (catalog number MDSR-37-E11). The optimized crystals were grown in MRC Maxi 48 Well Crystallisation Plates (Swissci) using droplets consisting of a 250 μL reservoir volume and 2 μL of reservoir solution mixed with 2 μL of IL22 / Fab complex. Prior to flash freezing in liquid nitrogen, the crystals were transferred to a 4 μL drop of antifreeze solution. This solution was prepared by mixing 40 μL of optimized reservoir solution with 10 μL of CryoMixes® 7 solution, which is included in the CryoProtX® kit (Molecular Dimensions MD1-61).CryoMixes® 7 contains 12.5% ​​v / v diethylene glycol, 12.5% ​​v / v ethylene glycol, 25% v / v 1,2-propanediol, 12.5% ​​v / v dimethyl sulfoxide, and 12.5% ​​v / v glycerol.

[0620] Diffraction data were collected at beamline I04 (Diamond Light Source, UK). The data were indexed and integrated using XDS [Kabsch, W. Acta Cryst. D66, 125-132 (2010)], followed by scaling using AIMLESS [Evans et al Acta Crystallogr D Biol Crystallogr. 2013; 69 (Pt 7): 1204-1214]. The IL22 / Fab structure was elucidated by molecular substitution using Phaser [McCoy et al J. Appl. Cryst. (2007). 40, 658-674] in the Phenix software suite [Adams et al Methods. 2011; 55(1): 94-106]. In this procedure, IL22 structure 1YKB [Xu et al Acta Crystallogr D Biol Crystallogr. 2005 Jul;61(Pt 7):942-50] and Fab structure 5BVJ [Rondeau et al MAbs. 2015;7(6):1151-60] were used as molecular substitution templates. Coot [P. Emsley et al (2010). Acta Crystallographica. D66:486-501] and phenix.refine [PVAfonine et al Acta Crystallogr D Biol Crystallogr 68,352-67 (2012)] were used in the following manual model completion and refinement cycle. MolProbity [Williams et al. (2018) Protein Science 27:293-315] was used to analyze the quality of the final model.

[0621] Three IL22 / 11041gL13gH14 Fab complexes are observed within the crystalline asymmetric unit.

[0622] Figure 9A shows the interaction between 11041gL13gH14 Fab and IL22, along with a detailed diagram of the interaction interface (Figure 9B). The epitopes on IL22 recognized by the Fab molecule were determined using NCONT in the CCP4 software suite [Winn MD et al Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt4):235-42]. IL22 amino acid numbering is based on UnitProtKB entry Q9GZX6.

[0623] When the contact distance with the Fab molecule is less than 4 Å, the IL22 epitope consists of residues Gln48, Glu77, Phe80, His81, Gly82, Val83, Ser84, Met85, Arg88, Leu169, Met172, Ser173, Arg175, Asn176, and Ile179.

[0624] When the contact distance with the Fab molecule is less than 5 Å, the IL22 epitope consists of residues Lys44, Phe47, Gln48, Ile75, Gly76, Glu77, Phe80, His81, Gly82, Val83, Ser84, Met85, Ser86, Arg88, Leu169, Met172, Ser173, Arg175, Asn176, and Ile179.

[0625] Table 24.11041gL13gH14 Fab light chain amino acids and their corresponding contacts on IL22. Residues in bold are involved in contacts between 4 and 5 Å. Other residues indicate a contact distance of ≤4 Å between the antibody and IL22. Sequential numbering is used. [Table 24]

[0626] Table 25.11041gL13gH14 Fab heavy chain amino acids and their corresponding contacts on IL22. Residues in bold are involved in contact between 4 and 5 Å. Other residues indicate a contact distance of ≤4 Å between the antibody and IL22. Sequential numbering is used. [Table 25]

[0627] The 11041gL13gH14 Fab molecule interferes with the interaction between IL22 and the IL22R1 receptor because the Fab light chain binds to the same epitope on IL22. (Figure 10)

[0628] Example 14: Structural determination of IL-22 in a complex of fezakinumab and 11070gL7gH16 Fab by cryo-EM IL-22 was expressed using Expi293 cells fused to an N-terminal human Fc tag. After removing the cells by centrifugation, the supernatant was loaded onto a 5 ml HiTrap Protein A column (Cytiva). The protein was eluted at pH 2.0 using a buffer gradient from PBS to 0.1 M sodium citrate. The hFc tag was cleaved using TEV protease, and IL-22 was separated from the cleaved tag by another pass through 4 ml of packed Protein A resin by gravity flow. After elution from the resin, IL-22 was further purified on a HiLoad 26 / 600 Superdex 75 pg column (Cytiva) equilibrated in PBS.

[0629] 70 microliters of 11070gL7gH16 Fab at 12.1 mg / ml, 153 microliters of fezakinumab Fab at 11.5 mg / ml, and 153 microliters of IL-22 at 1.36 mg / ml were mixed. 55 microliters were injected into a Superdex200 5 / 150 column equilibrated in 10 mM Hepes pH 7.4 and 150 mM NaCl. The fraction containing the 1.7 mg / ml IL-22+11070+fezakinumab complex was collected and used to prepare cryo-EM grids.

[0630] Immediately before use, a Quantifoil® R1.2 / 1.3 Holy Carbon grid (SPT Labtech) was glow discharged at 22 mA for 45 seconds in Pelco easyGlow®. IL22 containing 11070 g L7g H16 Fab and fezakinumab Fab, after gel filtration, was applied to a fresh glow discharge grid in a Vitrobot Mark IV (Thermo Fisher Scientific) chamber at 100% humidity and 4°C for 2 seconds. The grid was then absorbed onto new filter paper for 4 seconds using force 7 and placed in liquid ethane. The grid was initially screened for ice thickness and particle distribution using an in-house Glacios equipped with a Falcon3 camera, operating at 200 keV. Data was then collected using Cambridge Consortium's Krios2 with a Falcon4, operating at an accelerating voltage of 300 keV. 5700 videos were processed using EPU software with a defocus range of -1 to -2.5 μm, a pixel size of 0.67 Å, ​​and 49.36 e - / Å 2 The final electron flux was automatically collected in count mode with a 12.2-second exposure to distribute across 42 fractions. All subsequent data analysis was performed using Cryosparc, version 2.15 (Structura Biotechnology Inc). The video was aligned using patch motion, contrast transfer function parameters (CTF) were estimated using patch CTF, and particles were initially picked with a blob picker, yielding a total of 5.5M particles. The selected particles were binned twice to a 300-pixel box size and subjected to an initial two-dimensional classification, resulting in a selection of 488,000 particles with distinct features. Five initial models were constructed, two of which differed from each other at the glycosylation site of IL22. For a total of 240,000 particles, these two classes were pooled together, and heterogeneous refinement yielded a resolution estimate of 3.4 Å using the gold standard FSC0.143 criterion.

[0631] Using UCSF chimeras, two Fab molecules and the IL-22 structure were fitted to cryo-EM densities [Pettersen, et al J.Comput.Chem.25(13):1605-1612(2004).]. After further manual model construction using Coot [Emsley et al(2010)Acta Crystallographica.D66:486-501.], the maps were refined using the Autosharpen [Terwilliger, (2018)Acta Cryst.D74,545-559.] tool in Phenix [Liebschner et al.Acta Cryst.D75,861-877(2019)], and the models were further refined using the Real-space refinement [Afonine et al Acta Cryst.D74,531-544(2018)] tool in Phenix.

[0632] The epitopes on IL-22 recognized by 11070 and the fezakinumab Fab molecule were determined using NCONT in the CCP4 software suite [Winn et al Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt4):235-42]. The following IL-22 amino acid numbering is based on UnitProtKB entry Q9GZX6.

[0633] When the contact distance with the 11070gL7gH16 Fab molecule is less than 4 Å, the IL-22 epitope consists of residues: Glu77, Lys78, His81, Ser84, Met85, Ser86, Arg88, Asn176, and Ala177.

[0634] At a contact distance of less than 5 Å with the 11070gL7gH16 Fab molecule, the IL-22 epitope consists of the residues: Ile75, Gly76, Glu77, Lys78, Phe80, His81, Ser84, Met85, Ser86, Arg88, Leu169, Met172, Ser173, Asn176, and Ala177.

[0635] When the contact distance with the fezakinumab Fab molecule is less than 4 Å, the IL-22 epitope consists of residues Gln49, Tyr51, Phe105, Ser108, ​​Asp109, Gln112, Pro113, Tyr114, Gln116, Glu117, Pro120, Ala123, and Arg124.

[0636] At a contact distance of <5 Å with the fezakinumab Fab molecule, the IL-22 epitope consists of the residues: Gln49, Pro50, Tyr51, Ile52, Arg55, Phe105, Pro106, Ser108, ​​Asp109, Gln112, Pro113, Tyr114, Gln116, Glu117, Val119, Pro120, Phe121, Ala123, and Arg124.

[0637] Structural analysis reveals that 11070gL7gH16 Fab has a different epitope than IL-22 and then fezakinumab. Furthermore, 11070gL7gH16 Fab is similar to the epitope of 11041gL13gH14 Fab on IL-22 (Figures 11A and 1B). Similar to 11041gL13gH14 Fab, 11070gL7gH16 Fab blocks IL-22 signaling by interfering with the interaction with the IL22R1 receptor (Figure 12A). In contrast, fezakinumab blocks IL-22 signaling by interfering with the interaction between IL22 and IL-10R2 (Figure 12B).

[0638] Example 15: Construction and expression in cells of a multispecific antibody-transient plasmid. IL13 / IL22 TrYbe antibodies were designed using an anti-IL22 V region (11041gL13gH14) immobilized at the Fab position. The anti-albumin V region (645gL4gH5) and IL13 (1539gL8gH9) were reformatted to disulfide-linked scFv in HL orientation (dsHL) and linked to the C-terminus of the respective heavy and light chain constant regions via an 11-amino acid glycine-serine rich linker.

[0639] Light and heavy chain genes were independently cloned into proprietary mammalian expression vectors for transient expression under the control of the hCMV promoter. The following light and heavy chain sequences were used: Light chain: Heavy chain:

[0640] Both plasmids were transfected into CHO-S XE cell lines (UCB) using a commercially available ExpiCHO Expifectamine transient expression kit (Thermo Scientific) in equal proportions. The cultures were incubated in Corning roller bottles with vented caps at 37°C, 8.0% CO2, and 190 rpm. After 18–22 hours, the cultures were supplied with the appropriate amounts of CHO enhancer and HiTiter feed provided by the manufacturer. The cultures were re-incubated for a further 10–12 days at 32°C, 8.0% CO2, and 190 rpm. The supernatant was collected by centrifugation at 4000 rpm for 1 hour at 4°C and then filtered through a 0.45 μm filter followed by a 0.2 μm filter. Expression titers were quantified by Protein G HPLC using a 1 ml GE HiTrap Protein G column (GE Healthcare) and in-house prepared Fab standards.

[0641] Example 16: Development of mammalian cell lines To demonstrate stable expression of IL13 / IL22 TrYbe, a stable-expressing mammalian cell line was constructed. A CHO cell line was transfected with a vector containing 11041gL13gH14 Fab (IL22 binding domain), 650gH9gL8 dsscFv (IL13 binding domain), 645gH5gL4 dsscFv (albumin binding domain), and a selection marker. Sequences 61 and 65 were included in the vector used to construct the cell line. The cell line was cloned and evaluated for suitability to the appropriate manufacturing process. To assess protein quality and quantity and ensure optimal cell line selection, the cell line was evaluated in a small-scale model of a manufacturing feed batch bioreactor. A CHO cell line expressing sufficient levels of IL13 / IL22 TrYbe was selected.

[0642] Example 17: Purification of IL13 / IL22 TrYbe multispecific antibody The TrYbe protein was purified by a native A protein capture step followed by a preparative size exclusion polishing step. The clarified supernatant from standard transient CHO expression was loaded onto a MabSelect (GE Healthcare) column, given a contact time of 12 minutes, and washed with binding buffer (200 mM glycine, pH 7.4). The bound substance was eluted using a 0.1 M sodium citrate step at pH 3.2, neutralized with 2 M Tris / HCl, pH 8.5, and quantified by absorbance at 280 nm.

[0643] The purity of the eluted product was determined using size exclusion chromatography (SE-UPLC). Antibody (approximately 3 μg) was loaded onto a BEH200, 200 Å, 1.7 μm, 4.6 mm ID × 300 mm column (Waters ACQUITY) and developed at 0.35 mL / min with a constant composition gradient of 0.2 M phosphate at pH 7. Continuous detection was performed using absorbance at 280 nm and a multi-channel fluorescence (FLR) detector (Waters). The eluted TrYbe antibody was found to be 65% monomer.

[0644] The neutralized sample was concentrated using an Amicon Ultra-15 concentrator (10 kDa molecular weight cutoff membrane) and centrifuged at 4000 x g in a swing-out rotor. The concentrated sample was equilibrated in pH 7.4 PBS and applied to an XK26 / 60 Superdex200 column (GE Healthcare) developed at 2.5 ml / min with a constant composition gradient of pH 7.4 PBS. Fractions were collected and analyzed by size exclusion chromatography on a BEH200, 200 Å, 1.7 μm, 4.6 mm ID × 300 mm column (Aquity), developed at 0.35 mL / min with a constant composition gradient of 0.2 M phosphate at pH 7, and detected by absorbance at 280 nm and a multi-channel fluorescence (FLR) detector (Waters). The selected monomer fractions were pooled, filtered through a 0.22 μm sterile filter, and the final samples were assayed for concentration using an A280 Scanning on Cary UV spectrophotometer. Endotoxin levels were less than 1.0 EU / mg, as evaluated using Charles River's EndoSafe® portable test system equipped with a Limulus Amebocyte Lysate (LAL) test cartridge.

[0645] The monomeric state of the final TrYbe was determined by size exclusion chromatography using a BEH200, 200 Å, 1.7 μm, 4.6 mm ID × 300 mm column (Aquity). The spectroscopy was performed using a constant composition gradient of 0.2 M phosphate at pH 7 at 0.35 mL / min, and detection was performed using absorbance at 280 nm and a multi-channel fluorescence (FLR) detector (Waters). The final TrYbe antibody was found to contain less than 1% HMW species.

[0646] For analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), samples were prepared by adding either 4× Novex NuPAGE LDS sample buffer (Life Technologies) and 10× NuPAGE sample reducing agent (Life Technologies) or 100 mM N-ethylmaleimide (Sigma-Aldrich) to approximately 3 μg of purified protein, and the mixture was heated at 100°C for 3 minutes. The samples were loaded onto 15-well Novex 4-20% Tris-glycine 1.0 mm SDS-polyacrylamide gels (Life Technologies) and separated in Tris-glycine SDS electrophoresis buffer (Life Technologies) at a constant voltage of 225 V for 40 minutes. Novex Mark 12 broad-spectrum protein standards (Life Technologies) were used as standards. The gels were stained with Coomassie Quick Stain (Generon) and destained in distilled water.

[0647] In non-reducing SDS-PAGE, TrYbe with a theoretical molecular weight (MW) of approximately 100 kDa moved to approximately 120 kDa (Figure 13). Upon reduction of the TrYbe protein, both chains moved at a migration rate close to their respective theoretical molecular weights of approximately 50 kDa. Further bands on the non-reducing gel at approximately 45–50 kDa are due to the incomplete formation of the innate interchain disulfide (ds) bond between CH1 and CK in parts of the molecule and, being not fully reduced, do not move to the same positions as LC and HC in lane 2.

[0648] Example 18: Production and purification of KiH antibodies that bind to human IL13 and IL22. Parental monoclonal antibodies (mAbs) containing either T366W (knob mutation), L366S, L368A, or Y407V (hole mutation) were expressed and purified by standard chromatography methods including a protein A capture step followed by preparative size exclusion chromatography (SEC). To produce bispecific parental mAbs, they were mixed in a 1:1 ratio in the presence of 50 mM β-mercaptoethylamine at room temperature for 18 hours. Subsequently, high molecular weight species or parental mAbs were removed by a second preparative size exclusion using an S200 16 / 60 column equilibrated in PBS pH 7.4. The bispecificity percentage was determined by analytical HIC chromatography, and the purity percentage was determined by analytical SEC and SDS-PAGE. Endotoxin levels were determined for all materials and removed to a final level of less than 1 EU / mg using a high-volume endotoxin removal spin column (Pierce) as needed.

[0649] Example 19: Mass spectrometry - Sequence identity of IL13 / IL22 TrYbe molecules The sequence mass of IL13 / IL22 TrYbe was confirmed by liquid chromatography-mass spectrometry (LC-MS). Aliquots of 0.25 mg / mL of IL13 / IL22 TrYbe were reduced with 5 mM tris(2-carboxyethyl)phosphine (TCEP) in 150 mM ammonium acetate at 37°C for 40 minutes, followed by centrifugation and analysis. Data were acquired using a Waters ACQUITY UPLC System connected to a Waters Xevo G2 Q-ToF mass spectrometer operated with MassLynx® and processed using the OpenLynx® software package. LC conditions were as follows: BioResolveT RP mAb Polyphenyl, 450 Å, 2.7 μm column held at 80°C, flow rate 0.6 mL / min. The mobile phase buffers were water / 0.02% trifluoroacetic acid (TFA) / 0.08% formic acid (solvent A) and 95% acetonitrile / 5% water / 0.02% TFA / 0.08% formic acid (solvent B). A reversed phase gradient was run for 8.80 minutes with 5% to 50% solvent B using 95% solvent B washing and re-equilibriumization. UV data was acquired at 280 nm. The MS conditions were as follows: ion mode: ESI positive ion, decomposition mode, mass range: 400 to 5000 m / z and external calibration with NaI. The observed mass reduction was found to be consistent with the theoretical mass of each chain, i.e., 50,427.8 Da (theoretically 50,422.6 Da) for the light chain and 50,627.8 Da (theoretically 50,623.5 Da) for the heavy chain.

[0650] Example 20: Thermal stability of IL13 / IL22 TrYbe Thermal stability tests were performed to evaluate the steric stability of purified samples in pre-formulation storage buffer (PBS pH 7.4) and commonly used formulation buffer (pH 5.5). Thermal stability was measured using a fluorescence-based method (Thermofluor).

[0651] The reaction mixture contained 5 μL of 30×SYPRO® Orange Protein Gel Stain (Thermofisher Scientific) diluted from a 5000-fold concentrate in test buffer. 45 μL of 0.2 mg / mL of IL13 / IL22 TrYbe in either buffer was added to the dye, mixed, and 10 μL of this solution was dispensed in quadruple units into 384 PCR optical well plates and run on a QuantStudio real-time PCR system (Thermofisher). The PCR system heating device was set to 20°C and increased to 99°C at a rate of 1.1°C / min. The charge-coupled device monitored the fluorescence changes in the wells. The increase in fluorescence intensity was plotted, and the inflection point of the slope was used to generate the apparent midpoint temperature (Tm).

[0652] IL13 / IL22 TrYbe showed three unfolding transitions at 58.3°C (Tm1), 73.7°C (Tm2), and 81.4°C (Tm3) at PBS pH 7.4, respectively, attributed to dsscFv 1539 gL8gH9 (CA650 anti-IL13), dsscFv 645 gL4gH5 (anti-HSA), and Fab 11041 gL13gH14 (anti-IL22). (ii) As summarized in Table 26, the thermal stability of dsscFv 1539 gL8gH9 (CA650 anti-IL13) increased from 58.3°C to 65.2°C, and three transitions at 65.2°C (Tm1), 73.2°C (Tm2), and 81.3°C (Tm3) were also observed at formulation buffer pH 5.5.

[0653] Table 26. Thermal stability data from Thermofluor assays in two different buffers. [Table 26]

[0654] IL13 / IL22 TrYbe showed a slightly lower first unfolding transition in PBS pH 7.4 compared to IgG4 molecules (approximately 65°C; Ref1), but unlike IgG4 molecules, this transition is stabilized in more acidic buffers.

[0655] Example 21: Experimental pI (isoelectric point) of IL13 / IL22 TrYbe molecules The experimental pI (isoelectric point) of IL13 / IL22 TrYbe was obtained using a whole capillary imaging cIEF ICE3 system (ProteinSimple). The sample was prepared by mixing 30 μl of the sample (from 1 mg / ml stock in HPLC-grade water), 35 μl of 1% methylcellulose solution (Protein Simple), 4 μl of pH 3-10 amphoteric electrolyte (Pharmalyte), 0.5 μl of 4.65 and 0.5 μl of 9.77 synthetic pI markers (ProteinSimple), and 12.5 μl of 8 M urea solution (Sigma-Aldrich). The final volume was 100 μl using HPLC-grade water. The mixture was briefly vortexed to ensure complete mixing, and then centrifuged at 10,000 rpm for 3 minutes to remove air bubbles before analysis. The sample was focused at 1.5kV for 1 minute, followed by 3kV for 5 minutes, and A280 images of the capillary tube were acquired using ProteinSimple software (markers). The calibrated electrophoresis images were then integrated using Empower software (Waters).

[0656] Two peaks were observed: an acidic peak at pI 8.77 and a main species peak at pI 8.96. This was consistent with the theoretical value of 8.9 (non-reducing). The high pI allows for good manufacturability and a low tendency to aggregate in typical formulation buffers (pH 5-6).

[0657] Table 27. pI determination by cIEF [Table 27]

[0658] Example 22: Hydrophobic interaction chromatography (HIC) of IL13 / IL22 TrYbe molecules. Apparent hydrophobicity was measured using a 100 mm × 4.6 mm Dionex ProPac HIC-10 column (ThermoFisher Scientific) coupled to an Agilent HP1260 HPLC equipped with an online fluorescence detector. The mobile phases were 0.8 M ammonium sulfate, 50 mM phosphate pH 7.4 (Buffer A) and 50 mM phosphate pH 7.4 (Buffer B). 10 μg (10 μL) of IL13 / IL22 TrYbe was injected into the column. After holding at 0% B for 5 minutes, the protein was eluted over 45 minutes at a flow rate of 0.8 mL / min using a linear gradient from 0 to 100% B. Separation was monitored by intrinsic fluorescence using excitation at 280 nm and emission at 340 nm.

[0659] Table 28. HIC data for IL13 / IL22 TrYbe [Table 28]

[0660] IL13 / IL22 TrYbe exhibited low apparent hydrophobicity, as determined by this assay; i.e., a retention time of less than 10 minutes.

[0661] Example 23: Polyethylene glycol (PEG) precipitation assay A PEG precipitation assay was performed to evaluate high-concentration solubility in both PBS pH 7.4 and a common pharmaceutical buffer pH 5.5. Using PEG, protein solubility was reduced in a quantitatively definable manner by increasing the PEG concentration (w / v) and measuring the amount of protein remaining in the solution. This assay helped to mimic the effects of high concentrations without using conventional concentration methods.

[0662] Stock 40% PEG 3350 solution (W / V) was prepared in PBS pH 7.4 or formulation buffer pH 5.5. Serial titration was performed using a Viaflo-Assist Plus liquid processing robot (Integra) to obtain PEG 3350 concentrations ranging from 40% to 15.4%. To minimize non-equilibrium precipitation, sample preparation consisted of mixing the protein and PEG solution in a 1:1 volume ratio. 35 μL of PEG 3350 stock solution was added to 96-well v-bottom PCR plates (A1-H1) using a liquid processing robot. 35 μL of 2 mg / mL sample solution (unless otherwise specified) was added to the PEG stock solution to obtain a test concentration of 1 mg / mL. This solution was mixed by automated slow-repeat pipetting. After mixing, the sample plate was sealed and incubated at 37°C for 0.5 hours to redissolve non-equilibrium aggregates. The sample was then incubated at 20°C for 24 hours. Subsequently, the sample plates were centrifuged at 4000 × g for 1 hour at 20°C. 50 μL of the supernatant was dispensed into UV-Star®, half-area, 96-well, μClear®, and microplates. Protein concentrations were determined by UV spectrophotometric analysis at 280 nm using a FLUOstar Omega® multi-detection microplate reader (BMG LABTECH). The obtained values ​​were plotted against PEG percentage using a Graphpad prism, and the PEG midpoint (PEGmdpnt) score was derived from the midpoint of the sigmoid dose-response (variable gradient) fit.

[0663] IL13 / IL22 TrYbe showed high PEGmdpnt at PBS pH 7.4, suggesting a low tendency to aggregate. Compared to the sample tested at PBS pH 7.4, IL13 / IL22 TrYbe showed a significant increase in PEGmdpnt at formulation buffer pH 5.5, suggesting high concentration stability in typical formulation buffers.

[0664] Table 29. PEG midpoint data for samples in PBS and formulation buffer pH 5.5. [Table 29] *The sample did not reach baseline at the highest test concentration of PEG 3350. mdpnt While not precise, this reflects the low aggregation tendency of this sample in formulation buffer (pH 5.5).

[0665] Example 24: Effect of stress at the gas-liquid interface on IL13 / IL22 TrYbe (agitation assay) Proteins tend to unfold when exposed to an air-liquid interface where their hydrophobic surface is exposed to a hydrophobic environment (air) and their hydrophilic surface is exposed to a hydrophilic environment (water). Agitation of the protein solution creates a large gas-liquid interface, which can promote aggregation. This assay is useful for mimicking the stresses molecules experience during manufacturing (e.g., ultrafiltration) and potential transport.

[0666] IL13 / IL22 TrYbe samples in PBS pH 7.4 (typical storage buffer) and formulation buffer pH 5.5 ± Tween 80 (typical formulation buffer) were stressed by vortexing using an Eppendorf Thermomixer Comfort®. The samples were buffer-exchanged using a 7 mL Zeba® desalting column (Thermofisher) to each buffer, and the concentration was adjusted to 1 mg / mL using an appropriate extinction coefficient (1.72 Abs 280 nm, 1 mg / mL, path length 1 cm). Absorbance at 280 nm and 595 nm was obtained using a Varian Cary® 50-Bio spectrophotometer, and a zero-time reading was established. The samples in each buffer were subdivided into 1.5 mL conical Eppendorf® capped tubes (4 × 250 μL) and vortexed at 1400 rpm at 25 °C. Time-dependent aggregation (turbidity) was monitored by measuring the sample at 595 nm for 24 hours using a Varian Cary® 50-Bio spectrophotometer. The average and standard deviation of the triplicate readings were calculated and summarized in Table 30.

[0667] Table 30. Mean turbidity measurement of IL13 / IL22 TrYbe in PBS (pH 7.4) and formulation buffer (pH 5.5 + / - 0.03% Tween 80). [Table 30]

[0668] The highest aggregation tendency was observed in PBS, pH 7.4. When the sample was vortexed in pharmaceutical buffer (pH 5.5 ± Tween 80), almost no aggregation was observed (determined by OD at 595 nm). The sample is expected to be stable for long-term storage and transport in typical pharmaceutical buffer: pharmaceutical buffer, pH 5.5 ± 0.03% Tween 80.

[0669] Example 25: Deamidation and Asp isomerization stress research A stress study was set up to determine the deamidation / Asp isomerization tendencies of two identified sequence responsibilities, Asn(95)Ala(deamidation) and Asp(98)Ser, in the light chain CDR3 of the anti-IL22 domain of IL13 / IL22 TrYbe. The deamidation / Asp isomerization tendency / rate is unpredictable because it depends on the linear sequence, 3D structure, and solution properties.

[0670] Basal deamidation / Asp isomerization levels were also obtained at low levels, indicating low sensitivity, but these may vary due to different manufacturing batches / conditions.

[0671] IL13 / IL22 TrYbe was buffer-exchanged with (i) a buffer known to promote deamidation of Asn(N) residues (Tris, pH 8) and (ii) a buffer known to promote Asp(D) isomerization (acetate, pH 5). The final concentration was adjusted to approximately 5 mg / mL, and then divided into two aliquots. One was stored at 4°C and the other at 37°C for up to 4 weeks. The aliquots were immediately removed (T0, non-stress control) and stored at -20°C after 2 weeks and 4 weeks.

[0672] Mass spectrometry / peptide mapping Samples from the 2-week period were analyzed for chemical modification by liquid chromatography-mass spectrometry (LCMS) / peptide mapping as follows: Both stressed and unstressed samples (16 μL at 5 mg / mL) were incubated with 2 μL of dithiothreitol (DTT; 500 mM) and 60 μL of 8 M guanidine hydrochloride at 37°C for 40 minutes, and then capped with 6 μL of iodoacetamide (IAM; 500 mM) at room temperature for a further 30 minutes. The samples were then buffered with digestion buffer (7.5 mM Tris hydrochloride / 1.5 mM calcium chloride, pH 7.9), immediately added to trypsin, and incubated at 37°C for 3 hours. After quenching the digestion with 5 μL of 1% TFA (trifluoroacetic acid), the samples were analyzed by LCMS. This was performed using a Waters C18 BEH 2.1 mm × 150 mm, 1.7 μm column with a Thermo Q Exactive Orbitrap. Mobile phase A was 0.1% formic acid in water, and mobile phase B was 0.1% formic acid in acetonitrile.

[0673] Mass spectrometry and peptide mapping results showed that the basal deamidation of Asn(95) in the light chain CDR3 was approximately 10% after 2 weeks at pH 8 and 37°C, and increased to over 40% (40-60%, depending on the data analysis method).

[0674] In both unstressed (basic) and stressed samples, and under any buffering conditions, there was no evidence of chemical modification of Asp at D(98)Ser.

[0675] Aspartic acid isomerization typically results in the earlier elution of modified peptides than the corresponding unmodified sequences. No change in the elution profile was observed for trypsin peptides containing the Asp(98)Ser motif (residues 62–100 of the light chain), indicating that this site was not detected because isoAsp was not formed or because it eluted co-eluted with the unmodified sequence.

[0676] The deamidation motif on the light chain CDR, Asn(95)Ala, showed a high tendency for chemical modification, but this can be controlled by careful monitoring, avoiding prolonged exposure to high pH, ​​and formulation in low pH buffer (pH 5-6 or less). Asp isomerization at the Asp(98)Ser motif on the light chain CDR was not observed. Surface plasmon resonance (SPR) analysis

[0677] The effect of chemical modification (deamidation) of the Asn(95)Ala motif in the light chain CDR3 on the affinity for IL22 was evaluated. The binding rate and affinity of IL13 / IL22 TrYbe remained unchanged. Therefore, the efficacy of this molecule is not affected as a result of chemical modification.

[0678] Table 31. Binding kinetics of samples at T0 and 2 weeks at pH 8.0 (2 weeks / 37°C); KD = kd / ka. [Table 31]

[0679] Example 26: IL13 / IL22 TrYbe-based IL22R1 cross-blocking experiment To determine whether the binding of IL13 / IL22 TrYbe to IL-22 inhibits the binding of IL-22R1, a cross-blocking assay was performed using a Biacore T200 (GE Healthcare) scanner.

[0680] CM5 sensor chips were prepared by activating them with a 7-minute injection (10 μL / min-1) of an EDC / NHS (GE Healthcare) mixture, followed by a 7-minute injection of human Fab-specific goat Fab'2 (Jackson Immuno Research) at 50 μg / ml in acetate buffer pH 5.0 (GE Healthcare) to achieve an immobilization level of approximately 5500 RU. Finally, the surface was inactivated by a 7-minute injection (10 μL / min-1) of 1 M ethanolamine hydrochloride-NaOH (pH 8.5). The reference surface was prepared as described above, omitting the human Fc-specific capture antibody.

[0681] Cross-blocking was performed in HBS-EP+ buffer (GE Healthcare) at 25°C. Each analytical cycle included capture of IL13 / IL22 TrYbe on the chip surfa...

Claims

1. A multispecific antibody comprising at least two antigen-binding domains, wherein a first antigen-binding domain binds to IL13 (IL13-binding domain) and a second antigen-binding domain binds to IL22 (IL22-binding domain).

2. The multispecific antibody of claim 1 , wherein IL13 is human and / or cynomolgus IL13 and IL22 is human and / or cynomolgus IL22.

3. 3. The multispecific antibody of claim 1 or 2, wherein each antigen-binding domain comprises two antibody variable domains, optionally said two antibody variable domains being a VH / VL pair.

4. The multispecific antibody of any one of claims 1 to 3, wherein the IL13 binding domain and the IL22 binding domain are independently selected from Fab, scFv, Fv, dsFv and dsscFv.

5. 5. The multispecific antibody of any one of claims 1 to 4, wherein said multispecific antibody neutralizes one or more IL13 and / or IL22 activities, optionally wherein said antibody is capable of inhibiting or attenuating binding of IL22 to IL22 receptor 1 (IL22R1), and / or wherein said antibody binds to a region on IL22 such that it sterically blocks the interaction between IL22 and IL22R1, and / or wherein said antibody is capable of inhibiting or attenuating binding of IL22 to IL22 binding protein (IL22RA2), and / or wherein said antibody is capable of inhibiting or attenuating binding of IL13 to IL13Ralpha1.

6. The multispecific antibody according to any one of claims 1 to 5, wherein the antigen-binding domain that binds to IL22 has a dissociation equilibrium constant (KD) for human IL22 of less than 100 pM.

7. The multispecific antibody according to any one of claims 1 to 6, wherein the antigen-binding domain that binds to IL13 has a dissociation equilibrium constant (KD) for human IL13 of less than 100 pM.

8. the IL22 binding domain binds to an epitope on IL22, the epitope comprising five or more residues within the polypeptide VRLIGEKLFHGVSM (SEQ ID NO: 155) corresponding to residues 72-85 of the amino acid sequence of IL22 as defined by SEQ ID NO: 1; or the IL22 binding domain specifically binds to the polypeptide VRLIGEKLFHGVSM (SEQ ID NO: 155); or 8. The multispecific antibody of any one of claims 1 to 7, wherein the IL22 binding domain binds to an epitope of human IL22, said epitope comprising five or more residues selected from Lys44, Phe47, Gln48, Ile75, Gly76, Glu77, Phe80, His81, Gly82, Val83, Ser84, Met85, Ser86, Arg88, Leu169, Met172, Ser173, Arg175, Asn176 and Ile179 of human IL22 (SEQ ID NO: 1), as determined by a contact distance of less than 5A between the antibody and IL22.

9. The multispecific antibody according to any one of claims 1 to 8, further comprising a third antigen-binding domain that binds to serum albumin (albumin-binding domain).

10. a) a compound of formula (Ia): V H -CH 1 -X-V 1 (Ia) and a polypeptide chain of b) Formula (IIa): V L -C L -Y-V 2 (IIa) and a polypeptide chain of During the ceremony, V H represents a heavy chain variable domain; CH 1 represents Domain 1 of the heavy chain constant region; X represents a bond or a linker; Y represents a bond or a linker; V 1 represents a scFv, dsscFv, or dsFv; V L represents the light chain variable domain; C L represents a domain from the light chain constant region, e.g., Ckappa; V 2 represents a scFv, dsscFv or dsFv; In the formula, V 1 Or V 2 At least one of the following is dsscFv or dsFv; The multispecific antibody of claim 9.

11. V L and V H comprises an antigen-binding domain that binds to IL22; V 2 comprises an antigen-binding domain that binds to IL13; V 1 comprises an antigen-binding domain that binds to serum albumin, The multispecific antibody of claim 10.

12. a) a compound represented by formula (III): VH 1 -CH 1 -CH 2 -CH 3 (III) and a polypeptide chain of b) Formula (IV): 3L 1 -C L (IV) and a polypeptide chain of c) Formula (V): VH 2 -CH 1 -CH 2 -CH 3 (V) and a polypeptide chain of d) a compound of formula (VI): VL 2 -C L (VI) and a polypeptide chain of During the ceremony, VH 1 and VH 2 represents a heavy chain variable domain; CH 1 represents Domain 1 of the heavy chain constant region; CH 2 represents domain 2 of the heavy chain constant region; CH 3 represents domain 3 of the heavy chain constant region; VL 1 and VL 2 represents the light chain variable domain; C L represents a domain from the light chain constant region, e.g., Ckappa; In the formula, VH 1 and VL 1 comprises the IL22 binding domain, 2 and VL 2 comprises the IL13 binding domain, and the polypeptide chains of formulas III and V are 3 The other polypeptide contains a knob substitution T366W in the CH domain. 3 A pair of heavy chain polypeptides containing hole substitutions T366S, L368A and Y407V in the domain, numbering according to EU as in Kabat, A multispecific antibody according to any one of claims 1 to 8.

13. The IL22 binding domain is CDR-L1 comprising SEQ ID NO:8, CDR-L2 comprising SEQ ID NO:9, and a light chain variable region comprising a CDR-L3 comprising SEQ ID NO: 10; CDR-H1 comprising SEQ ID NO: 11, CDR-H2 comprising SEQ ID NO: 12, and CDR-H3 comprising SEQ ID NO: 13 and / or a heavy chain variable region comprising The IL13 binding domain is CDR-L1 comprising SEQ ID NO: 22, CDR-L2 comprising SEQ ID NO:23, and a light chain variable region comprising a CDR-L3 comprising SEQ ID NO:24; CDR-H1 comprising SEQ ID NO: 25, CDR-H2 comprising SEQ ID NO: 26, and and a heavy chain variable region comprising a CDR-H3 comprising SEQ ID NO:

27. A multispecific antibody according to any one of claims 1 to 12.

14. The albumin binding domain comprises: CDR-L1 comprising SEQ ID NO: 40, CDR-L2 comprising SEQ ID NO: 41, and a light chain variable region comprising a CDR-L3 comprising SEQ ID NO:42; CDR-H1 comprising SEQ ID NO: 43, CDR-H2 comprising SEQ ID NO: 44, and and a heavy chain variable region comprising a CDR-H3 comprising SEQ ID NO:

45. A multispecific antibody according to any one of claims 9 to 11.

15. 15. The multispecific antibody of claim 13 or 14, wherein each CDR contains up to three amino acid substitutions, and such amino acid substitutions are conservative.

16. the IL22-binding domain comprises a light chain variable region comprising the sequence set forth in SEQ ID NO: 14 and a heavy chain variable region comprising the sequence set forth in SEQ ID NO: 16; or the IL22 binding domain comprises CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences comprising SEQ ID NOs: 8, 9, 10, 11, 12 and 13, respectively, and the remainder of the light chain variable region and the heavy chain variable region have at least 90% identity or similarity to SEQ ID NOs: 14 and 16, respectively; or The multispecific antibody according to any one of claims 1 to 12, wherein said IL22 binding domain is a Fab comprising a light chain comprising the sequence as set forth in SEQ ID NO: 18 and a heavy chain comprising the sequence as set forth in SEQ ID NO:

20.

17. the IL13 binding domain comprises a light chain variable region comprising the sequence set forth in SEQ ID NO:28 and a heavy chain variable region comprising the sequence set forth in SEQ ID NO:29; or the IL13 binding domain comprises CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences comprising SEQ ID NOs: 22, 23, 24, 25, 26 and 27, respectively, and the remainder of the light chain variable region and the heavy chain variable region have at least 90% identity or similarity to SEQ ID NOs: 28 and 29, respectively; or the IL13 binding domain comprises a light chain variable region comprising the sequence set forth in SEQ ID NO:32 and a heavy chain variable region comprising the sequence set forth in SEQ ID NO:33; or 13. The multispecific antibody according to any one of claims 1 to 12, wherein the IL13 binding domain comprises CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences comprising SEQ ID NOs: 22, 23, 24, 25, 26 and 27, respectively, and the remaining parts of the light chain variable region and the heavy chain variable region have at least 90% identity or similarity to SEQ ID NOs: 32 and 33, respectively.

18. the light chain variable region and the heavy chain variable region of the IL13 binding domain are linked by a linker, the linker comprising the sequence shown in SEQ ID NO: 67; and / or The multispecific antibody according to any one of claims 1 to 11, wherein the IL13 binding domain is a scFv comprising the sequence as set forth in SEQ ID NO: 36 or a dsscFv comprising the sequence as set forth in SEQ ID NO:

38.

19. The IL22 binding domain is A light chain variable region comprising the sequence set forth in SEQ ID NO: 14; a heavy chain variable region comprising the sequence set forth in SEQ ID NO: 16; and The IL13 binding domain is A light chain variable region comprising the sequence set forth in SEQ ID NO: 28 or 32; and a heavy chain variable region comprising the sequence set forth in SEQ ID NO: 29 or 33. A multispecific antibody according to any one of claims 1 to 12.

20. (i) the IL22-binding domain is a Fab comprising a light chain comprising the sequence set forth in SEQ ID NO: 18 and a heavy chain comprising the sequence set forth in SEQ ID NO: 20; and (ii) the IL13 binding domain is an scFv comprising the sequence set forth in SEQ ID NO: 36, or a dsscFv comprising the sequence set forth in SEQ ID NO: 38; A multispecific antibody according to any one of claims 1 to 11.

21. the albumin binding domain comprises a light chain variable region comprising the sequence set forth in SEQ ID NO: 46 and a heavy chain variable region comprising the sequence set forth in SEQ ID NO: 47; or the albumin binding domain comprises a light chain variable region comprising the sequence set forth in SEQ ID NO:50 and a heavy chain variable region comprising the sequence set forth in SEQ ID NO:51; or the light chain variable region and the heavy chain variable region of the albumin binding domain are linked by a linker, the linker comprising the sequence shown in SEQ ID NO:69; or The multispecific antibody according to any one of claims 9 to 11, wherein the albumin binding domain is a scFv comprising the sequence as set forth in SEQ ID NO: 54 or a dsscFv comprising the sequence as set forth in SEQ ID NO:

56.

22. Y is a linker comprising the sequence shown in SEQ ID NO: 66, and / or 12. The multispecific antibody of claim 10 or 11, wherein X is a linker comprising the sequence shown in SEQ ID NO:

68.

23. comprising the sequence shown in SEQ ID NO:58 or SEQ ID NO:60, or comprising the sequence shown in SEQ ID NO:62 or SEQ ID NO:64, or 12. A multispecific antibody according to claim 10 or 11, comprising the sequence shown in SEQ ID NO: 60 and comprising the sequence shown in SEQ ID NO:

64.

24. An isolated polynucleotide encoding a multispecific antibody according to any one of claims 1 to 23.

25. An expression vector carrying the polynucleotide of claim 24.

26. A host cell comprising the vector of claim 25.

27. A method for producing a multispecific antibody according to any one of claims 1 to 23, comprising culturing a host cell according to claim 26 under conditions allowing the production of said antibody, and recovering the antibody produced.

28. A pharmaceutical composition comprising a multispecific antibody according to any one of claims 1 to 23 and a pharma- ceutically acceptable adjuvant and / or carrier.

29. A multispecific antibody according to any one of claims 1 to 23 or a pharmaceutical composition according to claim 28 for use as a medicament.

30. A multispecific antibody according to any one of claims 1 to 23 or a pharmaceutical composition according to claim 28 for use in the treatment or prevention of an inflammatory skin condition, comprising Optionally, said inflammatory skin condition is psoriasis, psoriatic arthritis, contact dermatitis, chronic hand eczema or atopic dermatitis.

31. A pharmaceutical composition comprising an antibody that binds to IL13 and an antibody that binds to IL22, the antibody that binds to IL13 neutralizes IL13, and the antibody that binds to IL22 neutralizes IL22; Each antibody comprises two antibody variable domains, a VH / VL pair, The antibody that binds to IL22 is CDR-L1 comprising SEQ ID NO:8, CDR-L2 comprising SEQ ID NO:9, and a light chain variable region comprising a CDR-L3 comprising SEQ ID NO: 10; CDR-H1 comprising SEQ ID NO: 11, CDR-H2 comprising SEQ ID NO: 12, and CDR-H3 comprising SEQ ID NO: 13 and / or a heavy chain variable region comprising The antibody that binds to IL13 is CDR-L1 comprising SEQ ID NO: 22, CDR-L2 comprising SEQ ID NO:23, and a light chain variable region comprising a CDR-L3 comprising SEQ ID NO:24; CDR-H1 comprising SEQ ID NO: 25, CDR-H2 comprising SEQ ID NO: 26, and and a heavy chain variable region comprising CDR-H3 comprising SEQ ID NO:27, wherein optionally each CDR contains up to three amino acid substitutions, wherein such amino acid substitutions are conservative, and wherein said antibody that binds to IL22 has a dissociation equilibrium constant (KD) for IL22 of less than 100 pM, and / or said antibody that binds to IL13 has a dissociation equilibrium constant (KD) for IL13 of less than 100 pM; Optionally, the antibody that binds IL13 and the antibody that binds IL22 are independently selected from a full length antibody, a Fab, a scFv, an Fv, a dsFv, and a dsscFv.

32. (i) the antibody that binds to IL22 comprises a light chain variable region comprising the sequence set forth in SEQ ID NO:14 and a heavy chain variable region comprising the sequence set forth in SEQ ID NO:16; or the antibody that binds IL22 comprises CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences comprising SEQ ID NOs: 8, 9, 10, 11, 12 and 13, respectively, and the remainder of the light chain variable region and the heavy chain variable region have at least 90% identity or similarity to SEQ ID NOs: 14 and 16, respectively; and / or (ii) the antibody that binds to IL13 comprises a light chain variable region comprising the sequence set forth in SEQ ID NO:28 and a heavy chain variable region comprising the sequence set forth in SEQ ID NO:29; or the antibody that binds IL13 comprises CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences comprising SEQ ID NOs: 22, 23, 24, 25, 26 and 27, respectively, and the remainder of the light chain variable region and the heavy chain variable region have at least 90% identity or similarity to SEQ ID NOs: 28 and 29, respectively; or the antibody that binds IL13 comprises a light chain variable region comprising the sequence set forth in SEQ ID NO:32 and a heavy chain variable region comprising the sequence set forth in SEQ ID NO:33; or 32. The pharmaceutical composition of claim 31 , wherein the antibody that binds IL13 comprises CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2 and CDR-H3 sequences comprising SEQ ID NOs: 22, 23, 24, 25, 26 and 27, respectively, and the remainder of the light chain variable region and the heavy chain variable region have at least 90% identity or similarity to SEQ ID NOs: 32 and 33, respectively.

33. 33. A pharmaceutical composition according to claim 31 or 32 for use in the treatment or prevention of an inflammatory skin condition, comprising Optionally, The pharmaceutical composition, wherein the inflammatory skin condition is psoriasis, psoriatic arthritis, contact dermatitis, chronic hand eczema or atopic dermatitis.

34. A combination of an antibody which binds and neutralises IL13 and an antibody which binds and neutralises IL22 for use in the treatment of an inflammatory skin condition, comprising: Optionally, the combination wherein said inflammatory skin condition is psoriasis, psoriatic arthritis, contact dermatitis, chronic hand eczema or atopic dermatitis.

35. A pharmaceutical composition comprising an antibody that binds to and neutralizes IL13 in combination with a pharmaceutical composition comprising an antibody that binds to and neutralizes IL22 for use in the treatment of an inflammatory skin condition, comprising: Optionally, the pharmaceutical composition, wherein said inflammatory skin condition is psoriasis, psoriatic arthritis, contact dermatitis, chronic hand eczema or atopic dermatitis.

36. A pharmaceutical composition comprising an antibody that binds to and neutralizes IL22 in combination with a pharmaceutical composition comprising an antibody that binds to and neutralizes IL13 for use in the treatment of an inflammatory skin condition, comprising: Optionally, the pharmaceutical composition, wherein said inflammatory skin condition is psoriasis, psoriatic arthritis, contact dermatitis, chronic hand eczema or atopic dermatitis.